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1 Foreword
This Ph.D. thesis is presented in two parts corresponding to the study of the
peptaibol Zervamicin II-2, and to the study of the peptaibols Hypomurocin A1, A3 and
A5.
The numbering of all molecules as well as the literature references are
continuous through all parts of the dissertation. The references are listed at the end of
this dissertation.
The experimental part of both parts is presented in a separate chapter at the end
of this work.
An overview of the entire work is given in the following summary.
1. Foreword
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2 Zusammenfassung
Die Verwendung von 3-Amino-2H-azirinen in der Peptidsynthese für den
Einbau von α,α-disubstituierte α-Aminosäuren ermöglicht die einfache
Kettenverlängerung von Oligopeptiden bzw. Aminosäuren. Diese Einheiten (die
Bekannteste davon ist Aib (1), 2-Aminoisobuttersäure oder 2-Methylalanin) kommen in
der Natur selten vor und führen in Peptiden zu sterischen Hinderungen und
eingeschränkten Konformationsfreiheiten.
Durch die Anwendung dieser Methode (‘Azirin/Oxazolon Methode’) wurden
verschiedene Aib-enthaltende Peptaibole oder Segmente von Peptaibolen erfolgreich
synthetisiert: das geschützte 6-16 Segment des Zervamicins II-2 und die Hypomurocine
A1, A3 und A5. Die in den Synthesen eingesetzten 3-Amino-2H-azirine sind folgende
(Figur 1):
N
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N
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OMeN
N
O
OMe
OBn
1 2 3
Figur 1. 3-Amino-2H-azirine 1, 2 und 3 als Baueinheiten
für Aib, Aib-Pro und Aib-Hyp
Die Aib-Sequenz wird durch die Azirin-Kupplung mit 1 in eine Peptidkette
eingebaut. Die Verwendung von 2 führt zum Einbau der Sequenz Aib-Pro und mit 3
wird die Sequenz Aib-Hyp eingebaut.
Der Vorteil der ‘Azirin/Oxazolon-Methode’ ist, dass es sehr einfach ist, diese
disubstituierten α,α-Aminosäuren einzubauen, da keine Kupplungsreagenzien benötigt
werden. Die Reaktion mit den 3-Amino-2H-azirinen 2 and 3, die zwei Aminosäuren
gleichzeitig einbauen, ist ebenfalls einfach und effizient. Durch die Verwendung dieser
Dipeptid-Synthone wird die Kupplung zwischen einer Aib-Einheit und der ebenfalls
sehr gehinderten Pro bzw. Hyp-Einheit vermieden.
Der erste Teil dieser Dissertation befasst sich mit der Synthese des geschützten
6-16 Segments 4 des Peptaibols Zervamicin II-2 (Figur 2), die mit Hilfe der 3-Amino-
2H-azirine 1, 2 und 3 mit guten bis sehr guten Ausbeuten gelang. Alle Versuche,
Kristalle von 4 für die Röntgen-Kristallstrukturbestimmung zu erhalten, waren
erfolglos.
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Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
4
Figur 2. Geschütztes 6-16 Segment 4 des Zervamicins II-2
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Der zweite Teil behandelt die Totalsynthesen und Konformationsstudien der drei
Hypomurocine A1, A3 und A5 (5, 6 und 7; Figur 3). Die Synthesen gelangen unter der
Verwendung des 3-Amino-2H-azirins 2 mit sehr guten Ausbeuten. Kristalle von
verschiedenen kleinen und grossen Segmenten und von Hypomurocin A3 (6), geeignet
für die Röntgen-Kristallstrukturbestimmungen, wurden für alle drei Hypomurocine
erhalten. Die Konformationstudien lieferten die, bei Anwesenheit von Aib, übliche
Helix-Konformation, auch wenn die Peptide die Helix-brechende Aminosäure Pro
enthält.
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Ac-Aib-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
6
Ac-Aib-Gln-Val-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol
7
Ac-Aib-Gln-Ile-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
Hypomurocin A1
Hypomurocin A3
Hypomurocin A5
Figur 3. Die Undecapeptaibole Hypomurocin A1, A3 und A5
Alle behandelten Projekte wurden mit Hilfe der ‘Azirin/Oxazolon-Methode’
erfolgreich und mit guten Ausbeuten abgeschlossen.
Zum Nachweis der Eigenschaft von Peptaibolen Ionenkanäle durch Membranen
zu bilden, wurde eine Reihe von biologischen Testen mit Bakterien, menschlichen
Zellen und Viren durchgeführt. Die Aktivität der Peptaibole wurde bestätigt, war jedoch
schwach.
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3 Summary
The use of 2H-azirin-3-amines in peptide synthesis for the introduction of α,α-
disubstituted α-amino acids allows the easy chain elongation of oligopeptides and/or
amino acids. In nature, these amino acids (the most famous of them being Aib (1), 2-
aminoisobutyric acid or 2-methylalanine) are rarely present and peptides containing Aib
are sterically hindered with limited conformational freedom.
By using 2H-azirin-3-amines, several Aib containing peptaibols or segments of
peptaibols were successfully synthesized: the protected 6-16 segment of the Zervamicin
II-2 and the Hypomurocins A1, A3 and A5. The involved 2H-azirin-3-amines in these
synthesis are shown in Figure 1:
N
N
Ph N
N
O
OMeN
N
O
OMe
OBn
1 2 3
Figure 1. 2H-Azirin-3-amines 1, 2 and 3 as Building Blocks
for Aib, Aib-Pro and Aib-Hyp, respectively
2H-Azirin-3-amine 1 is used to introduce Aib into a peptide chain. The dipeptide
synthon 2 allows the introduction of the sequence Aib-Pro and with 3 the sequence Aib-
Hyp is added.
The advantage of the ‘azirine/oxazolone method’ is the efficiency of the
introduction of these highly hindered disubstituted α,α-amino acids without the need of
coupling reagents. The use of the dipeptide synthons 2 and 3 is easy and efficient, and
allows to avoid the difficult coupling between an Aib unit and the also hindered Pro or
Hyp unit.
The first part of this dissertation deals with the synthesis of the protected 6-16
segment 4 of the peptaibol Zervamicin II-2 (Figure 2), which was achieved in good to
very good yields using the 2H-azirin-3-amines 1, 2 and 3. Attempts to get crystals
suitable for the X-ray crystal-structure determination of 4 failed.
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4
Figure 2. Protected 6-16 Segment 4 of Zervamicin II-2
The second part concerns the total synthesis and conformational studies of the
three Hypomurocins A1, A3 and A5 (5, 6 and 7; Figure 3). The syntheses were
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performed by using the 2H-azirin-3-amine 2 with very good yields. Crystals of various
small and long segments and Hypomurocin A3 (6), suitable for the X-ray structure
analysis, could be obtained in each series. The conformational studies have shown the
expected helical conformation due to the presence of Aib, even if it is immediately
followed by the ‘helix breaker’ unit Pro.
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Ac-Aib-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
6
Ac-Aib-Gln-Val-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol
7
Ac-Aib-Gln-Ile-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
Hypomurocin A1
Hypomurocin A3
Hypomurocin A5
Figure 3. The Undecapeptaibols Hypomurocins A1, A3 and A5 resp. 5, 6 and 7
In conclusion, all projects were successfully achieved with good yields by using
the ‘azirine/oxazolone method’.
In addition, to test the property of peptaibols to form ion channels through
membranes, a series of biological tests with bacteria, human cells and viruses was
carried out. The activity of the peptaibols was confirmed, although it was weak.
4. Topic of the Present Dissertation
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4 Topic of the Present Dissertation
All syntheses in this dissertation are solution phase syntheses.
4.1 Zervamicin I I-2
The protected 6-16 segment 4 of the Zervamicin II-2, which, in its unprotected
form, is also common to Zervamicin II-5, was selected as a model for the demonstration
of the use of the azirine/oxazolone method in peptaibol synthesis [1, 2]. The aim of the
present synthesis is to show that the introduction of the residues Aib, Aib-Pro, and Aib-
Hyp in the selected segment 4 can be carried out in an elegant way by using this
method.
4.2 Hypomuro cins A1, A3 and A5
As a second topic, the Hypomurocins were chosen because they contain two
Aib-Pro sequences. Moreover, due to the high similarity of the molecules of the
Hypomurocin A family and to make a structural comparison by three-dimensional
characterization, it was decided to synthesize three Hypomurocins of the A family. The
Hypomurocins A1, A3 and A5 were selected arbitrarily.
Additional work to the original project was the comparison of the synthetic
Hypomurocins A1, A3 and A5 with a sample of the natural Hypomurocin A family. This
comparison was successfully achieved by HPLC-MS analysis.
Finally, the biological activity and the toxicity of the three synthetic
Hypomurocins A1, A3 and A5 (5, 6 and 7) were tested by running in-vitro tests with
various biological material like bacteria, blood Agar plates, viruses and human cells.
4. Topic of the Present Dissertation
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5 Introduct ion
5.1 Peptaibols
In the coming decades, the synthesis of large quantities of peptides (from more
than 100 kg up to a multi-tonne scale per year) will be a great challenge. In the 1990's it
was generally thought that large-scale syntheses of peptides (up to 50 kg/year) are
economically nonsensical because of the inadequate production technology and the low
demand of peptides as pharmaceuticals. Simply stated, it was difficult and expensive to
synthesize peptides of more than 30 amino acids [3]. Since the knowledge of the
synthesis of peptides has increased as well as the interest in the treatment of diseases by
using peptides, it is to be expected that this field will be soon become industrially more
developed, thereby allowing access to low-cost material.
Since the first solid-phase peptide synthesis (SPPS) by Merrifield [4] in 1963,
interest in peptide synthesis has grown significantly, and a convenient way to prepare
long peptides was developed quite quickly. Nowadays, these syntheses are often fully
automated. Although this technique is still very common, it has some limitations on
purification and yields depending on the length of the peptide, and the batch is limited
to a few dozen kilograms per reactor. For larger batches, solution phase synthesis (SPS)
has proven to be a superior method. Moreover, whereas SPPS is a linear synthesis, SPS
allows a convergent preparation in which the amount of starting materials and,
therefore, the production costs can be reduced. For instance, expensive amino acids can
be introduced at a later step of the synthesis. Based on this and other optimization
factors, optimization matrices such as Hadamard matrices [5], have been developed and
have allowed to evaluate the fastest and cheapest synthesis.
Peptaibols are membrane-active oligopeptides isolated from fungal sources.
They have an antibacterial property due to their self-association in lipid membranes
forming ion channels through membranes [6]. They are linear amphiphilic
oligopeptides containing 11 to 20 amino acids characterized by the content of up to
50% of the non-proteinogen amino acid Aib (α-aminoisobutyric acid) and the presence
of an acetylated N-terminus and a reduced C-terminus alcohol function (e.g. Valol,
Leuol, Pheol) [7, 8], standing for the name 'pept-aib-ol' [9]. They also often contain the
Iva (α-ethyl alanine) residue [10, 11]. Aib is the simplest α,α-disubstituted amino acid
present in nature [12], and it is well known for its ability to induce helical folding of the
peptide chain [13]. This effect still dominates when amino acids such as proline (Pro)
and hydroxyproline (Hyp), known as “helix breaker”, are present [14].
Moreover, in a series of articles [15-26], the extraterrestrial origin of Aib and Iva
found in comet dust in the Cretaceous/Tertiary boundary has been debated. The origin
was confirmed, e.g. with the Murchison meteorite, which fell in Australia in 1969 and
was the first proof of amino acids in extraterrestrial material.
Recent work [27-30] on various peptaibols, i.e. Alamethicin F-30 (Akaji and
Kiso, 1995) [31], Zervamicin II-B (Ogrel and Raap, 1997) [32], Trichovirin I (Brückner
and Kosa, 2003 [33]; Luykx and Heimgartner, 2003 [34]), the crystal structure of
Antiamoebin (Karle and Balaram, 1998) [35], Peptaibolin (Crisma and Toniolo, 2001)
[36], lipopeptaibols (Toniolo, 2001) [37], the octameric model for the Trichotoxin
channel (Chugh and Wallace, 2002) [38, 39], illustrating their characterisation,
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structural study as well as their total synthesis, or simply the discovery of new
peptaibols like Cervinin from Mycogone cervina (Wilhelm and Sterner, 2004) [40],
confirm the interest and the growing accessibility of this chemistry. The first online
peptaibol database [41], recording over 300 molecules, and being developed and
maintained in London/UK by Chugh and Wallace is now accessible. It illustrates the
need for 'peptaibolists', i.e. the community of chemists working on peptaibols, to have
an updated and accurate system with the latest developments on peptaibols from the
name, sequences and fungal origin to the known X-ray structures and three-dimensional
NMR studies.
The antibiotic property of peptaibols is assumed to be a consequence of the helix
conformation of these Aib containing molecules. The peptaibol enters the membrane of
the cell and by self association of several molecules to form n-mers, n going up to 14
but is assumed to be in general 8. The n-mer creates an ion channel, leading to the
destabilization of the cell and finally to its dead or to the inhibition of its function
(Figure 4) [38], although the characterization of the n value has to be carefully
subjected to the models [39].
Figure 4. Octameric and Hexameric Models for Trichotoxin Channels [38, 39]
Moreover, if the length of the peptaibols is smaller than the width of the lipid
membrane, the peptaibols are also assumed to self associate in a head-to-tail [30] or
both head-to-tail and/or head-to-head fashion [42] (Figure 5). In the case of the head-to-
head association, the polarity barrier due to the inversion of the second peptaibol chain
in the channel has not been explained, and this model might not be appropriate with
regard to the diffusion of the ions.
The introduction of Aib into peptaibols was a difficult synthetic task for long
time (see [33]). During the last ten years, these difficulties have been surmounted by the
development of highly reactive coupling reagents and activated amino acids [32, 43,
44]. Furthermore, the fluoride activation of α,α-dialkylated α-amino acids and peptides
has been shown to allow convenient peptaibol synthesis on the solid phase [45, 46].
Although the solid phase peptide synthesis is now the method of choice for routine,
general and automated preparation of peptaibols, the solution phase synthesis has also
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some advantages. For example, any defined segment, not only the final product, can be
obtained, e.g. for structure analysis by X-ray crystallography and for testing the bio-
activity.
Figure 5. Postulated Head-to-Tail Dimerization Models for Short Peptaibols (cf. [30])
5.2 2H-Azirin-3 -amines
2H-Azirin-3-amines are three-membered amidines with a C-N double-bond in
endocyclic position. The most general synthesis is based on the procedure of Rens and
Ghosez [47]. A method, which avoids the use of phosgene, has been developed by
Villalgordo and Heimgartner [48] leading from the starting amide via an enolate
intermediate to the chloroenamine and the azirine.
The synthetic possibilities to use 2H-azirin-3-amines in organic chemistry are
numerous [2], and in the field of peptide chemistry, they are of particular help for the
construction of linear peptides with α,α-disubstituted α-amino acids, taking into
account that until the end of the 1990's, conventional chain elongation techniques either
failed or suffered from extreme difficulties. The general synthetic way to obtain 2H-
azirin-3-amines is presented in Scheme 1.
The use of thioamides, prepared by treatment with Lawesson reagent [49, 50],
does not belong to the original route described by Rens and Ghosez, but it allows to
considerably increase the yield of 16 [51]. The formation of the α-chloroenamine 13
occurs via nucleophilic attack of the thioamide 9 on the highly reactive phosgene. By
treatment of the ketiminium salt 14 with natrium azide, 15 leads to the formation of the
three-membered ring 16 with irreversible loss of nitrogen.
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Scheme 1. Synthesis of 2H-Azirin-3-amines
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5.3 The Azirin e/Oxazolone Method
Regarding the synthesis of peptaibols, at the beginning of the 90's Heimgartner
developed a synthetic method to introduce in solution highly hindered α,α-disubstituted
α-amino acids like Aib and Iva into peptides via the azirine/oxazolone method [2].
More recently Luykx [51], Pradeille [52] and Breitenmoser [53] have illustrated the
advantage of this method by the introduction of amino acids like Aib or dipeptide units
like Aib-Pro and Aib-Hyp by using the corresponding 2H-azirin-3-amines 1, 2 and 3,
respectively, as building blocks in peptide chain elongations, where conventional
techniques failed or gave low yields.
N
N
Ph
1
N
N
O
OMe
OBn
N
N
O
OMe
2 3
Figure 6. 2H-Azirin-3-amines as Building Blocks for Aib, Aib-Pro and Aib-Hyp
Until a few years ago, the introduction of such sterically demanding amino acids
was a problem, because the formerly predominant coupling techniques with
carbodiimides or via active esters did not allow these reactions to be performed with
reasonable yields [54-60]. Nowadays, these methods have been replaced by those which
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utilize new coupling reagents and activating additives, such as uronium and
phosphonium salts, which permit to carry out these coupling reactions with good yields
and without any appreciable epimerization or side product formation [61-70].
The reaction mechanism of the coupling of an amino or peptide acid 17 with 2H-
azirin-3-amines 16 is shown in Scheme 2. Protonation of N(1) of the azirine followed by
nucleophilic addition of the carboxylate leads to aziridine intermediate 18, which
undergoes a ring enlargement to give zwitterion 19. Ring opening of the latter then
yields peptide 20. Hydrolysis of 20 under mild conditions (3N HCl, THF/H2O, r.t.)
gives the peptide acid 22. It has been shown that oxazolone 21 is an intermediate and
can be prepared from 20 by treatment with gaseous HCl in non-nucleophilic solvents in
high yield. The direct coupling of 21 with an amino component is also possible [2, 71].
Scheme 2. Reaction Mechanism of the Coupling of an Amino or Peptide Acid with 2H-
Azirin-3-amines
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5.4 Coupling Reagents and Additives
For the coupling of two amino acids, they have to be activated with the help of
coupling reagents. Moreover, there is also the risk of epimerization during the coupling
(Scheme 3). In order to lower this risk, additives such as aminium/uronium and
phosphonium salts like HOAt and HOBt are added to the reaction mixture [70, 72]. The
currently accepted mechanism in the process of the racemization is based on an
oxazolone intermediate 26, from which via enolization both epimers can be formed. It
has been widely proved that the addition of HOBt as an additive was very efficient to
lower this racemization [73].
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Scheme 3. Mechanism of the Epimerization during the Coupling
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5.5 The Rama chandran Plot
The structure of peptides and proteins are classified in primary, secondary,
tertiary and quaternary structures, and the properties of these molecules are strongly
linked to their three-dimensional arrangement.
The primary structure corresponds to the sequence of amino acids in the peptide
chain. This chain, which contains the amide bonds, is called the peptide backbone.
The secondary structure of a segment of a polypeptide chain is the local spatial
arrangement of its main-chain atoms without regard to the conformation of its side
chains or to its relationship with other segments (IUPAC-IUB, 1970). The secondary
structure is characterized by the geometry of these chains and is defined by the ωi amide
bond torsion angle and two other torsion angles: ϕi being the dihedral angle about the
Ci-N bond and ψi being the dihedral angle about the Ci-CO bond for a given α-Ci atom
(Figure 7). Due to the delocalization of the lone-pair of the N-atom and the π-electrons
of the amide bond, the amide bond is almost planar and, therfore, the three-dimensional
arrangement is a result of ϕi and ψi.
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Figure 7. Torsion Angles ωi, ϕi and ψi in a Peptide Chain
The two torsion angles ϕi and ψi may take all possible values, but actually due to
energy reasons, only certain values are allowed. The graphic visualization of these
values is commonly used to determine the type of secondary structures taken by the
parts of the peptide chain and is called the Ramachandran Plot [74]. The
conformational freedom for a given amino acid in a peptide chain is illustrated in Figure
8. If we compare Ala (alanine) and Aib (methyl alanine), we immediately see the much
more restricted conformation of Aib due to the presence of a second methyl group as a
side chain at the α-C atom.
Figure 8. The Ramachandran Plot for Ala and Aib
There are mainly three types of regular structures in a peptide chain (helix, turn
and inverse turn) according to the ϕi and ψi values (Figure 9).
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α - Helix
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Figure 9. α-Helix, β-Turn and γ-Turn: the Three General Types of Secondary Structures
in a Peptide Chain
In the helix, the amino acid chain is twisted around a central axis in a regular
manner and the structure is stabilized by intrachain C=O----H-N H-bonds, the side
chains are pointing out of the helix. There are different types of helices (αL, αR, 310, π,
poly(Pro) I and II, and poly(Gly) II) distinguished by the H-bonding pattern, number of
residues per turn and the tightness of the coil. The classical (most common) right
handed αR-helix has an i+4 H-bonding pattern.
The idealized torsion angles ϕi and ψi for some secondary structures of peptides
are given in Table 1.
Table 1. Torsion Angles for some Secondary Structures of Peptides
Conformation ϕi+1 (°) ψi+1 (°) ϕi+2 (°) ψi+2 (°) n A H-bond
α-helix (right handed) -57 -47 -57 -47 3.6 13 i,i+4
310-helix -74 -4 -74 -4 3.0 10 i,i+3
π-helix -57 -70 -57 -70 4.4 16 i,i+5
Parallel β-sheet -119 +113 -119 +113 2.0
Antiparallel β-sheet -139 +135 -139 +135 2.0
β-Turn type I and I' ±60 ±30 ±90 0 10
β-Turn type II and II' ±30 ±120 ±80 0 10
β-Turn type III and III' ±60 ±30 ±60 ±30 10
γ-Turn +70 to +85 -60 to -70 7
Inverse γ-Turn -70 to -85 +60 to +70 7
n: number of residues per helical turn; A: atoms in the H-bonded loop.
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The tertiary structure is the three-dimensional arrangement of the whole
polypeptide. This includes the arrangement of the helices, β-sheets and turns as well as
eventually existing sulfur-sulfur bridges.
Some proteins consist of an assemblage of several tertiary structures, which is
called the quaternary structure. This is the case for instance with the four independent
protein chains of Hemoglobin which become an oligomer protein through self
assemblage.
5. Introduction
30
6. The Protected 6-16 Segment of Zervamicin II-2
31
6 The Protected 6-16 Segment of Zervamicin II-2
6.1 Introduction
The 16-residue peptaibols of the Zervamicin family are produced by
Emericellopsis Salmosynnemata. In 1981, Rinehart et al. have reported the structure of
eleven Zervamicin structures [75], and the crystal structure of Leu1-Zervamicin II B has
been established by Karle et al. in 1991 [76-78]. The solution phase synthesis of
Zervamicin II B was performed by Ogrel et al. [32].
The selected highlighted protected 6-16 segment 4 is common to Zervamicin II-2
and Zervamicin II-5 in its unprotected form (Figure 10):
Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
Ac-Trp-Ile-Gln-Aib-Ile-Thr-Aib-Val-Aib-Hyp-Gln-Aib-Hyp-Aib-Pro-Pheol
Ac-Trp-Ile-Gln-Iva-Ile-Thr-Aib-Val-Aib-Hyp-Gln-Aib-Hyp-Aib-Pro-Pheol
4
Zervamicin II-2
Zervamicin II-5
Figure 10. Zervamicins II-2 and II-5
In the past few years, the azirine/oxazolone method has been shown to provide
an efficient and elegant way to extend peptide chains with Aib, Aib-Pro and Aib-Hyp
units by using the 2H-azirin-3-amine derivatives 1-3 as building blocks. The preparation
of these synthons has been described recently (1 [79], 2 [51], 3 [53]). By using this
methodology, segments of the peptaibols Alamethicin F-30 [1], Trichotoxin A-50(G)
[80, 81], Antiamoebin I [81-83], and Trichovirin I 1B [51, 84] were prepared. Recently,
the conventional solution phase synthesis of Trichovirin I 4A was described [33]. The
successful coupling reactions with 1 and 2 have already been reported [1, 2, 51]. Their
coupling potential is now illustrated in the reactions with Z-Thr(OBn)-OH (29) (Scheme
7) and Z-Gln-Aib-Hyp(OBn)-OH (30) (Scheme 8), respectively. Furthermore, the
reactions of 3 with Z-Val-OH and Z-Gln-OH show its potential as an Aib-Hyp synthon.
6.2 Synthesis
6.2.1 Strategy of the Synthesis
In the protected 6-16 segment of Zervamicin II-2, there are three different Aib or
dipeptide units which can be introduced via the azirine/oxazolone method by using the
building blocks 1, 2, and 3, and which makes this molecule a versatile target for our
chemistry. The first idea was to split the molecule in two equal parts. Taking into
consideration the position of the different Aib units, the strategy was to prepare the
molecule 4 by condensation of a penta- and an hexapeptide, i.e. from Z-Thr(OBn)-Aib-
Val-Aib-Hyp(OBn)-OH (31) and H-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol (32; see Scheme
6). Moreover, if a strategy involves the use of H-Gln-OMe (for instance to be coupled
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with 31), caution must be taken because this compound rearranges easily to give 33
(within 2-3 days). A proposed reaction mechanism is shown in Scheme 4. This side
reaction might be the reason, why H-Gln-OMe is commercially not available.
Scheme 4. Proposed Reaction Mechanism for the Formation of 33
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After deprotection of the amine group, an intramolecular nucleophilic attack of
the nitrogen electron pair leads to the formation of the heterocycle 33.
Suitable crystals of 33 for an X-ray crystal-structure determination were
obtained (Figure 11). The crystals are enantiomerically pure, however the absolute
configuration of the molecule has not been determined. The enantiomer used in the
refinement was based on the known S-configuration of the starting material. The
structure of this molecule has previously been reported as the monohydrate [85]. Each
amide group of the molecule acts as a donor for H-bonds. The cyclic amide group forms
an intermolecular H-bond with the cyclic amide O-atom of a neighbouring molecule.
This interaction links the molecules into infinite chains. One of the H-atoms of the
exocyclic amide group forms an intermolecular H-bond with the cyclic amide O-atom
of a different neighbouring molecule and yields infinite chains. The other H-atom of the
exocyclic amide group forms an intermolecular H-bond with the exocyclic amide O-
atom of a third neighbouring molecule and yields infinite chains. The combination of all
interactions links the molecules into an infinite three-dimensional framework.
Figure 11. ORTEP Plot [86] of the Molecular Structure of 33 (50% probability
ellipsoids; arbitrary numbering of the atoms)
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6.2.2 Preparation  of the 2H-Azirin-3-amine(s)
The preparation of the 2H-azirin-3-amines 1, 2 and 3 actually concerned only
that of 3 as the two others were already available in the laboratory. According to
Breitenmoser's procedures [53], 1.63 g of 3 were synthesized from the thioamide 35and
purified by at least two successive flash column chromatographies. Although the
reaction time of the treatment of the corresponding amide 34 with Lawesson reagent did
not exceed 25 min, the side product 36 formed by the initial cyclization and subsequent
elimination of BnOH as reported in [53] was also observed here (Scheme 5). The yield
of this product was not determined.
Scheme 5. Preparation of the 2H-Azirin-3-amine 3
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6.2.3 Unsuccessfu l Synthesis
The first strategy was to prepare the protected segment 4 by the coupling of the
pentapeptide 31 with the C-terminal hexapeptide 32 (Scheme 6).
Scheme 6. First Strategy for the Preparation of 4
Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
4
TBTU/HOBt
TEA, MeCN
N2, r.t.
32
H-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol+Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-OH
31
The synthesis of the protected ester 37, which is the precursor of the desired
segment 31, was achieved according to Scheme 7: coupling of 29 with azirine 1
followed by selective hydrolysis gave 39 in quantitative yield. Coupling of the latter
with H-Val-OMe by using TBTU/HOBt yielded the tripeptide 40. Unexpectedly,
saponification of the ester with LiOH gave the acid 41 in only 32.8% yield. Reaction
with the Aib-Hyp synthon 3 led to 37 in 84.8% yield.
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Scheme 7. Synthesis of the Protected Ester 37
6N HCl, THFCH2Cl2
H-Val-OMe
LiOH
CH2Cl2
Z-Thr(OBn)-OH Z-Thr(OBn)-Aib-N(Me)(Ph) Z-Thr(OBn)-Aib-OH
38 (quant.)
1
N2, r.t. N2, 0°C-r.t.
TBTU/HOBt
TEA, MeCN
N2, r.t.
39 + Z-Thr(OBn)-Aib-Val-OMe
THF/MeOH/H2O (3:1:1)
N2, r.t. Z-Thr(OBn)-Aib-Val-OH
N2, r.t. Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-OMe
37 (84.8%)
29
40 (86%) 41 (32.8%)
41
+
39 (quant.)
3+
LiOH
31
Unfortunately, the planned synthesis of 31 according to Scheme 6 could not be
achieved, because the hydrolysis of its methyl ester Z-Thr(OBn)-Aib-Val-Aib-
Hyp(OBn)-OMe (37) failed. This surprising result was confirmed by several attempts to
hydrolyse 37 under different conditions. According to 1H-NMR and MS analysis, the
molecule was destroyed, with lost of the Z protecting group as well as the benzyloxy
group. The reason of this unexpected reaction remains unknown. Thus, the coupling
between 31 and 32 could not be tried, and the whole strategy had to be revised.
It is interesting to notice that the only hydrolysis in this synthesis of 37 (40→41)
yielded the expected product, but in very low yield, indicating a possible influence of
the threonine part of the molecule on the hydrolysis. Furthermore, the purification of 41
after the work up was difficult.
6.2.4 Successful Synthesis
As a consequence of the failure of the first strategy, we decided to synthesize 4
from the three sub-segments Z-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol 42, Z-Val-Aib-
Hyp(OBn)-OH 43, and Z-Thr(OBn)-Aib-OH 39. These three segments should then be
coupled by using the well-known TBTU/HOBt method that should avoid epimerisation
during segment condensations. Indeed, no epimerisation could be detected by NMR
analysis. The protective groups of the amino groups and the side chain hydroxy groups
were chosen to be stable under acidic and basic conditions [87]. Therefore, Z-protected
amino acids were used, and the OH group of Thr was benzylated as the OH group of the
Aib-Hyp synthon was.
The reaction of the Z-protected glutamine residue (Z-Gln-OH) with the Aib-Hyp
dipeptide synthon 3 in THF at room temperature gave the tripeptide 44 in 79% yield
(Scheme 8). Basic hydrolysis of the ester group of the latter with LiOH in
THF/methanol/water led to 30, which was coupled with azirine 2, the Aib-Pro dipeptide
synthon, to yield the pentapeptide 45. This azirine coupling was performed with 76%
yield. Another basic hydrolysis gave the pentapeptide acid 46, which was coupled with
L-Pheol by using the standard TBTU/HOBt method to give the C-terminal hexapeptide
42 in 66.2% yield. After deprotection of the N-terminus by hydrogenolysis, the
glutamine segment 32 was obtained in quantitative yield. It is worth mentioning that the
benzyloxy protecting group of the Hyp residue was stable under the chosen conditions
(10% Pd/C).
6. The Protected 6-16 Segment of Zervamicin II-2
35
Scheme 8. Synthesis of the Hexapeptide 32
LiOH
LiOH
MeOH,  r.t.
Z-Gln-OH Z-Gln-Aib-Hyp(OBn)-OMe Z-Gln-Aib-Hyp(OBn)-OH
Z-Gln-Aib-Hyp(OBn)-Aib-Pro-OMeZ-Gln-Aib-Hyp(OBn)-Aib-Pro-OH
Z-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol H-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
2
L-Pheol
H2, Pd/C
44 (78.7%) 30 (89.0%)
45 (76.4%)46 (75.4%)
42 (66.2%) 32 (quant.)
3
THF dry
N2, r.t.
THF/MeOH/H2O (3:1:1)
N2, r.t.
THF dry
N2, r.t.
THF/MeOH/H2O (3:1:1)
N2, r.t.
TBTU, HOBt
TEA, MeCN
N2, r.t.
+
Analogously, the reaction of the Z-protected valine residue Z-Val-OH with the
Aib-Hyp dipeptide synthon 3 led to the tripeptide 47 in 77% yield (Scheme 9). The
methyl ester group of the latter was hydrolyzed by treatment with LiOH in
THF/methanol/water to give 43 in 64.1% yield. Using the TBTU/HOBt method, 43 was
coupled with the glutamine 11-16 segment 32 to give the C-terminal nonapeptide 48 in
50% yield. Deprotection by hydrogenolysis of the N-terminus of the latter gave the 8-16
segment 49 in 88.1% yield.
Scheme 9. Synthesis of the Nonapeptide 49
LiOH
MeOH,  r.t.
Z-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
TBTU/HOBt
TEA, MeCN
N2, r.t.
Z-Val-OH Z-Val-Aib-Hyp(OBn)-OMe Z-Val-Aib-Hyp(OBn)-OH
47 (77%) 43 (64.1%)
3
THF dry
N2, r.t
THF/MeOH/H2O (3:1:1)
N2, r.t.
43 + 32
48 (50%)
49 (88.1%)
H-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
H2, Pd/C
+
Crystals of 47, suitable for an X-ray crystal-structure determination, could be
obtained from a mixture of methanol, hexane and ethyl acetate (Figure 12). The space
group permits the compound in the crystal to be enantiomerically pure, but the absolute
configuration of the molecule has not been determined. The enantiomer used in the
refinement was based on the known S-configuration of the Val moiety. Relative to the
(S)-Val moiety, C(8) and C(26) have the expected S- and R-configuration, respectively.
The amide groups form intermolecular hydrogen bonds which link the molecules into
two-dimensional networks. The amide group of Val forms an intermolecular H-bond
with the ester carbonyl O-atom at the opposite end of a neighboring molecule. This
interaction links the molecules into extended chains. The Aib amide group forms an
intermolecular H-bond with the adjacent amide O-atom of a different neighboring
molecule. This interaction also links the molecules into extended chains. The
combination of these interactions links the molecules into two-dimensional networks.
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Figure 12. ORTEP Plot [86] of the Molecular Structure of 47 (50% probability
ellipsoids; arbitrary numbering of the atoms)
The treatment of the OBn- and Z-protected threonine residue Z-Thr(OBn)-OH
with the Aib synthon 1 in CH2Cl2 at room temperature gave the dipeptide 38 in
quantitative yield (Scheme 10). This latter was hydrolyzed under the usual conditions,
i.e. with 3N HCl in a 1:1 mixture of THF/water, and the dipeptide 39 acid was obtained
in quantitative yield. The final coupling of 39 with the 8-16 segment 49 was achieved
by using the TBTU/HOBt method, and the C-terminal undecapeptide 4 was obtained in
32.8% yield.
Scheme 10. Synthesis of the Undecapeptide 4
6N HCl, THFCH2Cl2
Z-Thr(OBn)-OH Z-Thr(OBn)-Aib-N(Me)(Ph) Z-Thr(OBn)-Aib-OH
38 (quant.) 39 (quant.)
1
N2, r.t. N2, 0°C-r.t.
Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol
4 (32.8%)
TBTU/HOBt
TEA, MeCN
N2, r.t.39 + 49
+
Crystals of 38 suitable for an X-ray crystal-structure determination were
obtained from CDCl3 by slow evaporation of the solvent (Figure 13). The space group
permits the compound in the crystal to be enantiomerically pure, but the absolute
configuration of the molecule has not been determined. The enantiomer used in the
refinement was based on the assumption that the molecule has the 11S-configuration.
Relative to this, C(23) has the R-configuration. The molecule forms one intramolecular
and one intermolecular hydrogen bond, with the latter linking the molecules into
extended chains. The Aib amide group forms an intermolecular H-bond with the amide
O-atom of the secondary amide group of a neighboring molecule. This interaction links
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the molecules into extended chains. The amide group of Thr forms a weak
intramolecular H-bond with the benzyloxy O-atom, thereby forming a five-membered
loop.
Figure 13. ORTEP Plot [86] of the Molecular Structure of 38 (50% probability
ellipsoids; arbitrary numbering of the atoms)
The whole synthesis of the protected 6-16 segment 4 is resumed in Figure 14.
This overview shows that the yields are good to very good, except in some cases with
the TBTU/HOBt coupling method. The introduction of all Aib residues using the 2H-
azirin-3-amines 1, 2, and 3 proved to be ideally suited and was performed in 75% to
quantitative yield. The chosen protecting groups allowed the different conversions
under acidic and basic conditions in the synthesis.
Figure 14. Synthesis of the Protected 6-16 Segment 4 of Zervamicin II-2
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The Z protecting group was removed smoothly, whereas the benzyl protecting
groups of the threonine and the two hydroxy proline residues remained stable.
6.3 Conclusion
The protected eleven amino acid 6-16 segment 4 of the peptaibol Zervamicin II-
2 was synthesized by using the azirine/oxazolone method for the introduction of all Aib
residues. Whereas a 2,2-dimethyl-2H-azirin-3-amine was used as the building block for
Aib, methyl 2,2-dimethyl-2H-azirine-3-prolinate and -3-(3-hydroxyprolinate) proved to
be ideally suited as dipeptide synthons for the introduction of Aib-Pro and Aib-Hyp,
respectively. The coupling of Z-protected amino acids or peptide acids with the 2H-
azirin-3-amines were performed in 75% to quantitative yield.
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7 Hypomurocins A1, A3 and A5
7.1 Introduction
The Hypomurocin A family belongs to the SF4 peptaibol class [38], which is the
one with the less collected data about structure and conformation. The members of this
family are characterized by 11 to 14 residues and a Gln or an Asn residue in position 2,
they contain neither aromatic nor charged residues but two Pro residues at the same
place for all of the 11-residue molecules.
The total synthesis of HM A1 (5, 1-(N-acetyl-2-methylalanyl-L-glutaminyl-L-
valyl-L-valyl-2-methylalanyl-L-prolyl-L-leucyl-L-leucyl-2-methylalanyl)-N-[(1S)-1-
(hydroxymethyl)-3-methylbutyl]-L-prolinamide), HM A3 (6, 1-(N-acetyl-2-
methylalanyl-L-glutaminyl-L-valyl-L-leucyl-2-methylalanyl-L-prolyl-L-leucyl-L-
isoleucyl-2-methylalanyl)-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-L-prolinamide)
and HM A5 (7, 1-(N-acetyl-2-methylalanyl-L-glutaminyl-L-isoleucyl-L-isoleucyl-2-
methylalanyl-L-prolyl-L-leucyl-L-leucyl-2-methylalanyl)-N-[(1S)-1-(hydroxymethyl)-3-
methylbutyl]-L-prolinamide) is described here. These three peptaibols are
representatives of the 12 different Hypomurocins of the HM family, which is divided
into the subgroups of HM A (11 amino acids) and HM B (18 amino acids, Figure 15).
These peptaibols have been isolated from the ascomycetous fungus Hypocrea muroiana
Hino et Katsumoto using reverse phase HPLC (RP-HPLC) and their structures have
been characterized by GC-MS analysis [88].
Ac-Aib-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A1
Ac-Iva-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A2
Ac-Aib-Gln-Val-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol HM A3
Ac-Aib-Gln-Ile-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A4
Ac-Aib-Gln-Ile-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A5
Ac-Aib-Gln-Ile-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol HM A5a
Ac-Aib-Ser-Ala-Leu-Aib-Gln-Aib-Val-Aib-Gly-Aib-Aib-Pro-Leu-Aib-Aib-Gln-Valol HM B1
Ac-Aib-Ser-Ala-Leu-Aib-Gln-Aib-Val-Aib-Gly-Aib-Aib-Pro-Leu-Aib-Aib-Gln-Leuol HM B2
Ac-Aib-Ala-Ala-Leu-Aib-Gln-Aib-Val-Aib-Gly-Aib-Aib-Pro-Leu-Aib-Aib-Gln-Valol HM B3a
Ac-Aib-Ser-Ala-Leu-Aib-Gln-Iva-Val-Aib-Gly-Aib-Aib-Pro-Leu-Aib-Aib-Gln-Valol HM B3b
Ac-Aib-Ser-Ala-Leu-Aib-Gln-Aib-Val-Aib-Gly-Iva-Aib-Pro-Leu-Aib-Aib-Gln-Valol HM B4
Ac-Aib-Ser-Ala-Leu-Aib-Gln-Aib-Val-Aib-Gly-Iva-Aib-Pro-Leu-Aib-Aib-Gln-Leuol HM B5
Figure 15. Sequences of the 12 Hypomurocins (Ac = acetyl; Leuol, Valol = amino
alcohol at the C-terminus)
It is to be expected that the conformation of HM A1 (5), A3 (6) and A5 (7) is
helical due to the presence of several Aib moieties, as it is known for other peptaibols.
Because the HM A sequences contain two Aib-Pro units, they were attractive targets for
the application of the azirine/oxazolone method by using the Aib-Pro synthon 2. As
usual, we used the Z protecting group to allow transformations under basic and acidic
conditions, and the TBTU/HOBt coupling was used for segment condensations.
Furthermore, a structural study of HM A1, A3 and A5 by NMR spectroscopy and X-ray
crystallography was performed.
7. Hypomurocins A1, A3 & A5
40
7.2 Synthesis
7.2.1 Strategy of the synthesis
As this part of the work constitutes a project to synthesize HM A1, A3 and A5
and to compare their structures, the first requirement before starting the syntheses is a
good preparative protocol and an efficient strategy to minimize the number of steps for
all three syntheses. For this purpose, two questions had to be answered:
− is the number of steps in the syntheses depending on the way the molecules are
synthesized?
− what are the longest common sequences of HM A1, A3 and A5?
For the first question, a mathematical expression (Equation 1) was empirically
set up to calculate the number of steps for the synthesis of a peptaibol :
S = 2×L – 2×N – 3 (1)
L = Length in units of the peptaibol (e.g. for HM A1, L = 11).
N = Number of bi-moieties of Aib-X (X = Pro, Hyp,…) being introduced by the
azirine/oxazolone method. In our case, X = Pro and N = 2.
S = Number of steps to synthesize the peptaibol with the azirine/oxazolone
method.
As it is shown in Equation 1, the number S does not depend on the way the
synthesis is performed, but only on how many bi-moieties N can be introduced by the
azirine/oxazolone method, as well as the length L of the peptaibol. Thus for HM A1, A3
or A5, the required number of steps is the same and is based on L = 11 and N = 2 giving
a result of S = 15 steps. So for the three syntheses, we have "in the worst case" a total of
45 steps to carry out.
With the answer of the second question, we will considerably reduce this
number. Let's compare the common segments of our three targets (Figure 16). We
notice that the three peptaibols have the same sequence Ac-Aib-Gln, at the N-terminus.
1   2   3   4   5   6   7   8   9  10   11
Ac-Aib-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A1 (5)
Ac-Aib-Gln-Val-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol HM A3 (6)
Ac-Aib-Gln-Ile-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A5 (7)
Figure 16. Common Sequences of HM A1, A3 and A5
The first idea would be to prepare the dipeptide Ac-Aib-Gln-OH (50) by
coupling Ac-Aib-OH and H-Gln-OtBu and deprotecting the C-terminus of the resulting
molecule. The subsequent unknown coupling step between 50 and H-Val-OtBu (for HM
A1 and A3) or H-Ile-OtBu (for HM A5) might result in a substantial loss of material as
Gln bears a rather big side chain. As Ac-Aib-OH is either very expensive commercially
or has to be prepared by acetylating H-Aib-OH, a reaction which can be performed in
low yield only, we decided to introduce Aib in position 1 of the tripeptides Ac-Aib-Gln-
Val-OH (51) and Ac-Aib-Gln-Ile-OH (52) in the last step because the commercial
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starting materials for Gln, Val and Ile are cheap. Moreover, the tripeptide Ac-Aib-Gln-
Val-OH (51) can be used for the synthesis of both HM A1 and A3. Thus, Z-Gln-OH
must be coupled first with H-Val-OtBu resp. H-Ile-OtBu; the tert-butyl protection was
chosen to allow a smooth deprotection with TFA and to avoid the cleavage of the acetyl
group on Aib. The obtained products Z-Gln-Val-OtBu (53) and Z-Gln-Ile-OtBu (54)
should be deprotected to give H-Gln-Val-OtBu (55) and H-Gln-Ile-OtBu (56),
respectively, coupled with Ac-Aib-OH to lead to the two tripeptides 57 and 58, and
deprotected with TFA to yield 51 and 52 (Scheme 11).
Scheme 11. Strategy for the Synthesis of the Segments 1-3 51 and 52
(HM A1, HM A3) :  X = Val
Z-Gln-OH + H-X-OtBu Z-Gln-X-OtBu
53 :  X = Val
(HM A5) :  X = Ile 54 :  X = Ile
HOBt
TBTU
H-Gln-X-OtBu
55 :  X = Val
56 :  X = Ile
H2, Pd/C
Ac-Aib-OH +
55
56
HOBt
TBTU
Ac-Aib-Gln-X-OtBu
57 :  X = Val
58 :  X = Ile
TFA Ac-Aib-Gln-X-OH
51 :  X = Val
52 :  X = Ile
MeCN, TEA
N2
MeOH
MeCN, TEA
N2
The inspection of the rest of the three peptaibols in Figure 16 reveals that two
Aib-Pro sequences in positions 5-6 and 9-10 are in common, which should be
introduced by the azirine/oxazolone method at a C-terminal peptide or amino acid by
using methyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate 2 (Scheme 12):
Scheme 12. Reaction of the 2H-Azirin-3-amine 2
N
N
O O
R-COOH   + R-Aib-Pro-OMe
2
So, the following tripeptide sequences have to be prepared: Val-Aib-Pro, Leu-
Aib-Pro, and Ile-Aib-Pro. Whereas Val-Aib-Pro is only a segment of HM A1, Leu-Aib-
Pro is a common sequence in both HM A1 (residues 8-9-10) and HM A3 (residues 4-5-
6), which allows to use this segment in both syntheses. Moreover, HM A1 and HM A5
contain the same C-terminal pentapeptide Leu-Leu-Aib-Pro-Leuol (residues 7-11). This
will help to reduce the number of reaction steps. Finally, HM A3 and HM A5 contain
the common tripeptide sequence Ile-Aib-Pro (residues 8-9-10 for HM A3 and 4-5-6 for
HM A5). As the sequence Aib-Pro should be introduced at the very beginning of the
synthesis, a large amount of methyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinat has to
be prepared. This was not a real problem because, firstly, its synthesis is well known,
and secondly, its synthesis could be optimized significantly.
The complete strategy for the syntheses is shown in Figure 17 on the next page.
The common parts of HM A1, A3 and A5 are highlighted.
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Figure 17. Overview of the Syntheses of HM A1, A3 and A5
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We can see that the total number of steps for the synthesis of the three HM
sequences can be reduced to 31 which is about 2/3 of the initial number of 45. With the
goal of receiving 200 mg of each target molecule, a “backward calculation” (Figure 18)
with an hypothetical "pessimistic" yield for each step (Protocol A: 50-70% according to
the size of the peptide or amino acids to be coupled; protocol B: 70 %; protocol C: 70
%; protocol D: 70-85% according to the size of the peptide), was performed.
Figure 18. Calculation of the needed Amount of Material for the Synthesis of HM A1
(calculations for HM A3 and HM A5 are similar)
In accordance with our negative experience by coupling two long sequences in
the synthesis of the Zervamicin II-2 segment [52], we decided to prepare the three
Hypomurocins from the three segments 1-3, 4-6 and 7-11.
7.2.2 Preparation  of the 2H-Azirin-3-amine 2
As a relatively large amount of methyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-
prolinat was needed, an attempt to optimize the synthesis was made. The following
reactions were optimized for the synthesis of 2. These considerations should be
applicable for the synthesis of any 2H-azirin-3-amine, as long as a solution of COCl2 in
toluene is used (in contrast to the synthesis of 2 and 3 by using COCl2 gas [51]), and for
the 2H-azirin-3-amine, which does not contain the hydroxyproline unit in its second
position, to avoid the formation of 36 (see chapter 6.2.2 [53]).
The synthesis of the needed amount of 2 for the introduction of the sequence
Aib-Pro was prepared according to [51], and the desired quantity was estimated on the
basis of reported yields. In [51], the overall yield of 2 from methyl N-(2-
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methylpropanoyl)-L-prolinate (59) is reported to be ca. 30% (i.e. 59 → methyl N-(2-
methylpropanthioyl)-L-prolinate (60; 45 min reaction time, purification by flash column
chromatography on SiO2 and distillation, 60%) and 60 → 2 (purified by two subsequent
flash column chromatographies on SiO2, 52%)). Actually, we could considerably
optimize these procedures resulting in a reduction of time, costs and chemicals. In the
present work, the thionation of 59 to lead to 60 was carried out overnight and gave 60 in
93% yield (a small extract of the crude material was purified to determine the yield)
without any side reaction (Scheme 13).
Scheme 13. Thioamide Intermediate 60 in the Synthesis of 2
N
O CO2Me
Lawesson
reagent
N
S CO2Me
2. DABCO
3. NaN3
N
N
CO2Me
59 60 2
1. COCl2/Toluene
The thioamide 60 was filtered through a Celite pad, whereupon the color of the
mixture turned from deep brown to pale yellow. A thin layer chromatography of the
mixture indicated that only two very minor impurities remained, and the product was
used without further purification for the next step. At ca. 0°, 60 crystallized from the
crude mixture to give crystals that were suitable for an X-ray crystal-structure
determination (Figure 19).
Figure 19. ORTEP Plot [86] of the Molecular Structure of the Thioamide 60 (50%
probability ellipsoids; arbitrary numbering of the atoms)
The crystal of 60 was enantiomerically pure, and the absolute configuration of
the molecule has been determined independently by the diffraction experiment,
establishing that the molecule has the expected (6S)-configuration.
As it is known that 2H-azirin-3-amines frequently decompose on SiO2, it was
decided to avoid the purification and to use the crude material for the peptide synthesis.
With the aim of determining the yield of the synthesis of 2, the coupling reaction with
Z-Val-OH to give Z-Val-Aib-Pro-OMe (61), the yield of which has been reported [51],
was carried out. With the assumption of an 86% yield for the coupling reaction [51], the
purity of 2 could be estimated as ca. 80%. Therefore, the overall yield of the synthesis
of 2 from 59 was ca. 70% i.e., ca. 40% higher than reported for the previous synthesis.
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Of course, after the coupling reaction, the crude 61 contains the impurities of the
thioamide and azirine syntheses. But there has been no evidence of side effects or
alteration of the product due to these impurities, and, while it was not possible to purify
2 without significant loss of material, the tripeptide 61 could be easily purified by flash
chromatography.
In conclusion, the reaction time in the thioamide synthesis can be extended to 15
h without undesired side effects leading to an increase of the yield more than twice.
Furthermore, no purification of the 2H-azirin-3-amine 2 is necessary, thus avoiding the
loss of material during chromatography. The purity of 2 is about 80%, and the dragged
impurities are easily separable by flash column chromatography after the first coupling
with 2.
7.2.3 Hypomurocin A1
For the coupling of the segments and/or amino acids, the TBTU/HOBt method
was used successfully. The Z group was chosen to protect the N-terminus of peptides
and amino acids, and its deprotection was performed under an H2 atmosphere with Pd/C
(5%). The hydrolysis of methyl esters was achieved with LiOH (3 equiv.) in
THF/MeOH/H2O 3:1:1 overnight, and the tert-butyl ester was cleaved with TFA in 90
min.
Scheme 14. Synthesis of the Pentapeptide 67
Z-Leu-OH + 2 Z-Leu-Aib-Pro-OMe
62 (99%)
CH2Cl2
r.t., N2
Z-Leu-Aib-Pro-OH
63 (98%)
LiOH
r.t., N2
THF:MeOH:H2O
3:1:1
H-Leuol+63 Z-Leu-Aib-Pro-Leuol
64 (94%)
TBTU/HOBt
r.t., N2
TEA cat., MeCN
H-Leu-Aib-Pro-Leuol
65 (quant.)
H2, Pd/C
r.t.
Z-Leu-OH + 65
TBTU/HOBt
r.t., N2
TEA cat., MeCN
Z-Leu-Leu-Aib-Pro-Leuol
66 (86%)
H2, Pd/C
r.t.
H-Leu-Leu-Aib-Pro-Leuol
67 (98%)
The synthesis started with the coupling of Z-Leu-OH with the 2H-azirin-3-amine
2 in CH2Cl2 at room temperature overnight under an N2-atmosphere to give the
tripeptide 62 in 99% yield (Scheme 14). The latter was hydrolyzed to give 63 in 98%
yield. Until this step, the synthesis was run in triple quantity as 63 will be used in the
syntheses of HM A1, HM A3, and HM A5. A convenient amount of 63 was put aside
for the synthesis of HM A3. The hydrolyzed tripeptide 63 was coupled with the α-
amino alcohol H-Leuol in 94% yield. The resulting tetrapeptide 64 was quantitatively
deprotected under an H2 atmosphere (Pd/C) to give 65, which was coupled again with
Z-Leu-OH to give 66 in 86% yield. Deprotection of the latter gave the pentapeptide 67
in 98% yield, being the first major segment in the synthesis of HM A1. Here again, a
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convenient amount of the pentapeptide 67 was set aside for the synthesis of HM A5. No
particular problem was met in this part of the synthesis.
The synthesis of the segment 4-6 (Z-Val-Aib-Pro-OH; 68) of HM A1 was
carried out in analogy to that of the segment 7-11 by the coupling reaction of Z-Val-OH
with 2, followed by the hydrolysis of the resulting product 61 (Scheme 15). It is worth
mentioning that the coupling reaction occurred with the surprisingly high yield of 98%
by using 1.2 equiv. of 2.
Scheme 15. Synthesis of the Tripeptide 68
Z-Val-OH + 2 Z-Val-Aib-Pro-OMe
61 (98%)
CH2Cl2
r.t., N2
Z-Val-Aib-Pro-OH
68 (95%)
LiOH
r.t.,N2
THF:MeOH:H2O
3:1:1
Suitable crystals of 68 for an X-ray crystal-structure determination were grown
from MeOH (Figure 20). The asymmetric unit contains one molecule of 68 and
disordered solvent molecules, which are estimated to be one H2O and one MeOH
molecule. Both NH groups are involved in intermolecular H-bonds.
Figure 20. ORTEP Plot [86] of the Molecular Structure of the Tripeptide 68 (50%
probability ellipsoids; arbitrary numbering of the atoms)
The amide H-atom of Val1 forms an intermolecular H-bond with the C-terminal
carbonyl O-atom of a neighboring molecule. The amide H-atom of Aib2 forms an
intermolecular H-bond with the carbonyl O-atom of the Aib2 of a different neighboring
molecule. The combination of these interactions links the peptide molecules into a two-
dimensional network. The terminal COOH group probably forms a H-bond to a H2O
molecule, as a H···O distance of about 1.8 Å was detected during attempts to model the
solvent molecules.
The first critical step in the synthesis of HM A1 5 was expected to be the
coupling of the two segments 68 and 67. The TBTU/HOBt coupling led to the
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octapeptide 69 in 55% yield (Scheme 16) 1). This relatively low yield could indicate that
the conformation of the two peptides is somehow hindered, resulting in a difficult
coupling. The deprotection of the octapeptide 69 to give 72 was performed in 85%
yield.
Scheme 16. Synthesis of the Octapeptide 71
H-Leu-Leu-Aib-Pro-Leuol
68
67
69 (55%)
Z-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
HOBt/TBTU
71 (85%)
H2, Pd/C
H-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol69
(+ 70)
(+ 72)
Z-Val-Aib-Pro-OH
+
MeOH
TEA, MeCN
It is usually quite difficult to obtain good crystals of linear peptides, but, in the
case of 69, beautiful long needle crystals were obtained, so an X-ray crystal-structure
determination was carried out (Figure 21).
The space group permits the compound in the crystal to be enantiomerically
pure, but the absolute configuration of the molecule was not determined. The
enantiomer used in the refinement was based on the expected (S)-configuration of all
peptide units in the molecule, and the structure determination confirmed that no
unexpectedly inverted peptide units are present (cf. the (R)-proline unit in 72). The
asymmetric unit contains one molecule of 69 plus one half of a molecule of AcOEt,
which is disordered about a C2 axis. The terminal i-Pr atoms of both Leu moieties are
disordered over two conformations. The peptide molecules produce a complex pattern
of inter- and intramolecular H-bonds, although the intermolecular interactions merely
link the molecule into extended chains such that the N termini always point in the same
direction (Figure 23). The Leuol8 OH group forms an intramolecular H-bond with the
Pro7 carbonyl O-atom. The amide H-atom of Val1 forms an intermolecular H-bond with
the hydroxy O-atom of Leuol8 of a neighboring peptide molecule, while the amide H-
atom of Aib2 is H-bonded to the carbonyl O-atom of Pro7. The amide H-atoms of Leu4,
Leu5 and Leuol8 form intramolecular H-bonds with carbonyl O-atoms such that the
corresponding β-turns are formed. Consecutive segments of i,i+3 hydrogen-bonded
elements encode for the 310-helix, which therefore presents the dominating secondary
structural element in this peptide. In addition, the amide H-atom of Aib6 is involved in a
π-turn.
The molecular packing of 69 clearly shows the typical S-shape structure of the
helices. There are no intermolecular H-bonds between the polypeptide chains. The
disorder in some peptide side groups and the presence of AcOEt molecules in the
crystal have little influence on the S-shape structure, and there are no H-bonds between
                                                
1) The mixture, which was obtained after the coupling reaction, showed two different
spots on the TLC. After their separation and NMR characterisation, the main spot
proved to be the expected product 69, and the second one was very close to 69. The
MS of this minor product 70 proved that it had the same molecular weight as 69.
Nevertheless, this minor product was disregarded.
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the solvent and the helical peptide 69. This type of self-association is known for other
peptaibols, like, e.g., Trichotoxin A50E [38], which form transmembrane ion channels.
Figure 21. ORTEP Plot [86] of the Molecular Structure of 69 (conformation A; 50%
probability ellipsoids; arbitrary numbering of the atoms)
The superimposition of the two conformations of the peptide molecule 69 shows
their similarity (Figure 22).
Figure 22. Superimposition of the two Conformations A and B of the Molecular
Structure of 69
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The next step in the synthesis was the deprotection of the N-terminus of 69, i.e.
the hydrogenolytic cleavage of the Z group. The mixture showed again two spots on the
TLC, and two products, 71 and 72, were isolated. The NMR characterization
established that 71 (Rf(B) = 0.06) was the expected product.
a)
b)
Figure 24. a) ORTEP Plot [86] of the Molecular Structure of the Octapeptide 72 (50%
probability ellipsoids; arbitrary numbering of the atoms); b) The Molecular Packing
Projected down the b-Axis showing the H-Bonding Scheme (equivalent isotropic spheres
for atoms; uninvolved H-atoms omitted for clarity)
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The second one, 72 (Rf(B) = 0.24), has again a structure very similar to that of
71. The crystal structure of 72 was determined (Figure 24) and proved unequivocally
that 72 was the epimer of 71 with a (R)-configured Pro10 2).
The space group permits the compound 72 in the crystal to be enantiomerically
pure, but the absolute configuration of the molecule has not been determined. The
enantiomer used in the refinement was based on the presumed (S)-configuration for the
majority of the peptide units of the molecule. Based on this assumption, the molecule
has the (3S, 9S, 12S, 15S, 21R, 24S)-configuration. The asymmetric unit contains one
molecule of the peptide plus one site which is 50% occupied by a H2O molecule. The
intermolecular interactions link the peptide and H2O molecules into two-dimensional
networks. Each NH group of the molecule, except for the amide H-atom of Aib2, acts as
a donor for H-bonds. The NH2 group forms two intermolecular H-bonds. One
interaction is with the O-atom of the H2O molecule, while the second interaction is with
the carbonyl O-atom of Leu4 of a neighboring molecule. Although the H-atoms of the
H2O molecule could not be located reliably, the H-bond donor interactions of the H2O
molecule can be estimated from suitable O···O distances. The H2O molecule donates
one H-bond to the carbonyl O-atom of Leu4 (O···O = 2.91(1) Å) of 72 in the same
asymmetric unit, and a second H-bond to the carbonyl O-atom of Pro7 of a different
neighboring peptide molecule (O···O = 2.68(1) Å). The combination of all
intermolecular interactions generates a two-dimensional network of peptide and H2O
molecules. Aside from the amide H-atom of Aib2, the NH and OH groups form
intramolecular H-bonds. Similar to 69, the amide H-atoms of Leu4, Leu5 and Leuol8
form intramolecular hydrogen bonds which result in the corresponding β-turns, whereas
the amide proton of Aib8 is involved in a π-turn. The Leuol8 OH group forms an
intramolecular H-bond with the Pro7 carbonyl O-atom. Again, the 310 helix is the
dominating secondary structural element in this peptide.
According to the crystal structure of 72, in which the Pro10 residue has the (R)-
configuration, we conclude that 70 and 72 are the respective epimers of 69 and 71 with
(R)-Pro10. The only explanation of this surprising result is that an epimerization had
occurred either during the saponification 62 → 63 or the coupling of H-Leuol with 63
(Scheme 14), although at this stage of the synthesis, no epimerization was detected.
However, Pro residues are not expected to readily undergo racemization as reported in
the literature [73]. Moreover, the amounts of isolated 70 and 72 were very small and
represent ca. 1–2% yield. This epimerization shows that the introduction of the Leuol
unit into the peptide chain of HM A1 is a sensitive step. Therefore, it is advantageous to
carry out this coupling as early as possible in the synthesis.
The synthesis of the last segment Ac-Aib-Gln-Val-OH (51) of HM A1 was
performed by coupling Z-Gln-OH with H-Val-OtBu under the usual coupling
conditions with 80 % yield (Scheme 17). It was very difficult to purify the dipeptide Z-
Gln-Val-OtBu (53) as it has a Rf value close to those of the coupling or additive
reagents. Furthermore, the dipeptide was like a kind of plaster powder and was difficult
to dissolve in polar solvents like MeOH, MeCN. This dipeptide was deprotected at the
                                                
2) Based on this result, we propose that the above mentioned minor product 70, which
has been proved to be an isomer of 69 (Scheme 16), is the corresponding epimer with
an (R)-configured Pro residue. Most likely, 72 is the product of the hydrogenation of
70 as an impurity of 69 (see below).
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N-terminus, leading quantitatively to 55, which is a very viscous oil. The latter was
coupled with Ac-Aib-OH [26] under the usual conditions to give the tripeptide 57 in
only 63% yield, illustrating again the effect of steric hindrance due to the presence of
Aib. Finally, the tert-butyl ester 57 was cleaved with TFA to give 51 quantitatively.
According to our strategy, this last major sequence was synthesized in double amount
and a convenient portion was put aside for the synthesis of HM A3.
Scheme 17. Synthesis of the Tripeptide 51
H-Val-OtBu+ Z-Gln-Val-OtBu
53 (80%)
TBTU/HOBt
r.t., N2
TEA cat., MeCN
H-Gln-Val-OtBu
55 (quant.)
H2, Pd/C
r.t.
Ac-Aib-OH + 55
TBTU/HOBt
r.t., N2
TEA cat., MeCN
Ac-Aib-Gln-Val-OtBu
57 (63%)
TFA
1.5 h
51 (quant.)
Z-Gln-OH
Ac-Aib-Gln-Val-OH
The last step of the synthesis of HM A1 was the coupling of the tripeptide 51
and the octapeptide 71 (Scheme 18). Under the chosen conditions (TBTU/HOBt), the
yield of 5 was again low. This can be explained by a hindered spatial conformation due
to the generally observed rigid helical conformation of peptaibols.
Scheme 18. Last Coupling Reaction to give HM A1(5)
+
TBTU/HOBt
r.t., N2
TEA cat., MeCN
Hypomurocin  A1
5 (41%)
51 71
7.2.4 Hypomurocin A3
The synthesis of HM A3 started by synthesizing the unprotected segment 7-11,
i.e. H-Leu-Ile-Aib-Pro-Leuol (73, Scheme 19). The reaction of Z-Ile-OH with the 2H-
azirin-3-amine 2 gave the protected N-terminal tripeptide methyl ester 74 in 58% yield.
This low yield is unusual for a 2H-azirin-3-amine coupling and can be explained by the
partial decomposition of 2 in the crude fraction, which was kept for over one year
before use. The ester 74 was hydrolyzed with LiOH to give 75 in 80% yield. Until here,
the synthesis had to be run in double quantity according to our strategy. Half of the
amount of 75 was set apart for the synthesis of HM A5, and the synthesis of HM A3
was continued with the other half. The tripeptide Z-Ile-Aib-Pro-OH (75) was coupled
with H-Leuol to give the tetrapeptide Z-Ile-Aib-Pro-Leuol (76) in 63% yield.
Surprisingly, 76 gave crystals of good quality incredibly fast, which were
suitable for an X-ray crystal-structure determination (Figure 25). The tetrapeptide even
started to crystallize from the crude mixture after the evaporation of the solvent. The
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Scheme 19. Synthesis of the Pentapeptide 73
Z-Ile-OH 2 Z-Ile-Aib-Pro-OMe Z-Ile-Aib-Pro-OH
Z-Ile-Aib-Pro-LeuolH-Leuol H-Ile-Aib-Pro-Leuol
Z-Leu-Ile-Aib-Pro-Leuol H-Leu-Ile-Aib-Pro-LeuolZ-Leu-OH
74 (58%) 75 (80%)
76 (63%) 77 (quant.)
78 (97%) 73 (quant.)
+
CH2Cl2
H2, Pd/C
MeOH
N2, r.t.
LiOH, 3 equiv.
THF/MeOH/H2O
3:1:1
75 +
TBTU/HOBt
TEA, MeCN
N2, r.t.
77 +
TBTU/HOBt
TEA, MeCN
N2, r.t.
H2, Pd/C
MeOH
crystal structure shows that the hydroxy group and the adjacent amide H-atom of
Leuol4, form intramolecular H-bonds with the carbonyl O-atom of Ile1 that are seven
atoms back along the peptide backbone. This serves to maintain the helical
conformation of the peptide.
Figure 25. ORTEP Plot [86] of the Molecular Structure of 76 (50% probability
ellipsoids; H-atoms given arbitrary displacement parameters for clarity)
The amide H-atoms of Ile1 and Aib2, which are unable to form an intramolecular
interaction because of their position in the backbone, form intermolecular H-bonds with
the carbonyl O-atom of Pro3 of a neighboring peptide molecule, although the latter
interaction is very weak. These intermolecular interactions link the molecules into
extended chains.
The purification of the tetrapeptide 76 by flash column chromatography led to a
very small amount of a second product 79, which was crystallized and its structure
resolved by X-ray analysis (Figure 26). The structure of 79 proved to be almost
identically with that of 76 except for the configuration of the Pro3 residue, which is R.
Although peptide couplings with HOBt additives are known to reduce the
epimerization, we assume that the introduction of H-Leuol at this position is a weak
point in the synthesis as analogous results were obtained in the synthesis of HM A1.
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The yields for this coupling reaction are 63% for 76, and additional 1-2% of 79 were
isolated. Consequently, the epimerization occurs only to a small extent.
The X-ray crystal structure analysis of 79 (Figure 26) does not allow to draw
conclusions for bond lengths or angles that might appear to be unusual because of the
poor overall quality of the crystals. The precision of the geometric parameters is also
low for the same reason. The space group permitted the compound in the crystal to be
enantiomerically pure, but the absolute configuration of the molecule has not been
determined. The enantiomer used in the refinement was based on the known S-
configuration of most chiral centers in the molecule, but the configuration of Pro3 is R.
There are two symmetry-independent molecules in the asymmetric unit, which have
both the same stereochemistry.
Figure 26. ORTEP Plot [86] of the Molecular Structure of 79 (50% probability
ellipsoids; H-atoms given arbitrary displacement parameters for clarity)
Each hydroxy and amide group of each symmetry-independent molecule 79 acts
as a donor for H-bonds. The hydroxy group in each molecule forms an intramolecular
H-bond with the amide O-atom of the second peptide unit from the benzyl end of the
molecule. The amide H-atom of Ile1 in molecule A forms an intermolecular H-bond
with the hydroxy O-atom of molecule B. In turn, the corresponding amide group of
molecule B interacts in the same way with the original molecule A. The amide H-atom
of Aib2 in molecule A forms an intermolecular H-bond with the Aib2 amide O-atom
from an adjacent molecule A and thereby links the A molecules into extended chains.
The identical interaction links the B molecules into extended chains which run
antiparallel to the chains of A molecules. Finally, the amide H-atom of Leuol4 in
molecule A forms an intermolecular H-bond with the amide O-atom of the second
peptide unit from the benzyl end of the molecule. The combination of the intermolecular
interactions leads to a two-dimensional network of A and B molecules that lies parallel.
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The deprotection of 76 with Pd/C under an H2-atmosphere gave H-Ile-Aib-Pro-
Leuol (77) quantitatively, from which also suitable crystals for an X-ray structure
determination could be obtained (Figure 27).
The space group permits the compound 77 in the crystal to be enantiomerically
pure, but the absolute configuration of the molecule has not been determined. The
enantiomer used in the refinement was based on the known S-configuration of Ile1 in the
molecule. All stereogenic centers in the molecule have the S-configuration. The
asymmetric unit contains two molecules of the peptide, both of which are the same
stereoisomer, plus a site for a water molecule that is both partially occupied and
disordered about a C2-axis. Thus, the peptide/H2O ratio in the crystal is 8:1. The Ile
group in one of the independent peptide molecules (molecule B) is disordered over two
significantly different conformations. The conformations of molecules A and B also
differ significantly in the orientations of the Leuol4 end of the peptide chain. Each
independent peptide molecule displays one intramolecular and several intermolecular
hydrogen bonds. The intermolecular interactions link the peptide molecules into a two-
dimensional network.
In each of the symmetry-independent peptide molecules 77, the amide H-atoms
of Leuol4 form an intramolecular H-bond with the Aib2 amide O-atom that is seven
atoms back along the peptide backbone. In molecule A, the terminal amine group forms
intermolecular H-bonds with amide O-atoms of a neighboring molecule A (Pro3) and a
neighboring molecule B (Leuol4). The terminal amine group of molecule B only forms
one H-bond, that being with the Leuol4 amide O-atom of another molecule B.
Figure 27. ORTEP Plot [86] of the Molecular Structure A of 77 (50% probability
ellipsoids; H-atoms given arbitrary displacement parameters for clarity)
The amide H-atom of Aib2 of molecule A forms an intermolecular H-bond with
the hydroxy O-atom of the same neighboring molecule A that accepts the interaction
from the terminal amine group. This interaction links the A molecules into chains. The
amide H-atom of Aib2 of molecule B forms an intermolecular H-bond with the Leuol4
amide O-atom of a neighboring molecule A. Together, the intermolecular interactions
link the molecules into two-dimensional networks which lie parallel. Although the H-
atoms of the H2O molecule could not be located, the H2O molecule is close to the
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hydroxy O-atoms of peptide molecules A and B and can be assumed to be involved in
H-bonding interactions with these groups.
Finally, 77 was coupled to Z-Leu-OH to give the pentapeptide Z-Leu-Ile-Aib-
Pro-Leuol (78) in 97% yield, which was deprotected to give quantitatively 73, i.e. the
segment 7-11 of HM A3. It is worth to emphasize the surprisingly high yield of the
formation of 78. Then, 73 was coupled with Z-Leu-Aib-Pro-OH (63), which was set
apart in the synthesis of HM A1 (Chapter 7.2.3). The protected octapeptide Z-Leu-Aib-
Pro-Leu-Ile-Aib-Pro-Leuol (80) was obtained in 97% yield, which is again a
surprisingly high yield for such a coupling reaction. The octapeptide 80 was deprotected
to give H-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol (81) in 98% yield. Finally, HM A3 was
obtained by the successful coupling of 81 with Ac-Aib-Gln-Val-OH (51) in 68% yield
(Scheme 20). The latter had also been prepared in the synthesis of HM A1.
Scheme 20. Last Coupling Reaction to give HM A3 (6)
Z-Leu-Aib-Pro-OH Z-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol
H-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol
Ac-Aib-Gln-Val-OH
HM A3
H-Leu-Ile-Aib-Pro-Leuol+
63 73 80 (97%)
81 (98%)
51
6 (68%)
TBTU/HOBt
TEA, MeCN
N2, r.t.
80
MeOH
H2, Pd/C
TBTU/HOBt
TEA, MeCN
N2, r.t.
+
Suitable crystals of HM A3 for an X-ray structure determination could be
obtained (Figure 28). Surprisingly, HM A3 did crystallized in presence of the bacterium
E. Coli during the biological in-vitro assays. It is worth mentioning that no crystals were
formed in the analogous solution without E. Coli.
The crystals were quite small needles of poor quality and were very weakly
diffracting. As a result, there was a paucity of data and the overall quality of the
structure was significantly lower than desirable. The overall molecular conformation
was clearly defined, but the large standard uncertainties on the geometric parameters
mean that no far-reaching conclusions should be drawn from a detailed analysis of
individual bond lengths, bond angles or torsion angles. The space group permits the
compound in the crystal to be enantiomerically pure, but the absolute configuration of
the molecule has not been determined. The enantiomer used in the refinement was based
on the known (S)-configuration of all peptide units in the molecule. The structure
determination confirmed that there were no unexpectedly inverted peptide units present.
The asymmetric unit contains one peptide molecule and one disordered water molecule.
The peptide molecule displays disorder in several side chains. These are the terminal
two methyl groups of Leu4 and the terminal methyl groups of Leuol11, as well as three
of the ring C-atoms of Pro10. Most of the amide groups are involved in intramolecular
H-bonds, but a few intermolecular interactions exist and serve to link the peptide and
H2O molecules into a two-dimensional network (Figure 29).
The hydroxy group forms an intermolecular H-bond with the amide O-atom of
the central Pro6 of a neighboring molecule. This interaction links the peptide molecules
into extended chains. The primary amide group of the Gln2 side chain forms
intermolecular H-bonds with two different neighboring peptide molecules, with the
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acceptor amide O-atoms being on the Pro10 and Aib9 moieties. The amide H-atom of Aib1
forms an intermolecular H-bond with the O-atom of the disordered H2O molecule.
Although the H-atoms of the H2O molecule could not be located, suitable O···O distances
suggest that the water molecule donates two H-bonds. One interaction is with the
hydroxy O-atom in the peptide molecule from which the amide H-atom of Aib1
interaction originates, and thereby links pairs of peptide and H2O molecule into loops.
The second interaction is with the amide O-atom of the Gln2 side chain of a different
peptide molecule, which thereby links pairs of peptide and H2O molecule into chains. All
of the intermolecular H-bonding interactions combine to link the peptide and H2O
molecules into two-dimensional networks. With the exception of the amide H-atom of
Aib9, which is not involved in any H-bonding interaction, all amide groups not mentioned
above form intramolecular H-bonds with amide O-atoms. The amide H-atoms of Val3,
Pro6, Ile8, and Leuol11 form intramolecular H-bonds with the amide O-atoms that are
seven atoms back along the peptide backbone. The amide H-atoms of Gln2 forms an
intramolecular H-bond with the amide O-atom of the Gln2 side chain, thereby creating a
loop. The amide H-atoms of Leu4 and Aib5 do not interact as expected with the carbonyl
O-atoms of Aib1 and Gln2, respectively, but interact instead with the carbonyl O-atoms of
Ac and Aib1, respectively, to give loops.
7.2.5 Hypomurocin A5
The synthesis of HM A5 is rather short in comparison to those of HM A1 and
A3. It can be resumed to the synthesis of the segment 1-3 (Ac-Aib-Gln-Ile-OH; 52).
The other part of the synthesis is the coupling of the two segments 4-6 (Z-Ile-Aib-Pro-
OH; 75) from the HM A3 synthesis and 7-11 (H-Leu-Leu-Aib-Pro-Leuol; 67) from the
HM A1 synthesis and, after the deprotection of the segment 4-11, the coupling with 52.
The synthesis of 52 is analogous to that of 51 (Scheme 21).
Scheme 21. Synthesis of the Tripeptide 52
Z-Gln-OH + H-Ile-OtBu Z-Gln-Ile-OtBu
54 (90%)
HOBt
TBTU
H-Gln-Ile-OtBu
56 (quant.)
H2, Pd/C
Ac-Aib-OH + 56
HOBt
TBTU
Ac-Aib-Gln-Ile-OtBu
58 (66%)
TFA Ac-Aib-Gln-Ile-OH
52 (quant.)
MeCN, TEA
r.t., N2
MeOH
MeCN, TEA
r.t., N2
1.5 h
The coupling of Z-Gln-OH with H-Ile-OtBu gave the dipeptide 54 in 90% yield.
This compound had the same plaster-like properties as 53 in the synthesis of HM A1
and was also difficult to dissolve in polar solvents. The deprotection of 54 under an H2-
atmosphere (Pd/C) led quantitatively to 56 as a colorless oil. The coupling of Ac-Aib-
OH with 56 gave the tert-butyl protected tripeptide 58 in 66% yield. The latter was
hydrolyzed with TFA in 1.5 h to give 52, the segment 1-3 of HM A5 (7), in quantitative
yield.
Finally, the coupling of the three segments 1-3, 4-6 and 7-11 of HM A5 was
achieved by using the TBTU/HOBt method (Scheme 22).
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Scheme 22. Last Coupling Steps to give HM A5 (7)
Z-Ile-Aib-Pro-OH H-Leu-Leu-Aib-Pro-Leuol
75 67
Z-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
82 (64%)
H-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
HM A5
7 (31%)
52
83 (quant.)
+
TBTU/HOBt
Ac-Aib-Gln-Ile-OH
+
MeCN, TEA
r.t., N2
82
H2, Pd/C
MeOH
HOBt
TBTU
MeCN, TEA
r.t., N2
The Z-protected octapeptide 82 was obtained by the condensation of 75 and 67
with TBTU/HOBt in 64% yield. Suitable crystals of 82 for an X-ray crystal structure
determination were obtained (Figure 30). The deprotection of 82 under the usual
conditions gave the octapeptide 83 quantitatively, which was coupled to the previously
synthesized tripeptide 52 to give HM A5 in 31% yield.
The space group permits the compound in the crystal to be enantiomerically
pure, but the absolute configuration of the molecule has not been determined. The
structure determination of 82 confirms that all peptide units do indeed have the S-
configuration. There are two symmetry-independent molecules in the asymmetric unit.
Both have the same stereochemistry although their conformations are slightly different.
Some of the side chains in each molecule are disordered over two conformations: the i-
Pr side chain of Leuol8 and the entire side chain of Leu5 of molecules A and B,
respectively as well as the i-Pr side chain of Leu4 in molecule A and the entire side
chain of Ile1 in molecule B. In addition, Pro3 of each molecule has two envelope
conformations with the C-atom of the envelope flap being "up" or "down". The
asymmetric unit includes two molecules of the peptide plus two disordered solvent
molecules, which, from the arrangement of residual electron density peaks, appeared to
be AcOEt. The disorder of the solvent molecules could not be modeled adequately.
Therefore, the contribution of the solvent molecules to the intensity data was removed
by using the SQUEEZE routine [89] of the PLATON program [90].
The hydroxy group in each molecule forms an intramolecular H-bond with the
amide O-atom of Pro7, thereby forming a loop. The amide H-atom of Ile1 in molecule A
forms an intermolecular H-bond with the hydroxy O-atom of a neighboring molecule A.
This interaction links the A molecules into extended chains. The corresponding
interaction also links the B molecules into extended chains. The amide H-atom of Aib2
in molecule A forms an intermolecular H-bond with the amide O-atom of Leu5 of the
same neighboring molecule A that accepts the N-H...O interaction with the amide H-
atom of Ile1, so that this interaction is also a link in the chains described above.
Molecule B behaves in an identical fashion. The amide H-atoms of Leu4, Leu5, Aib6 and
Leuol8 form intramolecular H-bonds with the amide O-atoms that are seven atoms back
along the peptide backbone. Each of these interactions serve to maintain a fairly rigid
helical conformation of the peptide. The same pattern of intramolecular interactions
occurs in molecule B with one exception. The amide H-atom of Aib6 in molecule B,
does not interact as expected with the carbonyl O-atom of Pro3 in molecule B, but
interacts instead with the carbonyl O-atom of Aib2 in molecule B to give a loop.
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a)
b)
Figure 30. a) ORTEP Plot [86] of the Molecular Structure of 82 (conformation A, 50%
probability ellipsoids; arbitrary numbering of the atoms); b) Superimposition of the two
conformations A and B of the Molecular Structure of 82
The N···O and H···O distances for N(Aib6, molecule B)-H···O(Pro3, molecule B)
are 3.641(6) and 3.00 Å, respectively, and are well beyond the distance considered to be
an indication of an H-bonding interaction. Presumably this difference results from a
small difference in the turn structure of molecule B compared with that in molecule A.
Superposition of the two molecules shows that although the conformations at the Z-end
are similar, small deviations develop after the Pro3 unit.
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7.2.6 HPLC Corr elation between Synthetic and Natural Hypomurocins
The synthetic HM A1 (5), HM A3 (6) and HM A5 (7) peptaibols were analyzed
individually or as defined mixtures with the fraction containing the set of Hypomurocins
A (HM A) of the extract of the fungus H. muroiana by reversed-phase HPLC-ESI-MS.
Figure 32 shows representatively the base peak chromatogram (BPC) of the natural
fungus extract and of mixtures of the natural extract with the three synthetic materials.
According to Brückner and co-workers, the HM A fraction is a mixture composed of six
structurally similar peptaibols possessing three different quasi-molecular ions ([M +
H]+) [88]. In our experiment, the natural peptaibol HM A1 ([M + H]+, m/z 1161) was
recorded at tR 28.5 min, the three compounds HM A2, A3, and A4 ([M + H]+, m/z 1175
each) were all co-eluting at tR 29.5 min, and the isomeric HM A5 and A5a ([M + H]+,
m/z 1189 each) were recorded at tR 30.7 min (Figure 32d). It is easily recognised from
these chromatograms that the addition of synthetic HM A1 to the natural mixture
induces an increase of the peak at tR 28.9 min (Figure 32c). The same experiment
performed with synthetic HM A3 produces an increase of the peak at tR 29.7 min
(Figure 32b) and the addition of synthetic HM A5 results in an increase of the peak at tR
31.2 min (Figure 32a).
The synthetic peptaibols were further analysed by MS/MS to attest their amino
acid sequences (see Experimental Part). Due to the presence of two proline residues in
the HM A peptaibols, abundant fragment ions of the b- and y-type (Nomenclature of the
peptide fragment ions according to Roepstorff and Fohlman [91] and Biemann [92])
deriving from cleavages of the amide bond adjacent to the proline N-terminus, are
observed in the mass spectra. This gas-phase behaviour of proline-rich peptides has
already been reported [93]. In consequence, the intensities of the quasi-molecular ions
[M + H]+ observed for the HM A derivatives were low (<1% rel. intens.). The MS/MS
data obtained clearly indicated the amino acid sequence of the three synthetic
compounds and were identical with the ones recorded for the natural products, thus
confirming the structures proposed by Brückner and co-workers [88].
(see next page)
Figure 32. HPLC-ESI-MS Base Peak Chromatograms (BPC) Representing the
Hypomurocin A (HM A) Fraction of H. muroiana Spiked with Synthetic HM A5 (a), HM
A3 (b), and HM A1 (c) as well as the BPC of the Natural HM A Sample (d)
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7.2.7 Conclusion
In conclusion, the three Hypomurocins A1, A3 and A5 were successfully
synthesized. We have shown that the introduction of the two Aib-Pro units via the
azirine/oxazolone method occurs with almost quantitative yield. The yields were
conform or better than expected (see preliminary calculation). The ester hydrolysis with
LiOH and deprotection with TFA were also performed in very high yield, as well as the
deprotection of the Z group and the coupling of small peptide segments. As expected,
the sensitive points in the synthesis were the coupling reactions of the segments: they
have been achieved in 41% yield for the final coupling of 51 and 71 and 55% yield for
the coupling of 68 and 67 to give the octapeptide 69. The introduction of the hindered
Ac-Aib-OH was accomplished in 63% yield. In the case of HM A3 the yields were
excellent, being almost quantitative for five steps. Even the last coupling leading to HM
A3 was performed with high yield (68%). For HM A5, yields are also good, except for
the final coupling to give HM A5 in only 31% yield as well as for the introduction of
Aib1 with only 66% yield.
An epimerization occured at the Pro10 residue in the synthesis during the
preparation of the segments 8-11. This was the only epimerization observed in the
synthesis of the three Hypomurocins. Although the epimer could be separated and
isolated, its amount was negligible in term of yields.
These total syntheses illustrate the advantages of the azirine/oxazolone method
in the synthesis of peptaibols. Several intermediates or final products were obtained as
crystals suitable for X-ray structure determination, which confirmed the helical structure
of Aib containing oligopeptides. The final HPLC correlation between synthetic and
natural Hypomurocin proved to be in accordance, confirming thus the original analytical
work on the Hypomurocins of Brückner.
7.3 Three-Dim ensional NMR Investigations
These investigations concern only the Hypomurocin HM A1. The investigations
for HM A3 and HM A5 will be reported in a coming publication [94].
7.3.1 Three-Dimensional Model in Solution
As expected in the case of peptaibols, the presence of several Aib moieties in the
molecule induces a helical conformation despite the presence of Pro moieties, which
appear just after the Aib units in the HM A1 sequence.
The structure studies in (D6)DMSO solution by NMR spectroscopy, i.e. the
ROESY spectra, showed many characteristic sequential and medium-range NOE
connectivities which revealed a well-defined helical conformation of HM A1 with
tendencies for the formation of type I(III) β-turns (Figure 33).
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a)
b)
Figure 33. a) Superposition of the Final 20 NMR Structures for HM A1. The Residues
are Color-coded as Following: Aib blue, Gln red, Val orange, Pro green and Leu
brown; b) A Typical NMR Structure in Ball-and-Stick Representation. The Secondary
Structure is shown in Ribbon Representation
In particular, the presence of significant sequential NN NOEs, as well as the
medium-range αN (i,i+2), (i,i+3) and (i,i+4) and αβ (i,i+3) NOEs were clearly evident
for helical and turn-like motives (Figure 34). The calculated average structures display
a well-defined family of conformation with a RMSD value of the backbone atoms to the
mean structure of 0.64 Å, and, excluding the more flexible N- and C-terminal residues 1
and 11, of 0.47 Å.
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Figure 34. Summary of Sequential and Medium-Range of NOE Connectivities for HM
A1 in DMSO (left) and bound to DPC Micelles (right). NOE Intensities are represented
by the Line Thickness (the Hδ-Atoms of Pro are considered as Amide H-Atoms, and the
Hβ-Atoms of Aib as Hα-Atoms)
Considering the backbone torsion angles φ and ψ determined from the calculated
structures, distortions from the ideal φ,ψ angles of a right-handed α-helix were observed
(Table 2).
Table 2. 3JHN-Hα Coupling Constants Derived from the 1D 1H-NMR Spectra, and
Calculated φ and ψ Angles of the NMR Structures
Residue 3JHN-Hα  (Hz) φ (°) ψ (°)
Aib1 - -165 ± 86.1 8.3 ± 53.2
Gln2 5.4 -50.1 ± 74.3 3.3 ± 5.2
Val3 7.1 -91.9 ± 2.2 16.8 ± 0.6
Val4 8.5 -108.8 ± 0.2 -16.5 ± 0.4
Aib5 - -41.0 ± 1.8 -63.6 ± 0.6
Pro6 - -62.8 ± 0.8 -25.7 ± 4.7
Leu7 7.1 -81.1 ± 6.1 -26.2 ± 5.1
Leu8 9.2 -109.3 ± 0.6 22.5 ± 1.2
Aib9 - -39.3 ± 0.2 -54.7 ± 0.3
Pro10 - -67.6 ± 0.2 -1.2 ± 0.2
Leu11 8.9 -141.5 ± 8.5 50.6 ± 83.1
In particular, the large 3JHN-Hα coupling constants (>8.5 Hz) at residue 4, 8 and
11, resulting in extended torsion angles φ, are more likely in β-type structures. In the
case of residue 8, a type I β-turn was observed with Leu7-Leu8 at positions i+1 and i+2,
respectively.
Finally, HM A1 seems to adopt a stable mixed helical conformation in DMSO-
solution with typical structure elements of α-helices, 310-helices and type I β-turns.
7.3.2 Three-Dimensional Model in Deuterated Micelles
Earlier studies of the structures of peptaibols in solution have been performed
mainly in methanol [95]. Later, it was recognized that perdeuterated detergent micelles
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display superior properties and led to better-defined structures (see e.g. the work of
Anders et al. describing the structure of Chrysospermin [96] or by Condamine et al. in
the case of Trichorzianin TA VII [97]). Since HM A1 represents a membrane-active
peptide, the structure of the peptaibol in a membrane-mimicking environment was
determined by applying a methodology used earlier (see for example [98]) and
described in more detail in [99]. In the present studies, perdeuterated
dodecylphosphocholine (DPC) micelles [100] were used in order to mimick biological
membranes. The NOESY spectra in DPC micelles revealed rather strong sequential
correlations between amide H-atoms. In general, the latter were stronger than the
corresponding αN(i,i+1) correlations and proved that the backbone fold is
predominantly helical and not extended or unfolded. Moreover, some αβ(i,i+3) (or, in
the case of Aib: QB1/QB2-β(i,i+3) and a (non-interrupted) series of αN(i,i+3), and
αN(i,i+2) NOEs was observed (for a summary of the applied restraints see Figure 34).
The latter are usually observed in 310-helices but are usually absent for α-helically
folded peptides [101]. A superimposition of the output of the structure calculation on
the backbone atoms of all residues is displayed in Figure 35.
Figure 35. Left: Backbone Presentation of the Structure of HM A1 in DPC Micelles.
Backbone Atoms of all Residues have been used for the Superposition. The N Terminus
is at the Top. Right: Full-Atom Presentation of a Representative Conformer of HM A1,
in which the Nitrogen-Atoms have been numbered according to their Sequence Position
(color code is : N-atoms blue, O-atoms red, H-atoms white, and C-atoms gray. The
Orientation of the Molecule is the Same on the Left and Right)
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Although the number of medium-range restraints is rather high, the generated
structures cannot be classified according to the Kabsch-Sanders algorithm [102] into a
unique type of helices. Scalar coupling constants, 3JHN,Hα for all residues different from
Aib and Pro were also determined. The values are < 4 Hz (Gln2), 6.0 Hz (Val3), 5.9 Hz
(Val4), 4.2 Hz (Leu7) and 6.5 Hz (Leu8). Although values for stable helices are about 4
Hz, these values are significantly lower than the values for freely rotationally averaged
dihedral backbone angles (about 7 Hz) [103]. They also indicate that the backbone is
not perfectly rigid. Our failure to derive defined structures partly is attributed to residual
flexibility of the peptides, and to the inherently low proton density in such a short
peptide. However, the large number of medium-range NOEs shows that the peptide is
surprisingly well-defined in a membrane-mimicking environment. The presence of a
continuous stretch of αN(i,i+2) NOEs indicates that the structure is predominantly a
310-helix.
Furthermore, the atom coordinates from the structure of HM A1, as determined
by us in a membrane-mimicking environment, were used to compute a space-filling
model. Due to the placement of Pro6 and Pro10 at opposite sides of the helix and the
small steric requirements of this amino acid, the space-filling representation reveals a S-
like shape as in the crystal packing of the octapeptide Z-Val-Aib-Pro-Leu-Leu-Aib-Pro-
Leuol (69) in the HM A1 synthesis (Figure 23).
We notice reasonably good surface complementarities of the front- and backside
of the helix, which allows packing of individual peptide molecules against each other,
thereby maximizing hydrophobic contacts. It is assumed that the biological function of
peptaibols is exhibited by forming channels in membranes. The solution structure of
HM A1 (5) indicates a way, how individual molecules may form larger aggregates,
which result in membrane channels. Chugh et al. [38] have constructed a model of a
helical bundle of Trichotoxin A50E based on the crystal structure of the monomer. In
their model, individual helices aligned parallel to each other resulting in an octameric
aggregate, in which hydrophilic side-chains exclusively point into the center of the
channel. In contrast, the peptaibol HM A1 (5) exclusively consists of hydrophobic
residues. Moreover, the undecapeptide sequence is too short to form a membrane-
spanning helix. We therefore speculate that individual molecules pack against each
other as indicated in Figure 35 (see next page). Two rings, each one resulting from
joining a linear array of molecules, may then associate at the termini of the peptides
forming a longer tube that is now long enough to pass the membrane.
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7.4 In-vitro Bio logical Investigations
7.4.1 Bacteriological Assays
In order to complete this study, the biological and toxicological assays
performed with the three Hypomurocins 5, 6 and 7 are presented here. These
compounds are globally pretty similar (Figure 37) and do differ only in two or three
amino acids. The differences in the side chains are as follows: Ile3 can be regarded as
Val3 with an ethyl group instead of a methyl group, and Leu8 is an isomer of Ile8.
Furthermore, Leu4 can be considered as a "CH2-extended" Val4. All three
Hypomurocins contain only one hydrophilic residue Gln2, and all others residues are
hydrophobic. Thus, a similar reactivity in in-vitro assays can be expected.
1   2   3   4   5   6   7   8   9   10  11
Ac-Aib-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A1
Ac-Aib-Gln-Val-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol HM A3
Ac-Aib-Gln-Ile-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol HM A5
Figure 37. Differences in the Structures of HM A1(5), A3 (6) and A5 (7) are in Bold
The hemolytic activity was tested on blood agar plates prepared with sheep
blood on agar medium in Petri dishes. The peptaibols were dissolved in a H2O/MeOH
solution. In order to avoid the death of bacteria due to pure MeOH, as much as possible
water was added. On the other hand, in order to avoid the precipitation of
Hypomurocins in water, the minimal volume of MeOH was used. Several
concentrations (Table 3) for HM A1, A3 and A5 were used and some activity was
observed after the plates were left overnight at 37 °C for incubation. The plates were
prepared with 20 µl of solution poured over the plates.
Table 3. Ratio of Solvents in which the Hypomurocin is dissolved and Control Solutions
Peptaibol HM A1 HM A3 HM A5
Used Amount 4.4 mg 2.3 mg 2.2 mg
Control Solution a) Solution 1 Solution 2 Solution 2
H2O (%vol.) 60 % 70 % 70 %
MeOH (%vol.) 40 % 30 % 30 %
a) Solution mixture without substance
The plates still contained agar which could react with the substances. Thus, the
hemolyses were compared qualitatively to control samples. HM A1 has shown weak β-
hemolysis activity only at a concentration of 2.2 mg/ml, HM A3 has shown normal β-
hemolysis activity at a concentration of 2.3 mg/ml and weak β-hemolysis at a
concentration of 1.15 mg/ml, and HM A5 has shown very weak β-hemolysis activity
only at a concentration of 2.2 mg/ml. Lower concentrations did not show any activities.
The results are shown in Table 4.
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Table 4. Sheep Blood Plates Hemolysis Results for HM A1, A3 and A5
Substance µg/ml Hemolysis % Methanol Hemolysis
4400 strong 40 weak
HM A1 2200 weak 20 no
1100 no 10 no
2300 strong 30 weak
HM A3 1150 weak 15 no
575 no 7.5 no
2200 weak 30 weak
HM A5 1100 no 15 no
550 no 7.5 no
The MeOH used to dissolve the peptaibols already occasions the hemolysis of
the sheep erythrocytes at the highest used concentrations of 30-40%. Thus, only the
results with solutions containing 20% or less methanol can be taken into account. Under
these experimental conditions, HM A1 and A3 seem to have a greater hemolysis
activity as HM A5.
Another series of assays concerned the microbiological activity. Two Gram
positive (B. Subtilis and S. Aureus) and one Gram negative (E. Coli) bacteria strains
were used. For S. Aureus and E. Coli, the occasioned inhibition due to the MeOH in the
solvent was too close to the supposed inhibition of the peptaibols. Thus, the
experimental values could not be interpreted under these conditions. The minimal
inhibition concentrations (MICs) for B. Subtilis, E. Coli and S. Aureus are shown in
Table 5a, b and c, respectively.
Table 5. MICs for a) B. Subtilis; b) E. Coli; c) S. Aureus
a)
Entry MIC(µg/ml)
Lowest
Crystallization
Conc. (µg/ml) a)
Methanol Control
Smallest Inhibitor
Conc. (%)
HM A1
1 137 137 20
2 137 1100 20
3 68 137 20
4 68 550 20
HM A3
5 144 575 7.5
6 72 288 7.5
7 72 144 7.5
HM A5
8 550 275 15
9 275 137 7.5
10 275 275 7.5
11 550 68 15
a) Lowest concentration of the solution mixture, where the first crystallization was
 observed
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b)
Entry MIC(µg/ml)
Smallest Conc.
Crystallization
(µg/ml)
Methanol Control
Smallest Inhibitor
Conc. (%)
HM A1
12 550 550 5
13 1100 275 20
HM A3
14 288 288 3.6
15 1150 1150 15
16 575 288 15
HM A5
17 275 275 3.6
18 550 275 7.5
19 1100 137 > 15
c)
Entry MIC(µg/ml)
Smallest Conc.
Crystallization
(µg/ml)
Methanol Control
Smallest Inhibitor
Conc. (%)
HM A1
20 >2200 137 20
HM A3
21 575 575 15
HM A5
22 550 137 7.5
High concentration of MeOH inhibits the growth of B. Subtilis and E. Coli.
Methanol's MIC for B. Subtilis and E. Coli varies depending on the control solution
between a MeOH concentration of 7.5 and 20% for B. Subtilis and between 3.6 and
20% for E. Coli. This broad range over three dilution steps could be explained by
different MeOH contents in the control solutions or by an irregular evaporation of the
MeOH while the preparation of the experiment. Therefore, the MICs of the substances
must be interpreted carefully if they are close to the inhibition effect of the solvent. This
concerns HM A3 and HM A5 for B. Subtilis as well as all three substances for E. Coli.
Eventually, a MIC of 137 µg/ml for the substance HM A1 by B. Subtilis could be
observed. At higher concentrations, the substances crystallize. This crystal formation
reduces the concentration of the dissolved substance. Because a control series without
bacteria does not lead to crystals, a certain role played by the bacteria for the
crystallization can be assumed. Although the best crystallization was observed with HM
A1 in the samples containing B. Subtilis, only HM A3 crystals revealed to be suitable
for X-ray analysis. The results are summarized in Table 6.
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Table 6. Summary of the MICs Results with B. Subtilis
Peptaibol
Highest
Dissolved
Amount
(µg/ml)
MIC
(µg/ml)
Range where the
Peptaibol precipitates
(µg/ml)
HM A1 2200 68-137 137 - 1100
HM A3 1150 72-144 144 - 575
HM A5 1100 275-550 68 - 275
7.4.2 Virological Assays
The last serie of assays attempted with 5, 6 and 7 were done with human cells. A
first assay concerns the human cells alone being treated with the substances to evaluate
the maximal concentration of peptaibol supported by the cells before they are inhibited
i.e. before they die. Secondly, the human cells were infected by influenza viruses, and
the peptaibols were added shortly after in order to test any influence of the peptaibols on
the virus infection.
The preparation of the peptaibol solutions is resumed in Table 7. Here again, the
toxicity of MeOH versus the solubility of the peptaibols in water was a problem. It was
decided to use as much MeOH as possible to dissolve the peptaibol and to check this
water/MeOH solution alone with the human cells in a control series.
Table 7. Preparation of the Peptaibol Solutions
Peptaibol HM A1 HM A3 HM A5
Used Amount 4.4 mg 2.3 mg 2.2 mg
H2O 700 µl 600 µl 600 µl
MeOH 300 µl 400 µl 400 µl
• Assays without virus
The first attempt was carried out with solutions of the three Hypomurocins and
the human cells, as prepared in Table 7. The mixture was left for 24 h. The results
observed are shown in Table 8.
Table 8. Toxicological Results for the Hypomurocins on Human Cells (+: living cells;
 -: dead cells; +/-: part of the cells dead, part of them alive)
Concentrations a) HM A1 HM A3 HM A5
1:1 - - -
1:2 - - -
1:4 +/- - -
1:8 + + +/-
1:16 + + +
a) See Table 7. 1:1 = 4.4 mg/ml for HM A1, 2.3 mg/ml for
HM A3 and 2.2 mg/ml for HM A5
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First, all three Hypomurocins have a toxicological effect on the cells, as all cells
are dead at concentrations 1:1 and 1:2. The biological activities of the three
Hypomurocins are not the same, that of HM A5 seems to be much more efficient at
lower concentrations. This is quiet surprising if we consider that the three
Hypomurocins have almost the same structure and three-dimensional space occupation,
and assuming that their biological role is a function of the configuration and three-
dimensional structure. Finally, for weak concentrations, the Hypomurocins are no more
active. If the cells are left much longer than one week, they die at all concentrations.
The toxicological limit for the three peptaibols on these human cells are 0.14
mg/ml (1:16) for HM A5 (7), 0.29 mg/ml (1:8) for HM A3 (6) and 0.55 mg/ml (1:8) for
HM A1 (5) with the activity scala HM A5 > HM A3 > HM A1.
• Assays with virus
The cells status is observed for the first time 12 h after the incubation at 4 °C.
The results are shown in Table 9. The virus concentration Co for this assay is 0.1
MOI/cell. After 7-8 h, no trace of cell destruction could be detected. Preliminary tests
have shown that all cells are dead after 12 h with a virus concentration of 1 MOI/cell.
Table 9. Cells Status 12 h after Incubation at two Virus Concentrations (+: cells are
alive; -: cells are dead)
Co 0.5 CoConc. Control HM A1 HM A3 HM A5 Control HM A1 HM A3 HM A5
1:1 - + + + - + + +
1:2 - +/- +/- +/- - + + +
1:4 - +/- +/- +/- - +/- +/- +/-
1:8 - - - - - - - -
1:64 - - - - - - - -
For concentrations 1:4 to 1:64, the human cells were almost dead or all dead,
which shows that the virus had completely destroyed them. This means that the low
concentrations of peptaibols have had no effect on the activity of the virus, as the
concentration of peptaibols is too low to harm the human cells, this result relies only on
the virus effect.
For concentrations 1:1 and 1:2, the human cells are still alive and have been very
little destroyed or not at all destroyed by the virus. This means that the peptaibols
interact with the virus in such a way that both the virus and the peptaibols do not react
with the cells but rather together first. This might be because the peptaibols interact
strongly with the virus membranes, so that through ion channel opening the viruses are
destroyed or inhibited and can not infect the human cells.
The cells status is observed again after 18 h and 22 h, but no significant
difference was noticed in comparison with the effects observed after 12 h. At the
concentrations 1:2 and 1:4, the virus effect seemed to be slowed.
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7.4.3 Conclusions  from the Biological Tests
As expected in accordance to their length, the biological activity of the
Hypomurocins A1, A3 and A5 was weak but not negligible. Short peptaibols are known
to have a weaker activity than long peptaibols.
The peptaibols Hypomurocin A1, A3 and A5 have small effects on sheep blood
agar plates, against B. Subtilis, on human cells and they slow down or inhibit the action
of the influenza virus on human cells. From all three Hypomurocins, HM A3 is the most
active on blood agar plates, whereas HM A5 is most efficient on human cells.
Although these peptaibols differ only in their structures and have the same
global three-dimensional conformation, their biological activity is not equal.
7.5 Conclusion
The first total synthesis of Hypomurocins A1, A3 and A5 in solution phase has
been successfully achieved by using the azirine/oxazolone method for the introduction
of the Aib-Pro sequences included in this undecapeptaibols in one step by using methyl
2,2-dimethyl-2H-azirine-3-prolinate as the building block. The coupling reactions of the
Z-protected amino acids or peptide acids by using TBTU and HOBt led to the peptides
in good to very good yields. The peptides were purified by reverse-phase HPLC (RP-
HPLC) and characterized by NMR spectroscopy (1H, 13C, COSY, TOCSY, HSQC,
HMBC, ROESY), ESI-MS, IR spectroscopy, elemental analysis, optical rotation, and
X-ray crystallography. It was shown by RP-HPLC comparison that the synthetic
peptaibols were identical with the natural peptaibols.
A three-dimensional NMR analysis of HM A1 was carried out in DMSO and in
deuterated micelles to perform a structural comparison of the helix in solution and in
membranes. In all of these three-dimensional investigation, the typical helical
conformation was observed. Moreover, the usual S-like shape conformation observed in
the self-assembly of peptaibols to form ion channels has also been detected in the
presented structures.
Biological investigations have shown that the three peptaibols show some
biological activity. Experiments on blood agar plates, bacteria, viruses and human cells
illustrated the activity of the three peptaibols. But as known in the literature, as their
length do not exceed eleven residues, these effects are weak.
Despite their structural differences due to their side chains, the Hypomurocins
A1, A3 and A5 have shown high similarities in their conformation in solution, crystals
and micelles. Moreover, some differences were also detected in the biological activity
of HM A1, A3 and A5, HM A3 being the most active molecule in bacteriological tests,
and HM A5 being the most active one in the virological tests.
8. General Conclusion and Outlook
77
8 General Conclusion and Outlook
The solution-phase synthesis of the protected 6-16 segment of Zervamicin II-2
and the solution-phase total synthesis of the Hypomurocins A1, A3 and A5 were
successfully performed. The use of 2H-azirin-3-amines for the introduction of highly
hindered amino acids or dipeptide units such as Aib, Aib-Pro and Aib-Hyp into peptide
chains, which is referred to as the ‘azirine/oxazolone method’, was carried out with
good to very good yields. This method has been prooved as the method of choice for its
easiness and efficiency.
Structural investigations by different methods of the Hypomurocins A1, A3 and
A5 have shown the typical helical conformation, in accordance with the high proportion
of Aib moities in the molecules. This structural study is not fully completed and needs
to be consigned for HM A3 and A5. The detailed comparison of the structures of the
three Hypomurocins is an attractive task.
Biological investigations of the synthesized Hypomurocins was achieved as an
illustration of the property of peptaibols to form ion channels in membranes. As
expected in regard to the length of these peptaibols, the biological activity was weak.
As an outlook, the following aspects may be investigated in future:
- X-ray crystal-structure determination of HM A1 and A5 and their comparison
with HM A3
- Synthesis of one or several peptaibols of the Hypomurocin B family
- Investigation of their biological activities as performed with HM A1, A3 and A5
- Comparison of different properties (structure, activity…) of the Hypomurocin
and other SF4-family peptaibols
- Conductance analyses and determination of the n-mer ion channel model for HM
A1, A3 and A5 as a completion of this topic and as an illustration of this n value
for small peptaibols
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9 Experimental Part
9.1 General R emarks
9.1.1 Abbreviations
The amino acid and peptide nomenclature conforms to IUPAC-IUB rules (J.
Peptide Sci., 2003, 9, 1).
Å Angström
Ac acetyl
Aib α-aminoisobutyric acid
aq. aqueous
BnO benzyloxy
calc. calculated
CAMHB cation adjusted Mueller-Hinton bouillon
COSY COrrelation SpectroscopY
DABCO 1,4-diazabicyclo[2.2.2]octane
DMF dimethylformamide
DMSO dimethylsulfoxide
equiv.  equivalent
ESI-MS Electrospray Ionization Mass Spectrometry
g gram
GCMS Gas Chromatography/Mass Spectrometry
HETCOR HETeronuclear chemical shift CORrelation
HMBC Heteronuclear Multiple Bond Correlation
HOAt  1-hydroxy-7-azabenzotriazole
HOBt  1-hydroxybenzotriazole hydrate
HSQC  Heteronuclear Single-Quantum Correlation
h.v. high vacuum
Hyp L-trans-4-hydroxyproline
i-Pr isopropyl
IR infrared
Iva isovaline
l liter
Leuol L-leucinol ((S)-2-amino-4-methyl-1-pentanol)
Me methyl
MHB Mueller-Hinton bouillon
MIC minimal inhibition concentration
min minute(s)
MOI Multiplicity Of Infection. Ratio of infectious virus particles to cells
M.p. melting point
nm nanometers
NMR nuclear magnetic resonance
Pheol L-phenylalaninol ((S)-2-amino-3-phenyl-1-propanol)
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PLC preparative layer chromatography
prep. preparative
Pro L-proline
ROESY Rotating-frame Overhauser Enhancement SpectroscopY
RP-HPLC Reverse-Phase High Pressure Liquid Chromatography
r.t. room temperature
SPS solution-phase synthesis
SPPS solid-phase peptide synthesis
tBu tert-butyl
TBTU O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
TLC thin layer chromatography
TMS tetramethylsilane
TOCSY TOtal Correlation SpectroscopY
Valol L-valinol ((S)-2-amino-3-methyl-1-butanol)
Z benzyloxycarbonyl
9.1.2 Material and  Methods
Starting materials, reagents and solvents
The starting materials 2,2-dimethyl-2H-azirin-3-amine (1), methyl N-(2,2-dimethyl-2H-
azirin-3-yl)-L-prolinate (2), (2S,4R)-4-(benzyloxy)-N-(2,2-dimethyl-2H-azirin-3-yl)-L-
prolinate (3) and Ac-Aib-OH were prepared according to standard procedures [2], [51],
[53] and [81], respectively.
Amino acids and the amino alcohols Pheol and Leuol were purchased by Novabiochem
and Bachem, and are all L-configured.
Reagents and solvents were purchased from Acros, Fluka and Merck. All solvents were
purified by standard methods, and purchased chemicals where used without further
purification.
Chromatographic methods
Thin layer chromatography (TLC): on Merck TLC aluminium sheets, silica gel 60 F254.
Solvents systems used for the TLCs were AcOEt (A), AcOEt/MeOH 6:1 (B), and
AcOEt/MeOH 3:1 (C). The chromatograms were visualised with Schlittler reagent (1 g
of H2PtCl6 in 6 ml of H2O, addition of 20 ml of 1N HCl, followed by 22.5 g of KI
dissolved in 225 ml of H2O, and H2O to complete to 1 l).
Preparative layer chromatography (PLC): on Merck PLC plates (glass), silica gel 60
F254, 40-63 µm, 2 mm.
Flash column chromatography using Merck silica gel 60, 40-63 µm.
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Melting points
M.p.s were measured on a Büchi B-540 apparatus, uncorrected.
Optical rotations
Optical rotations were measured on an Perkin-Elmer 241 MC polarimeter.
Spectroscopic methods
Infrared (IR) spectra: IR spectra were recorded on a Perkin-Elmer Spectrum One
spectrometer, in KBr, absorptions in cm-1.
Nuclear magnetic resonance (NMR) spectra: 1H- and 13C-NMR spectra were recorded
at 300 K on a Bruker ARX-300 spectrometer at 300 and 75.5 MHz, resp., employing
CD3OD as solvent as well as internal standard or CDCl3 as solvent and TMS as internal
standard. For structural investigations of HM A1, A3 and A5, additional spectra were
recorded in d6-DMSO. Chemical shifts δ are given in ppm and coupling constants J in
Hz. COSY spectra were recorded either on a Bruker ARX-300 or Bruker DRX-600
spectrometer. TOCSY, HSQC, HMBC and ROESY spectra were recorded on a Bruker
DRX-600 spectrometer. All spectra were exploited with the NMR data-processing
software Mest-ReC [105].
Electrospray mass spectrometry (ESI-MS): ESI-MS were measured on a Finnigan TSQ-
700 triple-stage quadrupole instrument. The compounds were dissolved in MeOH
(HPLC grade) or in a 0.1% NaI solution in MeOH (c ≈ 5nmol/ml). ESI operating
conditions (positive mode): 16 scans average, capillary voltage 4500V, heated capillary
temperature 210 °C, N2 (30 PSI).
Elemental analysis
Elemental analysis were run on an Elemental Vario EL apparatus (C,H,N,S).
RP-HPLC systems (purification)
Analytic (I): Apparatus: Varian 2550 Variable l Detector and 2510 HPLC Pump.
Column: CC 250/4.6 Nucleosil 100-7 C8, Macherey-Nagel. Conditions: Flow rate 1
ml/min, reponse standard, mode normal, lamp D2, range 0.08.
Preparative (II): Apparatus: Jasco UV-975 UV/Vis Detector and PU-987 Pump.
Column: VP 250/21 Nucleosil 100-7 C8, Macherey-Nagel. Conditions: Flow rate 4
ml/min, reponse standard, mode normal, lamp D2, range 0.08. Solvent:
MeCN/MeOH/H2O 4/3/3 (v/v/v). Retention times tR in min and wave lengths λ in nm.
9. Experimental Part
82
RP-HPLC systems (correlation of synthetic and natural Hypomurocins)
HPLC-MS: Hewlett-Packard HP 1100 HPLC system (Hewlett-Packard, Palo Alto, CA,
U.S.A.) equipped with a HTS PAL autosampler (CTC Analytics, Zwingen, Switzerland),
connected to a Bruker ESQUIRE-LC quadrupole ion trap instrument (Bruker Daltonik
GmbH, Bremen, Germany) equipped with a Hewlett-Packard Electrospray (ESI) ion
source (Hewlett-Packard Co., Palo Alto, CA, U.S.A.).
Solvents and reagents: MeCN (HPLC grade, Scharlau, Barcelona, Spain), HCOOH
puriss. p.a. (Fluka, Buchs, Switzerland). H2O was purified with a MILLI-QRG apparatus
(Millipore, Milford, MA, U.S.A).
Samples preparation: Synthetic material (40 µg) was dissolved in a solution of
H2O/MeCN 9:1 (500 µl), and the fraction containing the natural HM A peptaibols was
dissolved in a solution of H2O/MeCN 9:1 (70 µl). Samples of 1 µl of the synthetic
peptaibol stock solution, of 1 µl of the natural HM A peptaibols stock solution, or of a
1:1 mixture of synthetic and natural stock solution were injected and analyzed by
HPLC-ESI-MS.
Column and chromatographic conditions: Interchrom Uptisphere C18 HDO column
(UP3HDOA5, 3 µm, 0.25×50 mm, Interchim, Montluçon, France), the eluent from the
HPLC was splitted using an Acurate high pressure pre-column flow splitter (LC
Packings, Amsterdam, The Netherlands) and the output flow was set at a rate of 3 µl
min–1. Mobile phase: gradient over 50 min from 10 to 90% of solvent B (solvent A:
0.1% solution of HCOOH in H2O, solvent B: 0.1% solution of HCOOH in MeCN).
MS conditions: Nebulizer gas (N2) 13 psi, dry gas (N2) 8 l min–1, dry temperature 280°,
capillary voltage 4500 V, end plate –500 V, capillary exit 70 V, and skimmer 1 19 V.
The MS acquisitions were performed at normal resolution (0.6 u full width at half
maximum), under ion charge control (ICC) conditions (10'000) in the mass range from
m/z 50 to 1300 and an m/z 50.2 trap drive value. The fragmentation experiments were
performed in the auto MS/MS mode by selecting 2 precursor ions, the isolation width
was 4 u, the fragmentation cut-off set by “fast calc”, and the fragmentation amplitude
set at 0.7 V in the “SmartFrag” mode.
X-ray crystal structures
Reports of the crystal structures of the following compounds are available with PD Dr.
A. Linden at the University of Zürich under the corresponding references:
6: HG 0534; 33: HG 0301; 38: HG 0422; 47: HG 0531; 60: HG 0424;
68: HG 0430; 69: HG 0458; 72: HG 0442; 76: HG 0426; 77: HG 0529;
79: HG 0455; 82: HG 0459; 84: HG 0352; 85: HG 0530;
Three-dimensional solution structure calculations
One- and two-dimensional 1H-NMR spectra were recorded at 600 MHz (Bruker DRX-
600 spectrometer), typically at a peptide concentration of 10-20 mg/ml in d6-DMSO at
9. Experimental Part
83
300 K. Distance restraints for the data derived from spectra recorded in DMSO or
methanol were obtained from ROESY spectra with a mixing time of 250 ms. Spectra
were typically collected with 1024 x 256 complex data points zero-filled prior to
Fourier transformation to 2048 x 1024, and transformed with a cosine-bell weighting
function. Data processing was carried out with XWIN-NMR (Bruker) and XEASY
[106]. The ROESY cross-peak intensities were corrected using the intensity-ratio
method in which correction factors due to the spin-lock pulse offset were included
[107]. Additionally, data were recorded in 90%H2O/10%D2O, 300mM d38-DPC, 20mM
MES buffer at 2mM peptide concentration, pH 6.0. Therein, spectra were assigned by
using a combination of 12 and 40 ms clean-TOCSY spectra [108] as well as an 120 ms
NOESY [109], [110] largely by following the sequential resonance assignment
methodology developed by Wüthrich and co-workers [101]. All structure calculations
were performed applying the simulated annealing protocol implemented in the program
DYANA [111], which is based on restrained molecular dynamics in torsion angle space.
Starting from 100 randomised conformations, a bundle of 20 conformations, which have
the lowest DYANA target energy function, was selected. The program MOLMOL [104]
was used for structure analysis and visualisation of the molecular models.
Biological assays
• Bacteriological assays
Bacteria strains:
B. Subtilis n.a.
S. Aureus ATCC25923
E. Coli ATCC25922
Method: Miniatur dilution test for the determination of MICs of antibiotica, according to
NCCLS guidelines
Bouillon solution: MHB or CAMHB (cation adjusted Mueller-Hinton bouillon),
prepared according guidelines NCCLS 32.3025/1 and 32.3009/1
• Virological assays
Virus strain:
Virus: Influenza A virus (FPV-B 293-T)
Designation: FLUA 183pA
Family: Orthomyxoviridae
Strain: Influenza A/FPV/Bratislava
Isolate: Bratislava
Serotype: H7N1
Human cells strain:
Human Embryonal Kidney Fibroblast Cells HEK 283
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9.2 Protocols
Protocol A: Peptide Coupling
To a solution of an N-protected amino acid or N-protected peptide and 1 equiv. of a C-
protected amino acid or C-protected peptide in MeCN were added 1 equiv. of TBTU
and HOBt (12% aq.). When the mixture was completely dissolved, 3 equiv. of TEA
were added. The reaction was stirred overnight at room temperature (N2 atmosphere)
and checked by TLC. After completion of the reaction, the mixture was washed three
times with brine. The organic layer was evaporated and the product was purified by
flash chromatography, or PLC.
Protocol B: Coupling with 2H-Azirin-3-amines
To a solution of 1.2 equiv. of the corresponding 2H-azirin-3-amine in THF or CH2Cl2, 1
equiv. of an N-protected amino acid or N-protected peptide was added, and the mixture
was stirred at room temperature overnight (N2 atmosphere). After completion of the
reaction, the solvent was evaporated and the product was purified by flash
chromatography, or PLC.
Protocol C: Saponification of Peptide Methyl Esters
To a solution of the peptide ester in a mixture of THF, MeOH, and H2O (3:1:1), 3 equiv.
of LiOH⋅H2O were added, and the mixture was stirred at room temperature overnight
(N2 atmosphere). After completion of the reaction (checked by TLC), the mixture was
acidified with 1N HCl to reach pH 1 and then extracted three times with CH2Cl2, the
organic layers were combined, dried on Na2SO4 and evaporated. The product was
purified by flash chromatography, or PLC.
Protocol D: Hydrogenolytic Deprotection
The N-protected peptide was dissolved in MeOH, and 5% Pd/C (1/3 of the weight of the
peptide) was added to the solution. The mixture was stirred overnight under H2
atmosphere at room temperature. After completion of the reaction (checked by TLC),
the solution was filtrated through a celite path and the solvent was evaporated. The
product was dried in high vacuum and used for the next reaction step without any
further purification.
Protocol E: Acidic Hydrolysis of Peptide Amides
To a solution of the peptide amide in THF, the same volume of 6N HCl was added at 0
°C and the reaction was stirred overnight at room temperature (N2 atmosphere). After
completion of the reaction (checked by TLC), the solution was extracted with CH2Cl2.
The organic layers were combined and dried over MgSO4. After evaporation of the
solvent, the product was dried in high vacuum and used for the next reaction step
without any further purification.
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9.3 Experimen ts
Synthesis of Z-Gln-Aib-Hyp(OBn)-OMe (44)
O N
H
H
N
N
O
O
OH2N
O
O
O
O
According to protocol B, the reaction was carried out with 50 mg (0.178 mmol) of Z-
Gln-OH and 57.3 mg (0.190 mmol) of 3 dissolved in 3 ml of dry THF. After 48 h, the
mixture was purified by flash chromatography (solvents systems (B) to (C)) and the
product was dried in high vacuum to obtain 81.5 mg (78.7%) of 44 as a slightly
yellowish foam. Rf(B) = 0.05, Rf(C) = 0.65. M.p. 75-78 °C.
IR (KBr): 698s, 740s, 1028s, 1053s, 1083s, 1178s, 1207s, 1244s, 1363s, 1414s, 1454s,
1531s, 1625vs, 1667vs, 1720vs, 2950m, 2988m, 3033m, 3063m, 3308s.
1H-NMR (300 MHz, CD3OD): 1.45 (br. s, 2 βCH3Aib), 1.78-2.12 (m, βCH2Gln,
βCH2aHyp), 2.12-2.25 (m, βCH2bHyp), 2.30 (t, J = 7.5 , γCH2Gln), 3.68 (s, OMe), 3.70-3.87
(m, δCH2Hyp), 4.17-4.27 (m, αCHGln, γCHHyp), 4.43-4.55 (m, αCHHyp, CH2OBn), 4.92,
5.00 (AB, J = 12.6, CH2Z), 7.20-7.36 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 24.7, 25.4 (2 q, 2 βCH3Aib), 29.1 (t, βCH2Gln), 32.3 (t,
γCH2Gln), 34.0 (t, βCH2Hyp), 52.5 (q, OMe), 53.7 (d, αCHGln), 55.5 (s, αCAib), 57.4 (t,
δCH2Hyp), 60.9 (d, αCHHyp), 67.7 (t, CH2Z), 72.1 (t, CH2OBn), 78.3 (d, γCHHyp), 128.7,
128.8, 129.0, 129.4 (4 d, 10 arom. CH), 138.0, 139.4 (2 s, 2 arom. C), 158.2 (s,
OCONHZ), 173.0, 174.3, 174.4, 177.6 (4 s, 4 CO).
ESI-MS (MeOH+NaI): 621.2 (40%, [M+K]+), 605.3 (100%, [M+Na]+), 583.3 (45%,
[M+H]+).
Synthesis of Z-Gln-Aib-Hyp(OBn)-OH (30)
O N
H
H
N
N
OH
O
OH2N
O
O
O
O
According to protocol C, the reaction was carried out with 893.4 mg (1.533 mmol) of 44
and 193.2 mg (4.600 mmol) of LiOH⋅H2O dissolved in 56 ml of a mixture of THF,
MeOH, and H2O (3:1:1). The mixture was stirred overnight, purified by flash
chromatography (solvents systems (B) to (C)), and the product was dried in high
vacuum to give 776 mg (89%) of 30 as a colorless foam. Rf(C) = 0.05. M.p. 110-114 °C.
IR (KBr): 640m, 698s, 739s, 1028s, 1054s, 1083s, 1178s, 1183s, 1248s, 1334s, 1366s,
1422s, 1454s, 1530s, 1621vs, 1667vs, 1712vs, 2940m, 2987m, 3033m, 3063m, 3324s.
9. Experimental Part
86
1H-NMR (300 MHz, CD3OD): 1.46 (br. s, 2 βCH3Aib), 1.81-2.13 (m, βCH2Gln,
βCH2aHyp), 2.14-2.27 (m, βCH2bHyp), 2.31 (t, J = 7.5, γCH2Gln), 3.68-3.83 (m, δCH2Hyp),
4.16-4.26 (m, αCHGln, γCHHyp), 4.42-4.55 (m, αCHHyp, CH2OBn), 4.94, 5.01 (AB, J =
12.7, CH2Z), 7.20-7.36 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 24.8, 25.2 (2 q, 2 βCH3Aib), 29.1 (t, βCH2Gln), 32.3 (t,
γCH2Gln), 34.4 (t, βCH2Hyp), 53.9 (d, αCHGln), 55.6 (s, αCAib), 57.6 (t, δCH2Hyp), 61.4 (d,
αCHHyp), 67.7 (t, CH2Z), 72.0 (t, CH2OBn), 78.3 (d, γCHHyp), 128.7, 128.8, 129.0, 129.4
(4 d, 10 arom. CH), 139.4, 138.0 (2 s, 2 arom. C), 158.2 (s, OCONHZ), 173.2, 174.1,
176.4, 177.7 (4 s, 4 CO).
ESI-MS (MeOH+NaI): 567.3 (100%, [M-H]+).
Synthesis of Z-Gln-Aib-Hyp(OBn)-Aib-Pro-OMe (45)
O N
H
H
N
N
H
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O
According to protocol B, the reaction was carried out with 170.9 mg (0.300 mmol) of 30
and 64.7 mg (0.330 mmol) of 2 dissolved in 10 ml of dry THF. Five drops of MeOH
were also added to the mixture. After stirring overnight, the solvent was carefully
evaporated and the remaining white product was washed repeatedly with THF. After
drying under vacuum, 174 mg (76.4%) of 45 were obtained as a white foam. Rf(C) =
0.35. M.p. 110-114 °C.
IR (KBr): 699s, 740s, 1028s, 1051s, 1093s, 1173s, 1206s, 1250s, 1365s, 1415s, 1454s,
1534s, 1654vs, 1718vs, 2946m, 2987m, 3033m, 3293s.
1H-NMR (300 MHz, CD3OD): 1.42, 1.46, 1.51 (3 br. s, 2 βCH3Aib, 2 βCH3Aib), 1.74-
2.02 (m, βCH2aGln, βCH2aHyp, γCH2Pro, βCH2aPro), 2.02-2.18 (m, βCH2bGln, βCH2bPro),
2.36 (t, J = 7.4, γCH2Gln), 2.34-2.48 (m, βCH2bHyp), 3.51 (d, J = 11.9, δCH2aHyp), 3.58-
3.77 (m, δCH2Pro), 3.68 (s, OMe), 3.89 (d, J = 11.9, δCH2bHyp), 4.08-4.19 (m, αCHGln,
γCHHyp), 4.38-4.45 (m, αCHPro), 4.46, 4.52 (AB, J = 11.9, CH2OBn), 4.57 (t, J = 8.4,
αCHHyp), 5.04, 5.12 (AB, J = 12.5, CH2Z), 7.23-7.38 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 24.6, 24.7 (2 q, 2 βCH3Aib), 25.4, 26.1 (2 q, 2 βCH3Aib),
26.8 (t, γCH2Pro), 28.6 (t, βCH2Pro), 28.9 (t, βCH2Gln), 32.4 (t, γCH2Gln), 34.9 (t,
βCH2Hyp), 49.2 (t, δCH2Pro), 52.4 (q, OMe), 54.9 (d, αCHGln), 56.2 (t, δCH2Hyp), 57.6,
57.7 (2 s, 2 αCAib), 61.8 (d, αCHHyp), 62.1 (d, αCHPro), 67.7 (t, CH2Z), 71.7 (t, CH2OBn),
78.4 (d, γCHHyp), 128.6, 128.7, 128.8, 129.1, 129.4, 129.5 (6 d, 10 arom. CH), 138.1,
139.4 (2 s, 2 arom. C), 158.4 (s, OCONHZ), 173.7, 174.2, 174.6, 174.7, 177.5 (5 s, 6
CO).
ESI-MS (MeOH+NaI): 787.5 (40%, [M+Na]+), 765.4 (10%, [M+H]+), 636.3 (100%).
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Synthesis of Z-Gln-Aib-Hyp(OBn)-Aib-Pro-OH (46)
O N
H
H
N
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H
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OH2N
O
O
O
O
N
OH
O
O
According to protocol C, the reaction was carried out with 373.5 mg (0.488 mmol) of 45
and 61.5 mg (1.465 mmol) of LiOH⋅H2O dissolved in 23 ml of a mixture of THF,
MeOH, and H2O (3:1:1). The mixture was stirred overnight, and the product was
purified by flash chromatography (solvents systems (B) to (C)) and dried in high
vacuum to give 276.3 mg (75.4%) of 46 as a white foam. Rf(C) = 0.10. M.p. 135-140
°C.
IR (KBr): 698m, 721m, 741m, 800m, 1028m, 1088s, 1136s, 1204vs, 1342s, 1366s,
1427vs, 1536s, 1667vs, 2943m, 2988m, 3293s.
1H-NMR (300 MHz, CD3OD): 1.42 (br. s, βCH3Aib), 1.47 (2 br. s, βCH3Aib, βCH3Aib),
1.51 (br. s, βCH3Aib), 1.80-2.02 (m, βCH2aGln, βCH2aHyp, γCH2Pro, βCH2aPro), 2.02-2.17
(m, βCH2bGln, βCH2bPro), 2.35 (t, J = 7.2, γCH2Gln), 2.40-2.48 (m, βCH2bHyp), 3.51 (d, J =
11.9, δCH2aHyp), 3.66-3.75 (m, δCH2Pro), 3.88 (d, J = 11.9, δCH2bHyp), 4.09-4.18 (m,
αCHGln, γCHHyp), 4.38-4.45 (m, αCHPro), 4.45-4.58 (m, CH2OBn, αCHHyp), 5.04, 5.11
(AB, J = 12.5, CH2Z), 7.20-7.37 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD) : 24.6, 24.8 (2 q, 2 βCH3Aib), 25.4, 26.1 (2 q, 2
βCH3Aib), 26.8 (t, γCH2Pro), 28.7 (t, βCH2Pro), 29.1 (t, βCH2Gln), 32.4 (t, γCH2Gln), 34.9 (t,
βCH2Hyp), 49.2 (t, δCH2Pro), 54.9 (d, αCHGln), 56.2 (t, δCH2Hyp), 57.7, 57.8 (2 s, 2
αCAib), 61.9 (d, αCHHyp), 62.1 (d, αCHPro), 67.7 (t, CH2Z), 71.7 (t, CH2OBn), 78.4 (d,
γCHHyp), 128.0, 128.2, 128.6, 128.7, 128.9, 129.1, 129.3, 129.4, 129.5 (9 d, 10 arom.
CH), 138.1, 139.4 (2 s, 2 arom. C), 158.9 (s, OCONHZ), 173.9, 174.1, 174.6, 176.0,
177.5 (5 s, 6 CO).
ESI-MS (MeOH+NaI): 789.5 (60%, [M+K]+), 773.4 (100%, [M+Na]+).
Synthesis of Z-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol (42)
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According to protocol A, a mixture of 152.7 mg (0.203 mmol) of 46, 30.8 mg (0.203
mmol) of Pheol, 65.3 mg (0.203 mmol) of TBTU, 31.3 mg (0.203 mmol) of HOBt, and
86 µl (0.610 mmol) of TEA in 15 ml of MeCN was stirred 24 h. The product was
purified by flash chromatography (solvents systems (B) to (C)) and dried in high
vacuum to give 119 mg (66.2%) of 42 as a white foam. Rf(C) = 0.20. M.p. 92-97 °C.
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IR (KBr): 700s, 743m, 1050s, 1081s, 1149m, 1176m, 1205m, 1248s, 1365s, 1409vs,
1454s, 1469s, 1543vs, 1646vs, 1720s, 2875m, 2940m, 2985m, 3031m, 3062m, 3289vs.
1H-NMR (300 MHz, CD3OD): 1.24-1.36 (m, βCH2aPro), 1.43, 1.45 (2 br. s, 2 βCH3Aib),
1.50 (s, 2 βCH3Aib), 1.62-1.74 (m, γCH2Pro), 1.76-1.96 (m, βCH2aGln, βCH2aHyp), 1.96-
2.22 (m, βCH2bGln, βCH2bPro), 2.33-2.42 (m, γCH2Gln), 2.45-2.57 (m, βCH2bHyp), 2.74 (dd,
J = 13.6, 10.2, CH2aOHPheol), 2.99 (dd, J = 13.6, 4.7, CH2bOHPheol), 3.44 (d, J = 12.3,
δCH2aHyp), 3.57-3.63 (m, βCH2Pheol), 3.63-3.79 (m, δCH2Pro), 3.96 (d, J = 12.1,
δCH2bHyp), 4.07-4.20 (m, αCHGln, γCHHyp, αCHPheol), 4.28-4.35 (m, αCHPro), 4.51, 4.55
(AB, J = 11.8, CH2OBn), 4.68 (t, J = 8.9, αCHHyp), 5.06, 5.15 (AB, J = 12.7, CH2Z), 7.22-
7.39 (m, 15 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 24.3, 24.7, 26.5 (3 q, 4 βCH3Aib), 26.4 (t, γCH2Pro), 28.7
(t, βCH2Pro), 30.0 (t, βCH2Gln), 32.7 (t, γCH2Gln), 35.5 (t, βCH2Hyp), 37.9 (t, CH2OHPheol),
50.0 (t, δCH2Pro), 54.6 (d, αCHGln), 55.4 (t, δCH2Hyp), 56.5 (d, αCHPheol), 57.9, 58.0 (2 s,
2 αCAib), 62.2 (d, αCHPro), 64.2 (d, αCHHyp), 65.2 (t, βCH2Pheol), 68.0 (t, CH2Z), 71.9 (t,
CH2OBn), 78.8 (d, γCHHyp), 127.2, 128.6, 128.8, 128.9, 129.1, 129.3, 129.4, 129.5, 130.6
(9 d, 15 arom. CH), 138.4, 139.6, 140.3 (3 s, 3 arom. C), 158.7 (s, OCONHZ), 174.2,
174.4, 174.6, 175.0, 175.2, 177.7 (6 s, 6 CO).
ESI-MS (MeOH+NaI): 906.6 (100%, [M+Na]+).
Synthesis of H-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol (32)
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According to protocol D, the reaction was carried out with 528.7 mg (0.598 mmol) of
42 dissolved in 117 ml of MeOH, and 176.2 mg of Pd/C. After drying the product in
high vacuum, 448.5 mg (quant.) of 32 were obtained as a yellowish foam. Rf(D) = 0.10.
M.p. 77-82 °C.
IR (KBr): 701m, 746m, 1049m, 1081m, 1148m, 1176m, 1204m, 1308m, 1364s, 1409vs,
1454s, 1470s, 1544vs, 1645vs, 2874m, 2939m, 2985m, 3029m, 3062m, 3289vs.
1H-NMR (300 MHz, CD3OD): 1.23-1.36 (m, βCH2aPro), 1.44, 1.49 (2 br. s, 2 βCH3Aib),
1.53, 1.54 (2 br. s, 2 βCH3Aib), 1.64-1.76 (m, γCH2Pro), 1.76-1.91 (m, βCH2aGln,
βCH2aHyp), 1.97-2.15 (m, βCH2bGln, βCH2bPro), 2.38 (t, J = 8.8, γCH2Gln), 2.55 (dd, J =
13.5, 8.5, βCH2bHyp), 2.75 (dd, J = 13.9, 10.2, CH2aOHPheol), 2.99 (dd, J = 13.7, 4.8,
CH2bOHPheol), 3.35-3.45 (m, δCH2aHyp), 3.59-3.64 (m, βCH2Pheol), 3.65-3.76 (m,
δCH2Pro), 3.76-3.85 (m, δCH2bHyp), 4.09 (d, J = 11.9, αCHPheol), 4.11-4.18 (m, αCHGln),
4.18-4.23 (m, γCHHyp), 4.31 (t, J = 7.6, αCHPro), 4.53, 4.59 (AB, J = 12.8, CH2OBn), 4.69
(t, J = 8.8, αCHHyp), 7.22-7.34 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 24.3, 24.8 (2 q, 2 βCH3Aib), 26.4 (q, βCH3Aib), 26.5 (q,
βCH3Aib), 26.6 (t, γCH2Pro), 30.8 (t, βCH2Pro), 32.0 (t, βCH2Gln), 32.8 (t, γCH2Gln), 35.6 (t,
βCH2Hyp), 37.9 (t, CH2OHPheol), 50.0 (t, δCH2Pro), 54.6 (d, αCHGln), 55.5 (d, αCHPheol),
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55.5 (t, δCH2Hyp), 57.7, 57.9 (2 s, 2 αCAib), 62.3 (d, αCHPro), 64.2 (d, αCHHyp), 65.2 (t,
βCH2Pheol), 71.9 (t, CH2OBn), 78.9 (d, γCHHyp), 127.2, 128.6, 128.8, 129.3, 129.5, 130.6
(6 d, 10 arom. CH), 139.6, 140.2 (2 s, 2 arom. C), 174.4, 174.7, 175.1, 176.9, 178.2 (5 s,
6 CO).
ESI-MS (MeOH+NaI): 772.5 (40%, [M+Na]+), 750.4 (50%, [M+H]+), 502.1 (100%).
Synthesis of Z-Val-Aib-Hyp(OBn)-OMe (47)
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According to protocol B, the reaction was carried out with 189.1 mg (0.752 mmol) of Z-
Val-OH and 227.2 mg (0.752 mmol) of 3 dissolved in 10 ml of dry THF. The product
was purified by flash chromatography (solvents systems (A) to (C)) and dried in high
vacuum to give 321.1 mg (77%) of 47 as a white foam. Rf(C) = 0.80. M.p. 130-134 °C.
IR (KBr): 697s, 738s, 755m, 788m, 996m, 1011m, 1028s, 1130vs, 1183vs, 1212vs,
1266s, 1280s, 1303m, 1333m, 1363vs, 1382m, 1418vs, 1455s, 1470s, 1498m, 1531vs,
1616vs, 1677vs, 1711vs, 1745vs, 2893m, 2962s, 3032m, 3064m, 3303m, 3367s.
1H-NMR (300 MHz, CD3OD): 0.92, 0.96 (2 d, J = 6.5, 2 γCH3Val), 1.45, 1.46 (2 br. s, 2
βCH3Aib), 1.93-2.07 (m, βCHVal, βCH2aHyp), 2.07-2.20 (m, βCH2bHyp), 3.58, 3.89 (ABX, J
= 10.8, 5.2, δCH2Hyp), 3.68 (s, OMe), 4.00 (d, J = 7.4, αCHVal), 4.18-4.27 (m, γCHHyp),
4.43-4.54 (m, CH2OBn, αCHHyp), 4.88, 5.01 (AB, J = 12.5, CH2Z), 7.20-7.37 (m, 10 arom.
CH).
13C-NMR (75.5 MHz, CD3OD): 18.6, 19.8 (2 q, 2 γCH3Val), 24.8, 25.4 (2 q, 2 βCH3Aib),
33.2 (d, βCHVal), 34.1 (t, βCH2Hyp), 52.6 (q, OMe), 53.6 (t, δCH2Hyp), 57.5 (s, αCAib),
60.9 (d, αCHHyp), 61.5 (d, αCHVal), 67.6 (t, CH2Z), 72.2 (t, CH2OBn), 78.1 (d, γCHHyp),
128.6, 128.7, 129.3 (3 d, 10 arom. CH), 138.0, 139.4 (2 s, 2 arom. C), 158.3 (s,
OCONHZ), 173.0, 174.2, 174.4 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 576.2 (100%, [M+Na]+).
Synthesis of Z-Val-Aib-Hyp(OBn)-OH (43)
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According to protocol C, the reaction was carried out with 309.12 mg (0.558 mmol) of
47 and 70.3 mg (1.675 mmol) of LiOH⋅H2O dissolved in 19 ml of a mixture of THF,
MeOH, and H2O (3:1:1). The product was purified by preparative TLC (solvents system
(D)) and dried in high vacuum to give 193.1 mg (64.1%) of 43 as a white powder. Rf(D)
= 0.20. M.p. 125-130 °C.
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IR (KBr): 697s, 737s, 1028s, 1095s, 1181s, 1238s, 1270s, 1306s, 1367s, 1430vs,
1454vs, 1524vs, 1616vs, 1713vs, 2874m, 2935s, 2965s, 3033m, 3256s.
1H-NMR (300 MHz, CDCl3): 0.88, 0.95 (2 d, J = 6.7, 2 γCH3Val), 1.52 (br. s, 2
βCH3Aib), 2.07-2.25 (m, βCHVal, βCH2aHyp), 2.25-2.40 (m, βCH2bHyp), 3.54-3.63 (m,
δCH2bHyp), 3.64-3.69 (m, δCH2aHyp), 3.96 (dd, J = 8.1, 6.3, γCHHyp), 4.15 (br. s,
αCHVal), 4.42, 4.52 (AB, J = 11.8, CH2OBn), 4.72 (t, J = 7.8, αCHHyp), 5.07 (br. s, CH2Z),
7.24-7.38 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CDCl3): 17.9 (q, γCH3Val), 19.7 (2 q, γCH3Val, βCH3Aib), 25.0 (q,
βCH3Aib), 30.6 (d, βCHVal), 33.0 (t, βCH2Hyp), 53.7 (t, δCH2Hyp), 57.3 (s, αCAib), 60.5 (d,
αCHHyp, αCHVal), 67.5 (t, CH2Z), 71.4 (t, CH2OBn), 78.4 (d, γCHHyp), 127.5, 127.9,
128.0, 128.3, 128.5 (5 d, 10 arom. CH), 138.1, 139.5 (2 s, 2 arom. C), 158.4 (s,
OCONHZ), 173.1, 173.8, 178.8 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 562.2 (100%, [M+Na]+).
Synthesis of Z-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol (48)
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According to protocol A, a mixture of 150 mg (0.2mmol) of 32, 107.9 mg (0.2 mmol) of
43, 64.2 mg (0.2 mmol) of TBTU, 30.7 mg (0.2 mmol) of HOBt, and 83.6 µl (0.6
mmol) of TEA in 12 ml of MeCN was stirred for 24 h. The product was purified by
preparative TLC (solvents system (C)) and dried in high vacuum to give 127.1 mg
(50%) of 48 as a white foam. Rf(C) = 0.40. M.p. 117-124 °C.
IR (KBr): 614m, 699s, 740m, 1028m, 1094s, 1176s, 1205m, 1265s, 1364s, 1411vs,
1454s, 1470s, 1543vs, 1647vs, 2875m, 2936m, 3031m, 3062m, 3291s.
1H-NMR (300 MHz, CD3OD): 0.97, 1.00 (2 d, J = 7.8, 2 γCH3Val), 1.21-1.35 (m,
βCH2aPro), 1.45, 1.48, 1.49, 1.52, 1.54, 1.57 (6 br. s, 6 βCH3Aib), 1.64-1.74 (m, γCH2Pro),
1.82-1.94 (m, 2 βCH2aHyp), 1.96-2.10 (m, βCH2bPro), 2.10-2.28 (m, βCH2abGln, βCHVal),
2.29-2.38 (m, γCH2Gln), 2.46-2.61 (m, 2 βCH2bHyp), 2.75, 2.99 (ABX, J = 13.4, 9.9,
CH2OHPheol), 3.49 (ABX, J = 12.6, 3.0, δCH2aHyp), 3.53-3.60 (m, δCH2bHyp), 3.59-3.64
(m, βCH2Pheol), 3.64-3.85 (m, δCH2abPro), 3.85-3.93 (m, δCH2bHyp), 4.04 (d, J = 6.2,
αCHVal), 4.09-4.21 (m, 2 γCHHyp, αCHPheol, δCH2aHyp), 4.28-4.36 (m, αCHGln, αCHHyp),
4.46-4.64 (m, 2 CH2OBn, αCHPro), 4.70 (t, J = 8.8, αCHHyp), 5.08, 5.20 (AB, J = 12.6,
CH2Z), 7.25-7.40 (m, 20 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 17.2, 19.8 (2 q, 2 γCH3Val), 24.1, 24.9, 26.1, 26.3, 26.4,
26.9 (5 q, 6 βCH3Aib; t, γCH2Pro), 28.0 (t, βCH2Gln), 29.8 (t, βCH2Pro), 31.4 (t, γCH2Gln),
33.0 (d, βCHVal), 34.8 (t, βCH2Hyp), 35.9 (t, βCH2Hyp), 37.7 (t, CH2OHPheol), 49.7 (t,
δCH2Pro), 54.5 (d, αCHGln), 54.8 (d, αCHPheol), 55.1 (t, δCH2Hyp), 57.7, 57.9 (2 s, 3
αCAib), 62.2 (d, αCHHyp), 62.9 (d, αCHHyp, αCHVal), 63.9 (d, αCHPro), 65.0 (t,
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βCH2Pheol), 67.8 (t, CH2Z), 71.6, 71.7 (2 t, 2 CH2OBn), 78.5 (d, 2 γCHHyp), 128.6, 128.7,
128.8, 129.3, 129.4, 129.5, 129.6, 130.6 (8 d, 15 arom. CH), 139.4, 140.0 (2 s, 4 arom.
C), 158.2 (s, OCONHZ), 173.7, 174.2, 174.5, 174.8, 174.9, 175.5 (6 s, 9 CO).
ESI-MS (MeOH+NaI): 1293.8 (80%, [M+Na]+), 658.4 (100%, [M+2Na]2+).
Synthesis of H-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-Pheol (49)
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According to protocol D, the reaction was carried out with 128.3 mg (0.101 mmol) of
48 in 28.5 ml of MeOH, and 42.7 mg of Pd/C. After drying the product in high vacuum,
101.1 mg (88.1%) of 49 were obtained as a yellowish foam. Rf(C) = 0.15. M.p. 107-113
°C.
IR (KBr): 614m, 699m, 740m, 1028m, 1079s, 1149m, 1176s, 1204m, 1311m, 1364s,
1410vs, 1454s, 1470s, 1544vs, 1645vs, 2873m, 2932s, 3030m, 3062m, 3294vs.
1H-NMR (600 MHz, CD3OD): 0.91, 1.01 (2 d, J = 6.9, 2 γCH3Val), 1.21-1.34 (m,
βCH2aPro), 1.454, 1.504, 1.516, 1.531, 1.552, 1.578 (6 br. s, 6 βCH3Aib), 1.64-1.75 (m,
γCH2Pro), 1.82-1.96 (m, 2 βCH2aHyp), 1.98-2.08 (m, βCH2bPro), 2.10-2.26 (m, βCH2abGln,
βCHVal), 2.26-2.44 (m, γCH2Gln), 2.45-2.63 (m, 2 βCH2bHyp), 2.75 (ABX, J = 13.5, 10.1,
CH2aOHPheol), 2.99 (ABX, J = 13.7, 5.0, CH2bOHPheol), 3.34 (d, J = 4.6, αCHVal), 3.44-
3.52 (m, 2 δCH2bHyp), 3.52-3.58 (m, 2 δCH2aHyp), 3.59-3.64 (m, βCH2Pheol), 3.64-3.86 (m,
δCH2abPro), 4.05-4.23 (m, 2 δCH2aHyp, γCHHyp, αCHPheol), 4.24-4.36 (m, γCHHyp, αCHGln,
αCHPro), 4.52-4.66 (m, 2 CH2OBn, αCHHyp), 4.70 (t, αCHHyp), 7.23-7.37 (m, 20 arom.
CH).
13C-NMR (150.9 MHz, CD3OD): 17.2, 19.8 (2 q, 2 γCH3Val), 24.0, 24.9, 26.1, 26.3, 27.2
(5 q, 6 βCH3Aib; t, γCH2Pro), 27.9 (t, βCH2Gln), 29.8 (t, βCH2Pro), 32.9 (t, γCH2Gln), 34.0
(d, βCHVal), 35.0 (t, βCH2Hyp), 35.5 (t, βCH2Hyp), 37.7 (t, CH2OHPheol), 49.7 (t, δCH2Pro),
54.4 (d, αCHGln), 54.8 (d, αCHPheol), 55.1 (t, 2 δCH2Hyp), 57.4, 57.7 (2 s, 3 αCAib), 62.2
(d, αCHHyp), 62.6 (d, αCHHyp), 64.1 (d, αCHPro), 65.0 (t, βCH2Pheol), 68.8 (d, αCHVal),
71.6 (t, 2 CH2OBn), 78.5, 78.7 (2 d, 2 γCHHyp), 128.6, 128.7, 128.8, 129.3, 129.4, 129.5,
130.6 (7 d, 15 arom. CH), 139.4, 140.0 (2 s, 3 arom. C), 174.1, 174.5, 174.8, 177.2 (4 s,
9 CO).
ESI-MS (MeOH): 1137.5 (100%, [M+H]+).
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Synthesis of Z-Thr(OBn)-Aib-N(Me)(Ph) (38)
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According to protocol B, the reaction was carried out with 138 mg (0.402 mmol) of Z-
Thr(OBn)-OH and 70 mg (0.402 mmol) of 1 dissolved in 16 ml of CH2Cl2. After 48 h,
the mixture was purified by preparative TLC (solvents system CH2Cl2/AcOEt (1.5:1))
and dried in high vacuum to give 208.4 mg (quant.) of 38 as a white foam. Rf(A) = 0.70.
M.p. 134-135 °C.
IR (KBr): 698s, 709s, 739s, 761s, 773s, 983s, 1027m, 1068s, 1095s, 1170m, 1214vs,
1286s, 1336m, 1360m, 1375m, 1397s, 1454s, 1467s, 1495vs, 1593s, 1630vs, 1676vs,
1721vs, 2896m, 2929m, 2969m, 2983m, 3027m, 3309s, 3421s.
1H-NMR (300 MHz, CDCl3): 1.09 (d, J = 6.5, γCH3Thr), 1.38, 1.54 (2 br. s, 2 βCH3Aib),
3.24 (br. s, CH3N(Me)), 3.82-3.89 (m, αCHThr), 3.94-4.03 (m, βCHThr), 4.37, 4.51 (AB, J =
11.4, CH2OBn), 5.10, 5.17 (AB, J = 12.2, CH2Z), 7.20-7.43 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CDCl3): 14.8 (q, γCH3Thr), 26.1, 27.1 (2 q, 2 βCH3Aib), 41.2 (q,
CH3N(Me)), 56.9 (d, αCHThr), 57.9 (s, αCAib), 66.8 (t, CH2Z), 71.4 (t, CH2OBn), 74.4 (d,
βCHThr), 127.8, 127.9, 128.1, 128.3, 128.5, 128.7, 129.5 (7 d, 15 arom. CH), 136.3,
137.7 (2 s, 2 arom. C), 144.6 (s, arom. CN(Ph)), 156.0 (s, OCONHZ), 169.6, 172.5 (2 s, 2
CO).
ESI-MS (MeOH+NaI): 540.6 (10%, [M+Na]+), 518.2 (27%, [M+H]+), 411.1 (100%),
303.0 (60%).
Synthesis of Z-Thr(OBn)-Aib-OH (39)
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According to protocol E, the reaction was carried out with 674.3mg (1.304 mmol) of 38
in a mixture of 12 ml of 6N HCl and 12 ml of THF. The temperature was allowed to rise
from 0 °C to room temperature overnight. After two times extraction with CH2Cl2, the
organic layer was dried with MgSO4, filtered, the solvent was evaporated and the
product was dried in high vacuum to give 560.2 mg (quant.) of 39 as a white foam.
Rf(A) = 0.33. M.p. 90-92 °C.
IR (KBr): 697vs, 737s, 1028s, 1069vs, 1174s, 1215vs, 1360vs, 1405vs, 1456vs, 1498vs,
1605vs, 1668vs, 1718vs, 2873m, 2933s, 2978s, 3033m, 3065m, 3349s.
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1H-NMR (300 MHz, CDCl3): 1.17 (d, J = 6.5, γCH3Thr), 1.48, 1.49 (2 br. s, 2 βCH3Aib),
4.03-4.13 (m, αCHThr), 4.34-4.41 (m, βCHThr), 4.48, 4.56 (AB, J = 11.6, CH2OBn), 5.09
(br. s, CH2Z), 7.22-7.34 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CDCl3): 14.9 (q, γCH3Thr), 28.9, 29.7 (2 q, 2 βCH3Aib), 56.3 (d,
αCHThr), 57.4 (s, αCAib), 67.0 (t, CH2Z), 71.4 (t, CH2OBn), 74.6 (d, βCHThr), 128.1,
128.2, 128.3, 128.5, 128.8, 128.9 (6 d, 10 arom. CH), 136.0, 137.7 (2 s, 2 arom. C),
156.2 (s, OCONHZ), 169.1, 177.8 (2 s, 2 CO).
ESI-MS (MeOH+NaI): 923.4 (13%, [2M-2H+3Na]+), 901.3 (17%, [2M-H+2Na]+),
879.4 (5%, [2M+Na]+), 451.1 (100%, [M+Na]+).
Synthesis of Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-Gln-Aib-Hyp(OBn)-Aib-Pro-
Pheol (4)
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According to protocol A, the reaction was carried out with 94 mg (0.083 mmol) of 49,
35.4 mg (0.083 mmol) of 39, 26.5 mg (0.083 mmol) of TBTU, 12.7 mg (0.083 mmol) of
HOBt, and 34.9 µl (0.248 mmol) of TEA in 8 ml of MeCN. The product was purified by
flash chromatography (solvents systems (B) to (D)) and dried in high vacuum to give 42
mg (32.8%) of 4 as a yellow foam. Rf(D) = 0.70. M.p. 115-120 °C.
IR (KBr): 699m, 740m, 1028m, 1078s, 1176s, 1207m, 1275m, 1364s, 1383s, 1410s,
1454s, 1469s, 1540vs, 1645vs, 2873m, 2934.83m, 2984m, 3031m, 3063m, 3293s.
1H-NMR (300 MHz, CD3OD): 0.88, 0.90 (2 d, J = 2.7, 2 γCH3Val), 1.23-1.34 (m,
βCH2aPro, γCH3Thr), 1.41, 1.46, 1.50, 1.51, 1.51, 1.54, 1.56, 1.58 (8 br. s, 8 βCH3Aib),
1.63-1.74 (m, γCH2Pro), 1.81-2.09 (m, 2 βCH2bHyp, βCH2bPro, βCH2bGln), 2.10-2.18 (m,
βCHVal, βCH2aGln), 2.20-2.38 (m, γCH2Gln), 2.45-2.58 (m, 2 βCH2bHyp), 2.75 (ABX, J =
13.6, 10.0, CH2aOHPheol), 2.98 (ABX, J = 13.5, 4.9, CH2bOHPheol), 3.50 (ABX, J = 12.4,
2.7, δCH2bHyp), 3.54-3.66 (m, δCH2bHyp, βCH2Pheol), 3.66-3.75 (m, δCH2aPro), 3.75-3.86
(m, δCH2bPro), 4.01-4.07 (m, δCH2aHyp), 4.10-4.36 (m, αCHVal, αCHGln, αCHPro, 2
γCHHyp, αCHPheol, δCH2aHyp, αCHThr, βCHThr), 4.45-4.75 (m, 2 αCHHyp, 3 CH2OBn),
5.14, 5.21 (AB, J = 12.7, CH2Z), 7.23-7.40 (m, 25 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 16.6 (q, γCH3Thr), 18.5, 19.7 (2 q, 2 γCH3Val), 24.0,
24.1, 24.2, 24.9, 26.1, 26.3, 27.0, 27.6 (7 q, 8 βCH3Aib; t, γCH2Pro), 27.9 (t, βCH2Gln),
29.8 (t, βCH2Pro), 31.1 (t, γCH2Gln), 32.7 (d, βCHVal), 35.4 (t, βCH2Hyp), 35.8 (t,
βCH2Hyp), 37.7 (t, CH2OHPheol), 49.7 (t, δCH2Pro), 54.4 (d, αCHGln), 54.8 (d, αCHPheol),
54.8, 55.1 (2 t, 2 δCH2Hyp), 57.7, 57.8, 58.1 (3 s, 4 αCAib), 60.3 (d, αCHHyp), 62.2 (d,
αCHHyp), 62.9 (d, αCHPro), 63.3 (d, αCHThr), 63.9 (d, αCHVal), 65.0 (t, βCH2Pheol), 68.0
(t, CH2Z), 71.6, 72.1 (3 t, 3 CH2OBn), 75.0 (d, βCHThr), 78.4 (d, γCHHyp), 128.5, 128.7,
128.9, 129.0, 129.1, 129.3, 129.4, 129.6, 130.6 (9 d, 25 arom. CH), 137.3, 139.3, 139.4,
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140.0 (4 s, 5 arom. C), 159.2 (s, OCONHZ), 173.7, 174.1, 174.5, 174.8, 175.0, 175.7,
177.1 (7 s, 11 CO).
ESI-MS (MeOH+NaI): 1569.9 (100%, [M+Na]+), 796.7 (60%, [M+2Na]2+).
Synthesis of Z-Thr(OBn)-Aib-Val-OMe (40)
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According to protocol A, the reaction was carried out with 525.2 mg (1.2257 mmol) of
39, 205.5 mg (1.2257 mmol) of H-Val-OMe·HCl, 393.6 mg (1.2257 mmol) of TBTU,
188.1 mg (1.2257 mmol) of HOBt, and 510 µl (3.6771 mmol) of TEA in 42 ml of
MeCN. The product was purified by flash chromatography (solvents systems
(Hexan/CH2Cl2 1:1) to (A)) and dried in high vacuum to give 569.5 mg (86%) of 40 as a
white foam. Rf(ethyl acetate/CH2Cl2 1:1) = 0.48.
1H-NMR (300 MHz, CD3OD): 0.85, 0.89 (2 d, J = 6.7, 2 γCH3Val), 1.22 (d, J = 6.1,
γCH3Thr), 1.44, 1.47 (2 br. s, 2 βCH3Aib), 2.00-2.12 (m, βCHVal), 3.68 (s, OMe), 3.90-
3.98 (m, βCHThr), 4.19 (d, J = 5.0, αCHThr), 4.25 (d, J = 6.1, αCHVal), 4.50, 4.61 (AB, J
= 11.6, CH2OBn), 5.11 (br. s, CH2Z), 7.25-7.36 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 16.5 (q, γCH3Thr), 18.9, 19.5 (2 q, 2 γCH3Val), 24.7, 26.2
(2 q, 2 βCH3Aib), 31.8 (d, βCHVal), 52.4 (q, CH3OMe), 58.2 (s, αCAib), 59.6 (d, αCHVal),
61.1 (d, αCHThr), 67.8 (t, CH2Z), 72.2 (t, CH2OBn), 76.0 (d, βCHThr), 128.7, 128.8, 128.9,
129.0, 129.3, 129.5 (6 d, 10 arom. CH), 138.1, 139.6 (2 s, 2 arom. C), 158.6 (s,
OCONHZ), 172.0, 173.5, 176.6 (3 s, 3 CO).
Synthesis of Z-Thr(OBn)-Aib-Val-OH (41)
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According to protocol C, the reaction was carried out with 516.1 mg (0.9528 mmol) of
40 and 120.1 mg (2.8585 mmol) of LiOH⋅H2O dissolved in 40 ml of a mixture of THF,
MeOH, and H2O (3:1:1). The product was purified by repeated flash column
chromatography and dried in high vacuum to give 165 mg (32.8%) of 41 as a white
foam. Rf(B) = 0.51.
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1H-NMR (300 MHz, CD3OD): 0.86, 0.92 (2 d, J = 6.7, 2 γCH3Val), 1.24 (d, J = 3.4,
γCH3Thr), 1.45, 1.48 (2 br. s, 2 βCH3Aib), 2.08-2.20 (m, βCHVal), 3.96-4.05 (m, βCHThr),
4.23 (d, J = 3.8, αCHThr), 4.10 (dd, J = 14.1, 7.1, αCHVal), 4.49, 4.61 (AB, J = 11.6,
CH2OBn), 5.14 (br. s, CH2Z), 7.25-7.40 (m, 10 arom. CH).
13C-NMR (75.5 MHz, CD3OD): 16.6 (q, γCH3Thr), 18.6, 19.6 (2 q, 2 γCH3Val), 24.7, 26.2
(2 q, 2 βCH3Aib), 31.8 (d, βCHVal), 58.3 (s, αCAib), 59.4 (d, αCHVal), 60.0 (d, αCHThr),
67.8 (t, CH2Z), 72.3 (t, CH2OBn), 76.0 (d, βCHThr), 128.7, 128.8, 128.9, 129.0, 129.3,
129.5 (6 d, 10 arom. CH), 138.1, 139.6 (2 s, 2 arom. C), 158.6 (s, OCONHZ), 172.1,
174.9, 176.5 (3 s, 3 CO).
Synthesis of Z-Thr(OBn)-Aib-Val-Aib-Hyp(OBn)-OMe (37)
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According to protocol B, the reaction was carried out with 56 mg (0.106 mmol) of 41
and 34.3 mg (1.114 mmol) of 3 dissolved in 4 ml of THF. The product was purified by
flash chromatography (solvents systems (A) to (C)) and dried in high vacuum to give
74.6 mg (84.8%) of 37 as a white foam. Rf(B) = 0.80. M.p. 75 °C.
IR (KBr): 3327s, 3064m, 3033m, 2961m, 2874m, 1671vs, 1529vs, 1455s, 1415s, 1382s,
1362s, 1272s, 1214s, 1175s, 1082s, 1028m, 739m, 698m.
1H-NMR (300 MHz, CD3OD): 0.84, 0.86 (2 d, J = 4.5, 2 γCH3Val), 1.25 (d, J = 6.3,
γCH3Thr), 1.38, 1.45, 1.48 (3 br. s, 2 βCH3Aib, 2 βCH3Aib), 1.91-2.02 (m, βCHVal), 2.13-
2.27 (m, βCH2Hyp), 3.69 (s, CH3OMe), 3.71-3.76 (m, δCH2bHyp), 3.86-4.02 (m, δCH2aHyp,
αCHThr), 4.02-4.09 (m, αCHVal), 4.19-4.28 (m, βCHThr, γCHHyp), 4.41-4.63 (m,
CH2Thr(OBn), CH2Hyp(OBn), αCHHyp), 5.09, 5.16 (AB, J = 12.7, CH2Z), 7.1-7.5 (m, 15 arom.
H).
13C-NMR (75.5 MHz, CD3OD): 16.7 (q, γCH3Thr), 18.3, 20.0 (2 q, 2 γCH3Val), 24.9,
25.2, 25.8, 26.7 (4 q, 4 βCH3Aib), 31.3 (d, βCHVal), 34.6 (t, βCH2Hyp), 52.5 (q, CH3OMe),
54.2 (t, δCH2Hyp), 57.7, 58.2 (2 s, 2 αCAib), 59.8 (d, αCHVal), 61.3 (d, αCHThr), 62.6 (d,
αCHHyp), 67.9 (t, CH2Z), 72.0, 72.2 (2 t, 2 CH2OBn), 75.4 (t, γCHHyp), 78.7 (d, βCHThr),
128.6, 128.7, 128.9, 129.0, 129.4, 129.5 (6 d, 15 arom. CH), 138.1, 139.4 (2 s, 3 arom.
C), 159.0 (s, OCONHZ), 172.6, 172.9, 174.4, 174.6, 176.7 (5 s, 5 CO).
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Synthesis of Z-Gln-Val-OtBu (53)
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According to protocol A, to Z-Gln-OH (2.5 g, 8.93 mmol) and H-Val-OtBu⋅HCl (1.871
g, 8.93 mmol) were added HOBt (1.507 g, 8.93 mmol) and TBTU (2.867 g, 8.93 mmol).
The mixture was completely dissolved in MeCN (560 ml) and TEA (3.76 ml, 26.78
mmol) was added. After the completion of the reaction, the mixture was purified by
flash chromatography to lead to the dipeptide 53 (3.108 g, 80%). White powder looking
like plaster. Rather insoluble in MeOH at r.t. M.p. 149 °C. Rf(B) = 0.78. RP-HPLC (II):
tR 21.07, λ 210.
IR (KBr): 3445m, 3326s, 2964m, 1720s, 1686s, 1652vs, 1529s, 1448m, 1414m, 1393m,
1371m, 1351m, 1286m, 1258s, 1241s, 1216m, 1161m, 1136m, 1042m, 698m.
1H-NMR (300 MHz, CD3OD): 0.95 (d, J = 6.6, 2 γCH3Val), 1.45 (br. s, 3 CH3OtBu), 1.82-
1.95 (m, βCH2aGln), 2.00-2.21 (m, βCHVal, βCH2bGln), 2.34 (t, J = 7.4, γCH2Gln), 4.19-
4.25 (m, αCHGln, αCHVal), 5.08 (s, CH2Z), 7.30-7.46 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 18.3, 19.4 (2 q, 2 γCH3Val), 28.2 (q, 3 CH3OtBu), 29.2 (t,
βCH2Gln), 31.7 (d, βCHVal), 38.8 (t, γCH2Gln), 55.6 (d, αCHGln), 59.7 (d, αCHVal), 67.7 (t,
CH2Z), 82.9 (s, COtBu), 128.9, 129.1, 129.4 (3 d, 5 arom. CHZ), 138.0 (s, arom. CZ),
158.3 (s, OCONHZ), 172.1, 174.3, 177.7 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 893.5 (35%, [2M+Na]+), 458.2 (100%, [M+Na]+).
Anal. calc. for C22H33N3O6 (MG 435.16): C 60.67, H 7.64, N 9.65; found: C 60.27, H
7.64, N 9.59.
[α] 23D  = −12.1 (c = 0.63, MeCN).
Synthesis of H-Gln-Val-OtBu (55)
H2N
H
N
O
OH2N
O
O
According to protocol D, the dipeptide 53 (760 mg, 1.745 mmol) was dissolved in
MeOH (60 ml). Pd/C was added and the reaction was left overnight under H2
atmosphere. After the end of the reaction and filtration on Celite, the solvent was
evaporated leading to the N-unprotected dipeptide 55 (525 mg, quant.). Sticky, colorless
oil. Rf(B) = 0.05. RP-HPLC (II): tR 23.61, λ 201.
IR (KBr): 3418vs, 2971s, 2934s, 1730vs, 1666vs, 1538s, 1491m, 1455m, 1394s, 1370s,
1314m, 1258m, 1151vs, 598m.
9. Experimental Part
97
1H-NMR (300 MHz, CD3OD): 0.93 (d, J = 6.9, 2 γCH3Val), 1.44 (br. s, 3 CH3OtBu), 1.71-
1.86 (m, βCH2aGln), 1.91-2.04 (m, βCHVal), 2.06-2.18 (m, βCH2bGln), 2.31 (t, J = 7.3,
γCH2Gln), 3.42 (t, J = 6.9, αCHGln), 4.18 (d, J = 5.2, αCHVal).
13C-NMR (75.5 MHz, CD3OD): 18.4, 19.5 (2 q, 2 γCH3Val), 28.3 (q, 3 CH3OtBu), 31.7 (d,
βCHVal), 32.4, 32.7 (2 t, βCH2Gln, γCH2Gln), 55.2 (d, αCHGln), 59.5 (d, αCHVal), 82.8 (s,
COtBu), 172.2, 177.1, 178.0 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 625.3 (15%, [2M+Na]+), 324.2 (100%, [M+Na]+).
[α] 20D  = −14.5 ( c = 1, MeOH).
Synthesis of Ac-Aib-OH
N
H
O
O
OH
A mixture of H-Aib-OH (2-Methylalanin; 430 mg, 4.1748 mmol), acetic acid anhydride
(1431 mg, 13.2504 mmol) and pyridine (1047 mg, 13.2504 mmol) was stirred for 17 h
at room temperature and then was heated to reflux for 1 h. Ice was added to the solution
to reach 0 °C, and the mixture was stirred at that temperature for 4 h. The solution was
evaporated, the solid residue was washed with ether, and recrystallized in MeOH to give
Ac-Aib-OH (424.9 mg, 70%). White crystal material. Rf(A) = 0.29.
1H-NMR (300 MHz, CD3OD): 1.91 (s, CH3Ac), 1.46 (br. s, 2 βCH3Aib).
13C-NMR (75.5 MHz, CD3OD): 23.1 (q, CH3Ac), 26.0 (2 q, 2 βCH3Aib), 57.5 (s, αCAib),
173.2, 178.6 (2 s, 2 CO).
Synthesis of Ac-Aib-Gln-Val-OtBu (57)
H
N
N
H
O
OH2N
O
O
N
H
O
O
According to protocol A, to the N-unprotected dipeptide 55 (580 mg, 1.92 mmol) and
Ac-Aib-OH (279 mg, 1.92 mmol) were added HOBt (295 mg, 1.92 mmol) and TBTU
(618 mg, 1.92 mmol). The mixture was completely dissolved in MeCN (111 ml) and
TEA (811 µl, 5.77 mmol) was added. After completion of the reaction, the mixture was
purified by flash chromatography to lead to the tripeptide 57 (555 mg, 67%). White
foam. Rf(B) = 0.22, Rf(C) = 0.74. M.p. 83-86 °C. RP-HPLC (II): tR 36.46, λ 206.
IR (KBr): 3313s, 2975m, 2934m, 1729s, 1663vs, 1535vs, 1452m, 1369s, 1294s, 1220m,
1149s, 1084s.
1H-NMR (300 MHz, CD3OD): 0.96 (d, J = 6.9, 2 γCH3Val), 1.44, 1.46 (2 br. s, 2
βCH3Aib), 1.47 (br. s, 3 CH3OtBu), 1.94-2.06 (m, βCH2aGln), 1.97 (s, CH3Ac), 2.10-2.21 (m,
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βCHVal, βCH2bGln), 2.32 (t, J = 7.6, γCH2Gln), 4.11 (d, J = 6.4, αCHVal), 4.37 (dd, J = 9.6,
4.6, αCHGln).
13C-NMR (75.5 MHz, CD3OD): 18.8, 19.5 (2 q, 2 γCH3Val), 23.1, 24.5 (2 q, 2 βCH3Aib),
26.7 (q, CH3Ac), 28.3 (q, 3 CH3OtBu; t, βCH2Gln), 31.5 (d, βCHVal), 32.5 (t, γCH2Gln), 54.4
(d, αCHGln), 57.8 (s, αCAib), 60.3 (d, αCHVal), 82.9 (s, COtBu), 172.1, 173.2, 174.1,
177.1, 178.2 (5 s, 5 CO).
ESI-MS (MeOH+NaI): 467.1 (3%, [M+K]+), 451.2 (60%, [M+Na]+), 429.2 (90%,
[M+H]+), 373.2 (100%).
Anal. calc. for C20H36N4O6 ⋅ 0.5 H2O (MG 437.53): C 54.90, H 8.52, N 12.81; found: C
55.06, H 8.38, N 12.68.
[α] 20D  = −32.5 (c = 1.75, AcOEt).
Synthesis of Ac-Aib-Gln-Val-OH (51)
H
N
N
H
OH
OH2N
O
O
N
H
O
O
At 0 °C, the tripeptide tert-butyl ester 57 (260 mg, 0.61 mmol) was dissolved in TFA
(15 ml) and left for 2.5 h under an N2 atmosphere. The reaction was quenched by
evaporating TFA. The residue was dissolved in a mixture of CH2Cl2/Et2O 1/1 (v/v) and
evaporated (3×) to lead to the C-unprotected tripeptide 51 (225 mg, quant.). White
powder. Rf(C) = 0.28. M.p. 70-74 °C. RP-HPLC (II): tR 16.00, λ 215.
IR (KBr): 3474vs, 3364vs, 3330vs, 2973m, 2936m, 1653vs, 1525vs, 1468m, 1433m,
1392m, 1370m, 1290s, 1197s, 1130s, 1083m, 1036m, 619m.
1H-NMR (300 MHz, CD3OD): 0.98 (d, J = 6.9, 2 γCH3Val), 1.44, 1.45 (2 br. s, 2
βCH3Aib), 1.90-2.03 (m, βCH2aGln), 1.97 (s, CH3Ac), 2.09-2.26 (m, βCHVal, βCH2bGln),
2.32 (t, J = 6.8, γCH2Gln), 4.26 (d, J = 5.7, αCHVal), 4.38 (dd, J = 9.6, 4.3, αCHGln).
13C-NMR (75.5 MHz, CD3OD): 18.6, 19.6 (2 q, 2 γCH3Val), 23.1, 25.3 (2 q, 2 βCH3Aib),
25.8 (q, CH3Ac), 28.3 (t, βCH2Gln), 31.6 (d, βCHVal), 32.5 (t, γCH2Gln), 54.5 (d, αCHGln),
57.7 (s, αCAib), 59.3 (d, αCHVal), 173.3, 174.1, 174.5, 177.2, 178.2 (5 s, 5 CO).
ESI-MS (MeOH+NaI): 395.3 (100%, [M+Na]+), 767.4 (10%, [2M+Na]+), 373.3 (18%,
[M+H]+).
[α] 20D  = −13.2 (c = 1, MeOH).
Synthesis of Z-Val-Aib-Pro-OMe (61)
O N
H
H
N
N
O
O
O
O
O
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According to protocol B, the 2H-azirin-3-amine 2 (230.4 mg, 1.176 mmol) was
dissolved in CH2Cl2 (20 ml), Z-Val-OH (246.2 mg, 0.98 mmol) was added and the
mixture was stirred overnight. The solvent was evaporated and the product purified by
flash chromatography to give the C-protected tripeptide 61 (426.8 mg, 97%). White
foam. Rf(A) = 0.58. M.p. 57-59 °C. RP-HPLC (II): tR 41.68, λ 216.
IR (KBr): 3311vs, 3065m, 3035m, 2964s, 2877m, 1745vs, 1662vs, 1620vs, 1538vs,
1470vs, 1455vs, 1414vs, 1364vs, 1342s, 1289vs, 1242vs, 1170vs, 1117m, 1095m, 1027s,
742m, 698s, 640m, 614m.
1H-NMR (300 MHz, CD3OD): 0.94, 0.97 (2 d, J = 6.9, 2 γCH3Val), 1.43, 1.45 (2 br. s, 2
βCH3Aib), 1.62-2.03 (m, βCHVal, βCH2Pro, γCH2Pro), 3.48-3.67 (m, δCH2Pro), 3.67 (s,
OMe), 3.89-3.95 (m, αCHVal), 4.38 (dd, J = 8.4, 3.8, αCHPro), 5.04, 5.10 (AB, J = 12.6,
CH2Z), 7.04 (d, J = 8.8, NHVal), 7.28-7.36 (m, 5 arom. CHZ), 8.47 (s, NHAib).
13C-NMR (75.5 MHz, CD3OD): 18.7, 19.7 (2 q, 2 γCH3Val), 24.4, 25.6 (2 q, 2 βCH3Aib),
26.6 (t, γCH2Pro), 28.8 (t, βCH2Pro), 32.0 (d, βCHVal), 49.1 (t, δCH2Pro), 52.5 (q, CH3OMe),
57.4 (s, αCAib), 61.5 (d, αCHVal), 62.0 (d, αCHPro), 67.5 (t, CH2Z), 128.7, 129.0, 129.5
(3 d, 5 arom. CHZ), 138.3 (s, arom. CZ), 158.5 (s, OCONHZ), 173.3, 174.0, 174.9 (3 s, 3
CO).
ESI-MS (MeOH+NaI): 917.4 (20%, [2M+Na]+), 469.9 (100%, [M+Na]+).
Anal. calc. for C23H33N3O6 ⋅ 0.5 H2O (MG 456.53): C 60.51, H 7.51, N 9.20; found: C
60.70, H 8.33, N 9.46.
[α] 23D  = −42.1 (c = 1, AcOEt).
Synthesis of Z-Val-Aib-Pro-OH (68)
O N
H
H
N
N
O
O
O
OH
O
According to protocol C, the peptide methyl ester 61 (600 mg, 1.34 mmol) was
dissolved in a mixture of THF, MeOH, and H2O (40 ml), and LiOH⋅H2O (169 mg, 4.02
mmol) was added. After the workup, the solvent was evaporated to give the C-
unprotected tripeptide 68 (552 mg, 95%). White foam. Rf(A) = 0.04. M.p. 88-91 °C.
RP-HPLC (II): tR 33.94, λ 207.
IR (KBr): 3441vs, 3063s, 2966vs, 2877s, 1709vs, 1659vs, 1538vs, 1471s, 1455vs,
1423vs, 1366s, 1340s, 1291s, 1238vs, 1176s, 1096m, 1027s, 739m, 698s, 673m, 615m.
1H-NMR (300 MHz, CD3OD): 0.93, 0.97 (2 d, J = 6.7, 2 γCH3Val), 1.47 (br. s, 2
βCH3Aib), 1.56-1.62 (m, γCH2aPro), 1.72-2.04 (m, βCHVal, βCH2Pro, γCH2bPro), 3.54-3.65
(m, δCH2Pro), 3.91 (d, J = 7.8, αCHVal), 4.28-4.32 (m, αCHPro), 5.03, 5.14 (AB, J = 12.6,
CH2Z), 7.28-7.36 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 18.7, 19.7 (2 q, 2 γCH3Val), 24.8, 25.6 (2 q, 2 βCH3Aib),
26.7 (t, γCH2Pro), 29.8 (t, βCH2Pro), 32.1 (d, βCHVal), 49.1 (t, δCH2Pro), 57.9 (s, αCAib),
61.8 (d, αCHVal), 64.8 (d, αCHPro), 67.6 (d, CH2Z), 128.8, 129.1, 129.5 (3 d, 5 arom.
CHZ). The quart. arom. CZ, the carbamate and the CO's could not be detected.
ESI-MS (MeOH+NaI): 456.3 (100%, [M+Na]+).
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Anal. calc. for C22H31N3O6 ⋅ 0.5 H2O (MG 442.51): C 59.71, H 7.29, N 9.50; found: C
59.63, H 7.06, N 9.66.
[α] 20D  = −82.1 (c = 1, MeOH).
Synthesis of Z-Leu-Aib-Pro-OMe (62)
O N
H
H
N
N
O
O
O
O
O
According to protocol B, the 2H-azirin-3-amine 2 (1.562 g, 7.969 mmol) was dissolved
in CH2Cl2 (125 ml), Z-Leu-OH (1.762 g, 6.64 mmol) was added and the mixture stirred
overnight. The solvent was evaporated and the product purified by flash
chromatography to give the C-protected tripeptide 62 (3.031 g, 99%). White foam.
Rf(A) = 0.65. M.p. 130-132 °C. RP-HPLC (II): tR 22.55, λ 216.
IR (KBr): 3288vs, 3064m, 2954s, 2874m, 1753vs, 1714vs, 1666vs, 1623vs, 1536vs,
1414vs, 1384s, 1365s, 1267vs, 1240vs, 1205s, 1163vs, 1120m, 1043s, 1028m, 750m,
697s, 643m.
1H-NMR (300 MHz, CD3OD): 0.93, 0.96 (2 d, J = 6.3, 2 δCH3Leu), 1.42, 1.43 (2 s, 2
βCH3Aib), 1.45-1.61 (m, βCH2Leu), 1.62-1.81 (m, γCHLeu, γCH2Pro), 1.81-1.98 (m,
βCH2Pro), 3.53-3.67 (m, δCH2Pro), 3.67 (s, CH3OMe), 4.19 (dd, J = 9.9, 5.3, αCHLeu), 4.38
(dd, J = 8.5, 3.6, αCHPro), 5.02, 5.14 (AB, J = 12.6, CH2Z), 7.28-7.36 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 21.8, 23.4 (2 q, 2 δCH3Leu), 24.4, 25.6 (2 q, 2 βCH3Aib),
25.9 (d, γCHLeu), 26.7 (t, γCH2Pro), 28.8 (t, βCH2Pro), 42.0 (t, βCH2Leu), 49.2 (t, δCH2Pro),
52.4 (q, CH3OMe), 54.3 (d, αCHLeu), 57.4 (s, αCAib), 62.1 (d, αCHPro), 67.5 (t, CH2Z),
128.6, 129.0, 129.5 (3 d, 5 arom. CHZ), 138.5 (s, arom. CZ), 158.4 (s, OCONHZ), 174.0,
174.4, 174.8 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 945.5 (5%, [2M+Na]+), 484.1 (100%, [M+Na]+).
Anal. calc. for C24H35N3O6 (MG 461.18): C 62.45, H 7.64, N 9.10; found: C 62.40, H
7.55, N 9.08.
[α] 20D  = −57.5 (c = 1.25, AcOEt).
Synthesis of Z-Leu-Aib-Pro-OH (63)
O N
H
H
N
N
O
O
O
OH
O
According to protocol C, the peptide methyl ester 62 (1.3 g, 2.82 mmol) was dissolved
in a mixture of THF, MeOH, and H2O (84 ml), and LiOH⋅H2O (355 mg, 8.45 mmol)
was added. After the workup, the solvent was evaporated to give the C-unprotected
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tripeptide 63 (1.223 g, 97%). White foam. Rf(A) = 0.09. M.p. 82-86 °C. RP-HPLC (II):
tR 30.39, λ 215.
IR (KBr): 3323vs, 3066s, 2958vs, 1722vs, 1619vs, 1536vs, 1418vs, 1366s, 1341s,
1248vs, 1178vs, 1120m, 1045s, 741m, 698s, 638m, 608m.
1H-NMR (300 MHz, CD3OD): 0.93, 0.96 (2 d, J = 6.3, 2 δCH3Leu), 1.44 (br. s, 2
βCH3Aib), 1.45-1.61 (m, βCH2Leu), 1.62-1.76 (m, γCHLeu), 1.76-1.85 (m, γCH2Pro), 1.85-
1.99 (m, βCH2Pro), 3.55-3.66 (m, δCH2Pro), 4.19 (dd, J = 9.9, 5.3, αCHLeu), 4.38 (dd, J =
8.4, 3.4, αCHPro), 5.02-5.14 (AB, J = 12.6, CH2Z), 7.28-7.36 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 21.8, 23.3 (2 q, 2 δCH3Leu), 24.4, 25.6 (2 q, 2 βCH3Aib),
25.8 (d, γCHLeu), 26.6 (t, γCH2Pro), 29.0 (t, βCH2Pro), 42.0 (t, βCH2Leu), 49.1 (t, δCH2Pro),
54.3 (d, αCHLeu), 57.4 (s, αCAib), 62.0 (d, αCHPro), 67.4 (t, CH2Z), 128.7, 129.0, 129.4
(5 d, 5 arom. CHZ), 138.4 (s, arom. CZ), 158.4 (s, OCONHZ), 173.9, 174.4, 176.1 (3 s, 3
CO).
ESI-MS (MeOH+NaI): 470.2 (100%, [M+Na]+).
Anal. calc. for C23H33N3O6 ⋅ H2O (MG 462.52): C 59.34, H 7.58, N 9.03; found: C
59.49, H 7.38, N 9.37.
[α] 20D  = −80.9 (c = 1, MeOH).
Synthesis of Z-Leu-Aib-Pro-Leuol (64)
O N
H
H
N
N
O
O
O
H
N
O
OH
According to protocol A, the Z protected tripeptide 63 (1.223 g, 2.733 mmol), H-
Leuol⋅HCl (419.9 mg, 2.733 mmol), HOBt (419.5 mg, 2.733 mmol), and TBTU (877.5
mg, 2.733 mmol) were dissolved in MeCN (170 ml), and TEA (1.15 ml, 8.199 mmol)
was added. After the completion of the reaction, the mixture was purified by flash
chromatography to give the tetrapeptide 64 (1.4 g, 94%). White powder. Rf(B) = 0.50.
M.p. 60-63 °C. RP-HPLC (II): tR 27.31, λ 207.
IR (KBr): 3292vs, 2957vs, 2871m, 1723vs, 1648vs, 1547vs, 1469s, 1412s, 1366s, 1253s,
1172m, 1044s, 740m, 698m.
1H-NMR (300 MHz, CD3OD): 0.86-0.98 (m, 2 δCH3Leu, 2 δCH3Leuol), 1.26-1.38 (m,
βCH2aLeu, βCH2aLeuol), 1.40, 1.44 (2 br. s, 2 βCH3Aib), 1.47-1.68 (m, βCH2bLeu,
βCH2bLeuol, γCHLeu, γCHLeuol), 1.68-1.82 (m, βCH2aPro, γCH2Pro), 2.11-2.22 (m,
βCH2bPro), 3.37-3.61 (m, δCH2abPro), 3.52 (d, J = 5.7, CH2OHLeuol), 3.93-4.06 (m,
αCHLeuol), 4.13-4.21 (m, αCHLeu), 4.37-4.45 (m, αCHPro), 5.05-5.17 (AB, J = 12.6,
CH2Z), 7.29-7.43 (m, 5 H, arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 21.9 (q, δCH3Leu), 22.3 (q, δCH3Leuol), 23.4(q, δCH3Leu),
24.0 (q, δCH3Leuol), 24.1 (q, βCH3Aib), 25.7 (d, γCHLeu), 25.9 (d, γCHLeuol), 26.1 (q,
βCH3Aib), 26.5 (t, γCH2Pro), 29.9 (t, βCH2Pro), 40.4 (t, βCH2Leuol), 41.6 (t, βCH2Leu), 49.5
(t, δCH2Pro), 51.0 (d, αCHLeuol), 55.1 (d, αCHLeu), 57.7 (s, αCAib), 64.1 (d, αCHPro), 65.7
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(t, CH2OHLeuol), 67.5 (t, CH2Z), 128.6, 128.9, 129.4 (3 d, 5 arom. CHZ), 138.2 (s, arom.
CZ), 158.0 (s, OCONHZ), 174.1, 174.3, 174.9 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 569.5 (100%, [M+Na]+), 547.4 (50%, [M+H]+).
Anal. calc. for C29H46N4O6 (MG 546.23): C 63.71, H 8.48, N 10.25; found: C 63.32, H
8.40, N 10.19.
[α] 20D  = −31.2 (c = 1, MeOH).
Synthesis of H-Leu-Aib-Pro-Leuol (65)
H2N
H
N
N
O
O
H
N
O
OH
According to protocol D, the tetrapeptide 64 (447 mg, 0.818 mmol) was dissolved in
MeOH (29 ml), Pd/C was added, and the mixture was stirred overnight under an H2
atmosphere. After completion of the reaction and filtration through Celite, the solvent
was evaporated leading to the N-unprotected tetrapeptide 65 (335 mg, quant.). Colorless
oil. Rf(B) = 0.09. RP-HPLC (II): tR 26.79, λ 203.
IR (KBr): 3292vs, 2956vs, 2871s, 1644vs, 1547vs, 1470s, 1411s, 1366s, 1196m, 1173m.
1H-NMR (300 MHz, CD3OD): 0.86-1.00 (m, 2 δCH3Leu, 2 δCH3Leuol), 1.27-1.43 (m,
βCH2aLeu, βCH2aLeuol), 1.47, 1.48 (2 s, 2 βCH3Aib), 1.49-1.66 (m, βCH2bLeuol, βCH2bLeu,
γCHLeuol), 1.72-1.86 (m, γCHLeu, βCH2aPro), 1.86-1.97 (m, γCH2abPro), 2.20-2.34 (m,
βCH2bPro), 3.37-3.49 (m, δCH2aPro, αCHLeu), 3.53 (d, J = 5.3, CH2OHLeuol), 3.77-3.87 (m,
δCH2bPro), 3.94-4.05 (m, αCHLeuol), 4.43 (dd, J = 8.4, 6.3, αCHPro).
13C-NMR (75.5 MHz, CD3OD): 22.3 (q, δCH3Leu, δCH3Leuol), 23.6 (q, δCH3Leu), 24.0(q,
δCH3Leuol), 24.2 (q, βCH3Aib), 25.7 (d, γCHLeu), 26.0 (d, γCHLeuol), 26.4 (q, βCH3Aib),
26.6 (t, γCH2Pro), 30.0 (t, βCH2Pro), 40.5 (t, βCH2Leuol), 44.9 (t, βCH2Leu), 49.6 (t,
δCH2Pro), 50.9 (d, αCHLeuol), 54.0 (d, αCHLeu), 57.5 (s, αCAib), 64.2 (d, αCHPro), 65.7 (t,
CH2OHLeuol), 174.1, 174.5, 177.3 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 435.3 (100%, [M+Na]+).
[α] 20D  = −6.1 (c = 1, MeOH).
Synthesis of Z-Leu-Leu-Aib-Pro-Leuol (66)
H
N
N
H
N
O
O
N
H
O
OH
N
H
O
O
O
According to protocol A, to a mixture of Z-Leu-OH (513.7 mg, 1.936 mmol), the N-
unprotected tetrapeptide 65 (789.8 mg, 1.936 mmol), HOBt (297.3 mg, 1.936 mmol),
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and TBTU (621.7 mg, 1.936 mmol) dissolved in MeCN (122 ml), TEA (816 µl, 5.809
mmol) was added. After the completion of the reaction, the mixture was purified by
flash chromatography to give the pentapeptide 66 (1.098 g, 86%). White powder. Rf(B)
= 0.48. M.p. 88-90 °C. RP-HPLC (II): tR 30.40, λ 210.
IR (KBr): 3416s, 3308s, 2957vs, 2871m, 1702vs, 1646vs, 1534s, 1469s, 1452s, 1421s,
1386s, 1366s, 1342m, 1310m, 1262s, 1222m, 1172m, 1151m, 1122m, 1083s, 1050s,
697m.
1H-NMR (300 MHz, CD3OD): 0.85-1.00 (m, 2 δCH3Leu, 2 δCH3Leu, 2 δCH3Leuol), 1.29-
1.42 (m, βCH2aLeu, βCH2aLeu, βCH2aLeuol), 1.42, 1.45 (2 s, 2 βCH3Aib), 1.48-1.57 (m,
βCH2bLeu, βCH2bLeu, βCH2bLeuol), 1.57-1.73 (m, γCHLeu, γCHLeu, γCHLeuol), 1.74-1.85 (m,
βCH2aPro), 1.85-1.96 (m, γCH2Pro), 2.19-2.29 (m, βCH2bPro), 3.43-3.56 (m, CH2OHLeuol,
δCH2aPro), 3.67-3.77 (m, δCH2bPro), 3.94-4.03 (m, αCHLeuol), 4.03-4.10 (m, αCHLeu),
4.39-4.47 (m, αCHLeu, αCHPro), 5.07-5.15 (m, CH2Z), 7.30-7.40 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 21.7, 22.1 (2 q, 2 δCH3Leu), 22.3 (q, 2 δCH3Leuol), 23.3,
23.5 (2 q, 2 δCH3Leu), 24.1, 24.3 (2 q, 2 βCH3Aib), 25.9, 26.1, 26.2 (3 d, γCHLeu, γCHLeu,
γCHLeuol), 26.7 (t, γCH2Pro), 30.1 (t, βCH2Pro), 40.7, 40.9, 41.9 (3 t, βCH2Leu, βCH2Leu,
βCH2Leuol), 49.7 (t, δCH2Pro), 51.1 (d, αCHLeuol), 52.9 (d, αCHLeu), 55.8 (d, αCHLeu),
57.9 (s, αCAib), 64.3 (d, αCHPro), 65.8 (t, CH2OHLeuol), 67.9 (t, CH2Z), 128.7, 129.1,
129.6 (3 d, 5 arom. CHZ), 138.1 (s, arom. CZ), 158.9 (s, OCONHZ), 174.2, 174.4, 174.6,
175.7 (4 s, 4 CO).
ESI-MS (MeOH+NaI): 682.4 (100%, [M+Na]+).
Anal. calc. for C35H57N5O7 ⋅ H2O (MG 677.88): C 62.01, H 8.77, N 10.33; found: C
61.80, H 9.07, N 10.25.
[α] 23D  = −33.4 (c = 1, AcOEt).
Synthesis of H-Leu-Leu-Aib-Pro-Leuol (67)
H
N
N
H
N
O
O
N
H
O
OH
H2N
O
According to protocol D, the pentapeptide 66 (1.10 g, 1.667 mmol) was dissolved in
MeOH (60 ml), Pd/C was added, and the mixture was stirred overnight under an H2
atmosphere. After completion of the reaction and filtration through Celite, the solvent
was evaporated leading to the N-unprotected pentapeptide 67 (856.2 mg, 98%). White
foam. Rf(B) = 0.11. M.p. 45-50 °C. RP-HPLC (II): tR 30.48, λ 210.
IR (KBr): 3302vs, 2957vs, 2871s, 1648vs, 1546vs, 1469s, 1455s, 1411s, 1385s, 1366s,
1341m, 1196m, 1172m.
1H-NMR (300 MHz, CD3OD): 0.90-0.98 (m, 2 δCH3Leu, 2 δCH3Leu, 2 δCH3Leuol), 1.28-
1.55 (m, βCH2Leu, βCH2Leuol), 1.44 (s, 2 βCH3Aib), 1.55-1.74 (m, γCHLeu, βCH2Leu,
γCH2Leu, γCHLeuol), 1.74-1.85 (m, βCH2aPro), 1.85-1.95 (m, γCH2Pro), 2.19-2.29 (m,
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βCH2bPro), 3.39-3.58 (m, CH2OHLeuol, αCHLeu, δCH2aPro), 3.64-3.77 (m, δCH2bPro), 3.95-
4.03 (m, αCHLeuol), 4.35-4.51 (m, αCHPro, αCHLeu).
13C-NMR (75.5 MHz, CD3OD): 21.9, 22.0, 22.3, 22.5, 23.4, 23.6, 24.1, 24.2 (8 q, 2
δCH3Leu, 2 δCH3Leu, 2 δCH3Leuol, 2 βCH3Aib), 25.9, 26.1 (2 d, γCHLeu, γCHLeu, γCHLeuol),
26.7 (t, γCH2Pro), 30.1 (t, βCH2Pro), 40.8, 41.9, 44.4 (3 t, βCH2Leu, βCH2Leu, βCH2Leuol),
49.7 (t, δCH2Pro), 51.2 (d, αCHLeuol), 52.5 (d, αCHLeu), 57.9 (s, αCAib), 59.3 (d, αCHLeu),
64.2 (d, αCHPro), 65.8 (t, CH2OHLeuol), 174.3, 174.4, 174.5, 178.3 (4 s, 4 CO).
ESI-MS (MeOH+NaI): 548.5 (100%, [M+Na]+), 526.5 (70%, [M+H]+).
[α] 20D  = −50.3 (c = 1, MeOH).
Synthesis of Z-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol (69)
N
H
H
N
N
O
O
H
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O
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O N
H
H
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O
O
O
According to protocol A, to a mixture of the tripeptide Z-Val-Aib-Pro-OH 68 (38 mg,
0.0875 mmol), the N-unprotected pentapeptide 67 (46 mg, 0.0875 mmol), HOBt (13.4
mg, 0.0875 mmol), and TBTU (28.1 mg, 0.0875 mmol) dissolved in MeCN (6 ml),
TEA (37 µl, 0.263 mmol) was added. After the completion of the reaction, the mixture
was purified by flash chromatography to lead to the octapeptide 69 (45 mg, 55%).
White powder. Rf(B) = 0.24. M.p. 125-130 °C. RP-HPLC (II): tR ca. 100, λ 200.
IR (KBr): 3444vs, 2959s, 2873m, 1725s, 1644vs, 1540vs, 1470s, 1454s, 1416vs, 1366m,
1265s, 1233m, 1172m, 1027m, 699m, 619m.
1H-NMR (500 MHz, CD3OD): 0.84, 0.87 (2 d, J = 6.7, 2 δCH3Leuol), 0.89, 0.91 (2 d, J =
6.7, 2 δCH3Leu), 0.95-1.02 (m, 2 γCH3Val, 2 δCH3Leu), 1.31-1.37 (m, βCH2aLeuol), 1.45,
1.48 (2 s, 2 CH3Aib, 2 CH3Aib), 1.55-1.76 (m, βCH2aPro, βCH2bLeuol, γCHLeuol,
γCHLeu, βCH2Leu), 1.73-1.81 (m, γCHLeu, βCH2aPro), 1.82-1.90 (m, γCH2Pro, γCH2aPro),
1.91-1.98 (m, γCH2bPro, βCH2Leu), 2.14-2.21 (m, βCHVal), 2.23-2.33 (m, βCH2bPro,
βCH2bPro), 3.32-3.36 (m, δCH2aPro), 3.46-3.60 (m, CH2OHLeuol, δCH2Pro), 3.80-3.85 (m,
δCH2bPro), 3.92 (d, J = 6.1, αCHVal), 3.94-4.01 (m, αCHLeuol), 4.16-4.20 (m, αCHLeu),
4.31 (dd, J = 8.5, 6.7, αCHPro), 4.43-4.46 (m, αCHPro, αCHLeu), 5.09, 5.20 (AB, J = 12.8,
CH2Z), 7.32-7.41 (m, 5 arom. CHZ).
13C-NMR (125.7 MHz, CD3OD): 19.9, 21.0 (2 q, 2 γCH3Val), 21.2, 22.1 (2 q, 2
δCH3Leu), 23.5, 23.6, 23.7, 24.2, 24.3 (5 q, 2 δCH3Leuol, 2 βCH3Aib, 2 δCH3Leu), 25.8 (d,
γCHLeu), 26.0 (d, γCHLeuol), 26.1 (q, βCH3Aib), 26.1 (d, γCHLeu), 26.7 (t, γCH2Pro), 26.8
(q, βCH3Aib), 27.0 (t, γCH2Pro), 29.9 (t, βCH2Pro), 30.2 (t, βCH2Pro), 31.5 (d, βCHVal),
40.4 (2 t, βCH2Leu, βCH2Leuol), 41.3 (t, βCH2Leu), 49.9 (t, δCH2Pro), 50.3 (t, δCH2Pro),
51.2 (d, αCHLeuol), 53.2 (d, αCHLeu), 55.2 (d, αCHLeu), 57.8 (s, αCAib), 57.9 (s, αCAib),
63.2 (d, αCHVal), 64.3 (d, αCHPro), 65.1 (d, αCHPro), 65.8 (t, CH2OHLeuol), 67.9 (t,
CH2Z), 128.9, 129.1, 129.5 (3 d, 5 arom. CHZ), 138.3 (s, arom CZ), 158.4 (s, OCONHZ),
174.2, 174.3, 174.6, 174.9, 175.0, 175.9 (6 s, 7 CO).
ESI-MS (MeOH+NaI): 963.5 (100%, [M+Na]+), 493.2 (15%, [M+2Na]2+).
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Anal. calc. for C49H80N8O10 (MG 940.39): C 62.53, H 8.57, N 11.91; found: C 62.37, H
8.40, N 11.64.
[α] 20D  = −7.2 (c = 1, MeOH).
Z-Val-Aib-Pro-Leu-Leu-Aib-(R)Pro-Leuol (70)
N
H
H
N
N
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O
After the purification of 69 by flash chromatography, a small fraction was isolated and
identified as 70 (< 5 mg, see 1) and 2)). White solid. Rf(B) = 0.40.
1H-NMR (300 MHz, CD3OD): due to the low amount of substance, the spectra quality
of the spectra is low. But a visual comparison with the spectra of 70 shows substantial
differences.
ESI-MS (MeCN, MeOH, H2O): 964.0 (20%, [M+Na]+), 727.6 (20%), 642.6 (10%),
529.3 (20%), 409.4 (100%).
Synthesis of H-Val-Aib-Pro-Leu-Leu-Aib-Pro-Leuol (71)
N
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H
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According to protocol D, the Z protected octapeptide 69 (533 mg, 0.566 mmol) was
dissolved in MeOH (19 ml), Pd/C was added, and the mixture was stirred overnight
under an H2 atmosphere. After the completion of the reaction and filtration through
Celite, the solvent was evaporated leading to the N-unprotected octapeptide 71 (388 mg,
85%). White foam. Rf(B) = 0.06. M.p. 110-115 °C. RP-HPLC (II): tR 40.12, λ 202.
IR (KBr): 3302vs, 2958vs, 2872m, 1646vs, 1540vs, 1470s, 1413s, 1385m, 1365m,
1285m, 1196m, 1172m, 618m.
1H-NMR (300 MHz, CD3OD): 0.85 (d, J = 5.9, δCH3Leuol), 0.88-0.92 (m, δCH3Leuol,
γCH3Val, δCH3Leu, δCH3Leu), 0.97 (d, J = 6.6, δCH3Leu), 0.98 (d, J = 6.6, δCH3Leu), 1.03
(d, J = 6.6, γCH3Val), 1.32-1.37 (m, βCH2aLeuol), 1.47, 1.49, 1.52, 1.55 (4 s, 2 βCH3Aib, 2
βCH3Aib), 1.57-1.63 (m, βCH2bLeuol), 1.64-1.77 (m, γCHLeu, γCHLeu, γCHLeuol, βCH2Leu),
1.72-1.82 (m, βCH2aPro, βCH2aPro), 1.85-1.91 (m, γCH2aPro), 1.92-1.98 (m, γCH2bPro,
βCH2Leu), 2.00 (t, J = 6.6, γCH2Pro), 2.17-2.22 (m, βCHVal), 2.25-2.30 (m, βCH2bPro),
2.35-2.40 (m, βCH2bPro), 3.26 (d, J = 4.4, αCHVal), 3.33-3.37 (m, δCH2aPro), 3.46-3.57
(m, CH2OHLeuol, δCH2aPro), 3.80-3.84 (m, δCH2bPro), 3.90-3.94 (m, δCH2bPro), 3.95-3.99
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(m, αCHLeuol), 4.19 (dd, J = 11.7, 4.4, αCHLeu), 4.36 (t, J = 8.1, αCHPro), 4.43-4.47 (m,
αCHPro, αCHLeu).
13C-NMR (75.5 MHz, CD3OD): 17.2, 20.1 (2 q, 2 γCH3Val), 21.2, 21.4 (2 q, 2
δCH3Leuol), 22.3 (q, δCH3Leu), 23.7, 23.8 (2 q, δCH3Leu, δCH3Leu, βCH3Aib), 24.3 (q,
δCH3Leu), 24.4 (q, βCH3Aib), 25.9 (d, γCHLeu), 26.1 (d, γCHLeu), 26.3 (q, βCH3Aib), 26.3
(d, γCHLeuol), 26.8 (t, γCH2Pro), 27.2 (q, βCH3Aib), 27.2 (d, γCH2Pro), 30.1 (t, βCH2Pro),
30.2 (t, βCH2Pro), 33.0 (d, βCHVal), 40.5 (t, βCH2Leu, βCH2Leuol), 41.4 (t, βCH2Leu), 50.1
(t, δCH2Pro), 50.3 (t, δCH2Pro), 51.2 (d, αCHLeuol), 53.1 (d, αCHLeu), 55.0 (d, αCHLeu),
57.6 (s, αCAib), 57.9 (s, αCAib), 61.4 (d, αCHVal), 64.3 (d, αCHPro), 65.2 (d, αCHPro),
65.9 (t, CH2OHLeuol), 174.2, 174.4, 174.6, 175.3, 175.8, 177.7 (6 s, 7 CO).
ESI-MS (MeOH+NaI): 829.6 (100%, [M+Na]+), 426.3 (20%, [M+2Na]2+).
Anal. calc. for C41H74N8O8 ⋅ 0.5 H2O (MG 816.09): C 60.34, H 9.26, N 13.73; found: C
60.10, H 9.29, N 13.35.
[α] 23D  = −2.7 (c = 1.8, AcOEt).
H-Val-Aib-Pro-Leu-Leu-Aib-(R)Pro-Leuol (72)
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After the purification of 71 by flash chromatography, a small fraction was isolated and
identified as 72 (< 10 mg, see 1), 2) and Figure 24). White crystals. Rf(B) = 0.24.
1H-NMR (300 MHz, CD3OD): 0.85 (d, J = 5.4, δCH3Leuol), 0.88-1.00 (m, δCH3Leuol,
γCH3Val, δCH3Leu, δCH3Leu, δCH3Leu, δCH3Leu, γCH3Val), 1.32-1.39 (m, βCH2aLeuol), 1.44,
1.45, 1.46, 1.47 (4 s, 2 βCH3Aib, 2 βCH3Aib), 1.53-1.85 (m, βCH2bLeuol, γCHLeu, γCHLeu,
γCHLeuol, βCH2Leu, βCH2aPro, βCH2aPro), 1.85-1.99 (m, γCH2aPro, γCH2bPro, βCH2Leu),
1.99-2.01 (m, γCH2Pro), 2.17-2.34 (m, βCHVal, βCH2bPro), 2.35-2.43 (m, βCH2bPro), 3.34-
3.44 (m, δCH2aPro, αCHVal), 3.44-3.59 (m, CH2OHLeuol, δCH2aPro), 3.63-3.76 (m,
δCH2bPro), 3.76-3.89 (m, δCH2bPro), 3.89-4.02 (m, αCHLeuol), 4.18-4.26 (m, αCHLeu),
4.26-4.38 (m, αCHPro), 4.39-4.48 (m, αCHPro, αCHLeu).
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Synthesis of Hypomurocin A1, Ac-Aib-Gln-Val-Val-Aib-Pro-Leu-Leu-Aib-Pro-
Leuol (5)
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According to protocol A, the tripeptide Ac-Aib-Gln-Val-OH (51; 153.7 mg, 0.413
mmol), the N-unprotected octapeptide 71 (333 mg, 0.413 mmol), HOBt (63.3 mg, 0.413
mmol), and TBTU (132.5 mg, 0.413 mmol) were dissolved in MeCN (27 ml), and TEA
(174 µl, 1.238 mmol) was added. After the completion of the reaction, the mixture was
purified by flash chromatography to give the undecapeptaibol 5 (197 mg, 41%). White
powder. Rf(C) = 0.35. M.p. 163-165 °C. RP-HPLC (II): tR 51.38, λ 215.
IR (KBr): 3309vs, 2960s, 2873m, 1647vs, 1535vs, 1470s, 1414s, 1385m, 1366m,
1287m, 1195m, 1172m, 619m.
1H-NMR (600 MHz, CD3OD): 0.84 (d, J = 6.6, δCH3Leu), 0.88 (d, J = 6.6, δCH3Leu),
0.90 (d, J = 6.6, δCH3Leuol), 0.92 (d, J = 6.6, δCH3Leu), 0.97 (d, J = 6.6, γCH3Val), 0.99
(d, J = 6.6, δCH3Leuol), 1.00 (d, J = 6.6, δCH3Leu), 1.02 (2 d, J = 6.6, γCH3Val, γCH3Val),
1.07 (d, J = 6.6, γCH3Val), 1.33-1.37 (m, βCH2bLeuol), 1.46 (3 s, 2 βCH3Aib, βCH3Aib),
1.49 (s, βCH3Aib), 1.52 (s, βCH3Aib), 1.55 (s, βCH3Aib), 1.56-1.61 (m, βCH2bLeu,
βCH2aLeuol), 1.62-1.81 (m, βCH2bPro, γCHLeu, βCH2bPro, γCHLeuol, βCH2abLeu), 1.82-1.91
(m, γCHLeu, γCH2bPro), 1.95-2.02 (m, βCH2aLeu, γCH2bPro, γCH2aPro), 2.04 (s, CH3Ac),
2.05-2.15 (m, γCH2aPro, βCH2Gln), 2.17-2.23 (m, βCHVal), 2.25-2.32 (m, βCH2aPro,
βCHVal), 2.33-2.36 (m, βCH2aPro), 2.38-2.43 (m, γCH2bGln), 2.46-2.50 (m, γCH2aGln),
3.32-3.36 (m, δCH2bPro), 3.49, 3.54 (ABX, J = 11.0, 5.9, CH2OHLeuol), 3.52-3.56 (m,
δCH2bPro), 3.80-3.86 (m, δCH2aPro, δCH2aPro), 3.94-3.98 (m, αCHLeuol), 3.96 (d, J = 8.1,
αCHVal), 4.06 (dd, J = 7.3, 4.4, αCHGln), 4.11 (d, J = 7.3, αCHVal), 4.17 (dd, J = 11.7,
3.7, αCHLeu), 4.33 (t, J = 8.1, αCHPro), 4.43-4.48 (m, αCHPro, αCHLeu).
13C-NMR (150.9 MHz, CD3OD): 19.6, 19.7 (2 q, γCH3Val, γCH3Val), 20.1 (q, γCH3Val,
γCH3Val), 21.0 (q, δCH3Leu), 21.2 (q, δCH3Leu), 22.1 (q, δCH3Leuol), 23.2 (q, CH3Ac), 23.6
(q, δCH3Leu), 23.7 (q, δCH3Leu), 23.8 (q, βCH3Aib), 24.2 (q, δCH3Leuol, βCH3Aib), 24.3 (q,
βCH3Aib), 25.9 (d, γCHLeu), 26.1 (q, βCH3Aib), 26.1 (d, γCHLeuol), 26.2 (d, γCHLeu), 26.5
(t, βCH2Gln), 26.8 (t, γCH2Pro), 26.8 (q, βCH3Aib), 27.0 (q, βCH3Aib), 27.1 (t, γCH2Pro),
30.1 (t, βCH2Pro), 30.2 (t, βCH2Pro), 30.7 (d, βCHVal), 31.5 (d, βCHVal), 32.3 (t, γCH2Gln),
40.4 (t, βCH2Leuol), 40.5 (t, βCH2Leu), 41.4 (t, βCH2Leu), 50.4 (t, δCH2Pro), 50.7 (t,
δCH2Pro), 51.2 (d, αCHLeuol), 53.1 (d, αCHLeu), 55.1 (d, αCHLeu), 57.5, 57.9, 58.0 (3 s,
αCAib, αCAib, αCAib), 57.6 (d, αCHGln), 61.6 (d, αCHVal), 63.0 (d, αCHVal), 64.4 (d,
αCHPro), 65.2 (d, αCHPro), 65.8 (t, CH2OHLeuol), 173.8, 174.3, 174.4, 174.6, 174.7,
174.8, 175.1, 175.2, 176.1, 178.0, 178.5 (11 s, 12 CO).
ESI-MS (MeOH+NaI): 1184.1 (27%, [M+Na]+), 603.7 (100%, [M+2Na]2+).
Anal. calc. for C57H100N12O13 ⋅ 2.5 H2O (MG 1206.53): C 56.74, H 8.77, N 13.93;
found: C 56.63, H 8.57, N 13.73.
[α] 23D  = +3.3 (c = 0.9, AcOEt).
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Synthesis of Z-Ile-Aib-Pro-OMe (74)
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According to protocol B, 2 (1782.4 mg, 7.266 mmol) was dissolved in CH2Cl2 (80 ml),
Z-Ile-OH (1752.5 mg, 6.605 mmol) was added, and the mixture was stirred overnight.
Then, the solvent was evaporated and the crude product purified by flash
chromatography to give 74 (1559 mg, 51%). White foam. Rf(A) = 0.65. M.p. 115-117
°C. RP-HPLC (II): λ 219.
IR (KBr): 3279vs, 3065s, 3036m, 2966vs, 2928s, 2877m, 1752vs, 1718vs, 1666vs,
1622vs, 1540vs, 1454vs, 1416vs, 1384s, 1364vs, 1271vs, 1241vs, 1205vs, 1162vs,
1125s, 1095m, 1046s, 1027s, 947w, 924w, 912w, 852w, 777m, 754 m, 739s, 697s,
646m, 616m.
1H-NMR (300 MHz, CD3OD): 0.86-0.97 (m, γCH3Ile, δCH3Ile), 1.13-1.30 (m, γCH2aIle),
1.43, 1.45 (2 s, 2 βCH3Aib), 1.47-1.57 (m, γCH2bIle), 1.58-1.68 (m, γCH2aPro), 1.69-1.80
(m, βCH2bPro, βCHIle), 1.80-1.95 (m, γCH2bPro, βCH2aPro), 3.46-3.57 (m, δCH2aPro), 3.57-
3.65 (m, δCH2bPro), 3.67 (s, OMe), 3.93-4.00 (m, αCHIle), 4.38 (dd, J = 8.4, 3.7,
αCHPro), 5.02, 5.14 (AB, J = 12.6, CH2Z), 7.07 (br. d, J = 8.8, NHIle), 7.25-7.38 (m, 5
arom. CHZ), 8.49 (br. s, NHAib).
13C-NMR (75.5 MHz, CD3OD): 11.1 (q, δCH3Ile), 15.9 (q, γCH3Ile), 24.5 (q, βCH3Aib),
25.7 (q, βCH3Aib), 25.9 (t, γCH2Ile), 26.7 (t, γCH2Pro), 28.8 (t, βCH2Pro), 38.2 (d, βCHIle),
49.1 (t, δCH2Pro), 52.5 (q, OMe), 57.6 (s, αCAib), 60.5 (d, αCHIle), 62.0 (d, αCHPro), 67.5
(t, CH2Z), 128.7, 129.0, 129.5 (3 d, 5 arom. CHZ), 138.4 (s, arom. CZ), 158.4 (s,
OCONHZ), 173.5, 173.9, 174.8 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 498.2 (20%), 484.2 (100%, [M+Na]+).
Anal. calc. for C24H35N3O6 · 0.5 H2O (MG 470.51): C 61.27, H 7.71, N 8.93; found: C
61.33, H 7.89, N 8.87.
[α] 20D  = − 69.0 (c = 0.10, MeOH).
Synthesis of Z-Ile-Aib-Pro-OH (75)
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According to protocol C, 74 (1.71 g, 3.70 mmol) was dissolved in a mixture of THF,
MeOH, and H2O (126 ml), and LiOH⋅H2O (466 mg, 11.11 mmol) was added. After the
workup, the solvent was evaporated to give 75 (1.32 g, 80%). White foam. Rf(A) = 0.09.
M.p. 90-92 °C. RP-HPLC (II): tR 29.22, λ 218.
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IR (KBr): 3417vs, 3036s, 2965vs, 2933vs, 2877s, 1713vs, 1611vs, 1535vs, 1455vs,
1403vs, 1251vs, 1175s, 1130s, 1089s, 1042vs, 1027s, 983m, 911w, 880w, 850w, 821w,
776m, 737s, 697s, 661m, 619m.
1H-NMR (300 MHz, CD3OD): 0.86-0.95 (m, γCH3Ile, δCH3Ile), 1.06-1.23 (m, γCH2aIle),
1.44, 1.46 (2 s, 2 βCH3Aib), 1.50-1.59 (m, γCH2bIle), 1.59-1.68 (m, γCH2aPro), 1.69-1.95
(m, γCH2bPro, βCH2Pro, βCHIle), 3.47-3.66 (m, δCH2Pro), 3.97 (t, J = 8.3, αCHIle), 4.38
(dd, J = 8.4, 3.5, αCHPro), 5.02, 5.15 (AB, J = 12.5, CH2Z), 7.06 (br. d, J = 8.8, NHIle),
7.26-7.37 (m, 5 arom. CHZ), 8.49 (br. s, NHAib).
13C-NMR (75.5 MHz, CD3OD): 11.2 (q, δCH3Ile), 15.9 (q, γCH3Ile), 24.6 (q, βCH3Aib),
25.7 (q, βCH3Aib), 26.0 (t, γCH2Ile), 26.7 (t, γCH2Pro), 29.1 (t, βCH2Pro), 38.2 (d, βCHIle),
49.1 (t, δCH2Pro), 57.6 (s, αCAib), 60.5 (d, αCHIle), 62.0 (d, αCHPro), 67.5 (t, CH2Z),
128.7, 129.0, 129.5 (3 d, 5 arom. CHZ), 138.4 (s, arom. CZ), 158.5 (s, OCONHZ), 173.5,
173.9, 176.1 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 470.1 (100%, [M+Na]+).
[α] 20D  = − 48.6 (c = 1.00, MeOH).
Synthesis of Z-Ile-Aib-Pro-Leuol (76)
O N
H
H
N
N
O
O
O
H
N
O
OH
According to protocol A, a mixture of 75 (1.237 g, 2.76 mmol), H-Leuol · HCl (424.7
mg, 2.76 mmol), TBTU (887.5 mg, 2.76 mmol), and HOBt (373 mg, 2.76 mmol) was
dissolved in MeCN (160 ml), and TEA (1166 µl, 8.29 mmol) was added. After
completion of the reaction, the mixture was purified by flash chromatography to give 76
(946.5 mg, 63%). White solid. Rf(B) = 0.57. M.p. 192-195 °C. RP-HPLC (II): tR
49.53, λ 219.
IR (KBr): 3466vs, 3392s, 3294vs, 3005s, 2972vs, 2877s, 1720vs, 1630vs, 1555vs,
1514vs, 1469s, 1413vs, 1381s, 1363m, 1327s, 1310m, 1286s, 1245vs, 1198s, 1171s,
1150m, 1087s, 1067s, 1037s, 1009m, 992m, 914w, 867w, 792w, 758s, 721m, 701m,
651w, 625m.
1H-NMR (300 MHz, CD3OD): 0.86-0.96 (m, 2 δCH3Leuol, γCH3Ile, δCH3Ile), 1.10-1.38
(m, βCH2aLeuol, γCH2aIle), 1.41, 1.47 (2 br. s, 2 βCH3Aib), 1.50-1.85 (m, βCH2bLeuol,
γCH2bIle, γCHLeuol, γCH2Pro, βCH2aPro, βCHIle), 2.10-2.20 (m, βCH2bPro), 3.33-3.43 (m,
δCH2aPro), 3.46 (d, J = 5.3, CH2OHLeuol), 3.63-3.71 (m, δCH2bPro), 3.90-4.00 (m,
αCHLeuol), 4.01 (d, J = 8.1, αCHIle), 4.40 (dd, J = 8.5, 5.3, αCHPro), 5.03, 5.13 (AB, J =
12.7, CH2Z), 7.26-7.38 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 11.6 (q, δCH3Ile), 16.3 (q, γCH3Ile), 22.2, 23.9 (2 q, 2
δCH3Leuol), 24.3, 26.0 (2 q, 2 βCH3Aib), 26.1 (t, γCH2Pro), 26.1 (d, γCHLeuol), 26.6 (t,
γCH2Ile), 30.0 (t, βCH2Pro), 38.0 (d, βCHIle), 40.7 (t, βCH2Leuol), 49.6 (t, δCH2Pro), 51.2
(d, αCHLeuol), 57.9 (s, αCAib), 61.4 (d, αCHIle), 64.2 (d, αCHPro), 65.8 (t, CH2OHLeuol),
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67.7 (t, CH2Z), 128.8, 129.0, 129.5 (3 d, 5 arom. CHZ), 138.3 (s, arom. CZ), 158.4 (s,
OCONHZ), 174.1, 174.5, 174.6 (3 s, 3 CO).
ESI-MS (MeOH+NaI): 569.3 (100%, [M+Na]+).
Anal. calc. for C29H46N4O6 · H2O (MG 564.72): C 61.68, H 8.57, N 9.92; found: C
61.98, H 8.21, N 9.99.
[α] 20D  = − 28.7 (c = 1.00, MeOH).
Z-Ile-Aib-(R)Pro-Leuol (79)
O N
H
H
N
N
O
O
O
H
N
O
OH
After the purification of 76 by flash chromatography, a small fraction was isolated and
identified as 79 (~10 mg, ~1%, see Figure 26). White crystals.
Synthesis of H-Ile-Aib-Pro-Leuol (77)
H2N
H
N
N
O
O
H
N
O
OH
According to protocol D, to a solution of 76 (946.5 mg, 1.731 mmol) in MeOH (67 ml),
Pd/C was added and the mixture was stirred under an H2 atmosphere overnight. After
completion of the reaction and filtration through Celite, the solvent was evaporated to
give 77 (738 mg, quant.). White foam. Rf(B) = 0.13. M.p. 140-141 °C. RP-HPLC (II): tR
25.02, λ 218.
IR (KBr): 3406vs, 3360s, 3278vs, 3071w, 2958s, 2933s, 2875m, 1639vs, 1548s, 1504m,
1465s, 1453m, 1406s, 1380m, 1361m, 1305w, 1279w, 1236w, 1195w, 1173m, 1149m,
1093w, 1073w, 1048w, 1033w, 708w, 618w.
1H-NMR (300 MHz, CD3OD): 0.88-0.96 (m, 2 δCH3Leuol, δCH3Ile), 1.05 (d, J = 6.8,
γCH3Ile), 1.14-1.28 (m, γCH2aIle), 1.29-1.40 (m, βCH2aLeuol), 1.48, 1.49 (2 s, 2 βCH3Aib),
1.45-1.57 (m, βCH2bLeuol, γCH2bIle, γCHLeuol), 1.76-1.97 (m, γCH2Pro, βCH2aPro, βCHIle),
2.18-2.31 (m, βCH2bPro), 3.38 (d, J = 4.2, αCHIle), 3.46-3.56 (m, CH2OHLeuol, δCH2bPro),
3.72-3.82 (m, δCH2aPro), 3.94-4.04 (m, αCHLeuol), 4.43 (dd, J = 8.2, 5.8, αCHPro).
13C-NMR (75.5 MHz, CD3OD): 12.1 (q, δCH3Ile), 16.3 (q, γCH3Ile), 22.2, 23.8 (2 q, 2
δCH3Leuol), 24.3 (q, βCH3Aib), 25.1 (t, γCH2Pro), 26.1 (d, γCHLeuol), 26.3 (q, βCH3Aib),
26.7 (t, γCH2Ile), 30.1 (t, βCH2Pro), 39.8 (d, βCHIle), 40.7 (t, βCH2Leuol), 49.6 (t, δCH2Pro),
50.1 (d, αCHLeuol), 57.8 (s, αCAib), 60.3 (d, αCHIle), 64.3 (d, αCHPro), 65.8 (t,
CH2OHLeuol), 174.4, 174.7, 175.4 (3 s, 3 CO).
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ESI-MS (MeOH+NaI): 435.3 (100%, [M+Na]+).
Anal. calc. for C21H40N4O4 · 0.5 H2O (MG 421.58): C 59.83, H 9.80, N 13.29; found: C
60.13, H 9.96, N 13.17.
[α] 20D  = − 5.2 (c = 0.50, MeOH).
Synthesis of Z-Leu-Ile-Aib-Pro-Leuol (78)
H
N
N
H
N
O
O
N
H
O
OH
N
H
O
O
O
According to protocol A, a mixture of 77 (700 mg, 1.70 mmol), Z-Leu-OH (450.1 mg,
1.70 mmol), TBTU (544.8 mg, 1.70 mmol), and HOBt (260.5 mg, 1.70 mmol) was
dissolved in MeCN (70 ml), and TEA (715 µl, 5.09 mmol) was added. As 77 was not
very soluble in MeCN, 20 ml DMF were added. After completion of the reaction, the
mixture was purified by flash chromatography to give 78 (1086 mg, 97%). White foam.
Rf(B) = 0.70. M.p. 88-90 °C. RP-HPLC (II): tR 29.18, λ 218.
IR (KBr): 3308vs, 3035m, 2960vs, 2874s, 1704vs, 1648s, 1544vs, 1468s, 1454s, 1410s,
1384s, 1366s, 1342m, 1263s, 1172m, 1120m, 1043s, 739w, 697m, 616m.
1H-NMR (300 MHz, CD3OD): 0.86-0.98 (m, 2 δCH3Leu, 2 δCH3Leuol, δCH3Ile, γCH3Ile),
1.10-1.26 (m, γCH2aIle), 1.28-1.39 (m, βCH2aLeuol), 1.40, 1.43 (2 s, 2 βCH3Aib), 1.44-1.64
(m, βCH2Leu, βCH2bLeuol, γCH2bIle, γCHLeuol), 1.64-1.77 (m, γCHLeu), 1.77-1.85 (m,
βCH2aPro), 1.80-1.97 (m, γCH2Pro, βCHIle), 2.14-2.25 (m, βCH2bPro), 3.51 (t, J = 5.6,
CH2OHLeuol), 3.56-3.64 (m, δCH2Pro), 3.94-4.04 (m, αCHLeuol), 4.12-4.18 (m, αCHLeu),
4.23 (d, J = 7.2, αCHIle), 4.39-4.45 (m, αCHPro), 5.09, 5.16 (AB, J = 12.7, CH2Z), 7.26-
7.38 (m, 5 arom. CHZ). 
13C-NMR (75.5 MHz, CD3OD): 11.5 (q, δCH3Ile), 16.3 (q, γCH3Ile), 21.9 (q, δCH3Leu),
22.2 (q, δCH3Leuol), 23.4 (q, δCH3Leu), 23.8 (q, δCH3Leuol), 24.2 (q, βCH3Aib), 25.8 (q,
βCH3Aib), 25.9 (t, γCH2Pro), 26.0 (d, γCHLeuol), 26.1 (d, γCHLeu), 26.7 (t, γCH2Ile), 30.1 (t,
βCH2Pro), 37.5 (d, βCHIle), 40.7 (t, βCH2Leuol), 41.9 (t, βCH2Leu), 49.3 (t, δCH2Pro), 51.0
(d, αCHLeuol), 55.4 (d, αCHIle), 58.0 (s, αCAib), 59.0 (d, αCHLeu), 64.2 (d, αCHPro), 65.8
(t, CH2OHLeuol), 67.7 (t, CH2Z), 128.7, 129.1, 129.6 (3 d, 5 arom. CHZ), 138.3 (s, arom.
CZ), 158.6 (s, OCONHZ), 173.1, 174.4, 174.6, 175.4 (4 s, 4 CO).
ESI-MS (MeOH+NaI): 682.3 (44%, [M+Na]+), 435.3 (100%).
Anal. calc. for C35H57N5O7 · 0.5 H2O (MG 668.41): C 62.89, H 8.75, N 10.48; found: C
62.62, H 8.91, N 10.54.
[α] 20D  = − 56.9 (c = 1.00, MeOH).
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Synthesis of H-Leu-Ile-Aib-Pro-Leuol (73)
H
N
N
H
N
O
O
N
H
O
OH
H2N
O
According to protocol D, to a solution of 78 (1033 mg, 1.565 mmol) in MeOH (60 ml),
Pd/C was added and the mixture was stirred under an H2 atmosphere overnight. After
completion of the reaction and filtration through Celite, the solvent was evaporated to
give 73 (821 mg, quant.). White foam. Rf(B) = 0.15. M.p. 76-77 °C. RP-HPLC (II): tR
30.15, λ 220.
IR (KBr): 3311vs, 2959vs, 2874s, 1648vs, 1547vs, 1469s, 1408s, 1385s, 1366s, 1307m,
1243w, 1198m, 1172m, 1103w, 1068w, 1038w, 618w.
1H-NMR (300 MHz, CD3OD): 0.86-1.00 (m, 2 δCH3Leu, 2 δCH3Leuol, δCH3Ile, γCH3Ile),
1.15-1.33 (m, γCH2aIle), 1.31-1.40 (m, βCH2aLeu, βCH2aLeuol), 1.46 (br. s, 2 βCH3Aib),
1.47-1.65 (m, βCH2bLeu, βCH2bLeuol, γCH2bIle, γCHLeuol), 1.66-1.78 (m, γCHLeu), 1.79-2.00
(m, βCH2aPro, γCH2Pro, βCHIle), 2.16-2.27 (m, βCH2bPro), 3.50-3.64 (m, αCHLeu,
CH2OHLeuol), 3.64-3.74 (m, δCH2Pro), 3.97-4.07 (m, αCHLeuol), 4.28 (d, J = 7.3, αCHIle),
4.43 (dd, J = 9.0, 5.3, αCHPro). 
13C-NMR (75.5 MHz, CD3OD): 11.5 (q, δCH3Ile), 16.3 (q, γCH3Ile), 22.2 (q, δCH3Leuol),
22.2 (q, δCH3Leu), 23.5 (q, δCH3Leuol), 23.8 (q, δCH3Leu), 24.0 (q, βCH3Aib), 25.5 (q,
βCH3Aib), 25.6 (t, γCH2Pro), 25.9 (d, γCHLeuol), 26.1 (d, γCHLeuol), 26.5 (t, γCH2Ile), 29.9
(t, βCH2Pro), 37.6 (d, βCHIle), 40.5 (t, βCH2Leuol), 45.2 (t, βCH2Leu), 49.5 (t, δCH2Pro),
50.9 (d, αCHLeuol), 54.2 (d, αCHIle), 57.9 (s, αCAib), 58.9 (d, αCHLeu), 64.1 (d, αCHPro),
65.8 (t, CH2OHLeuol), 173.3, 174.2, 174.4, 177.7 (4 s, 4 CO).
ESI-MS (MeOH+NaI): 548.3 (100%, [M+Na]+).
Anal. calc. for C27H51N5O5 · 1.5 H2O (MG 552.73): C 58.67, H 9.85, N 12.67; found: C
58.84, H 9.73, N 12.48.
[α] 20D  = − 46.7 (c = 1.00, MeOH).
Synthesis of Z-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol (80)
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According to protocol A, a mixture of 73 (781.2 mg, 1.49 mmol), Z-Leu-Aib-Pro-OH
63 (665 mg, 1.49 mmol), TBTU (477.2 mg, 1.49 mmol), and HOBt (228.2 mg, 1.49
mmol) was dissolved in MeCN (110 ml), and TEA (627 µl, 4.46 mmol) was added.
After completion of the reaction, the mixture was purified by flash chromatography to
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give 80 (1381 mg, 97%). White foam. Rf(B) = 0.22, Rf(C) = 0.35. M.p. 116-117 °C. RP-
HPLC (II): λ 218.
IR (KBr): 3442vs, 3296vs, 3036m, 2958vs, 2926s, 2874s, 1722s, 1648vs, 1539vs, 1469s,
1454s, 1415s, 1383s, 1365s, 1342m, 1304m, 1260s, 1220m, 1202m, 1172s, 1126w,
1047m, 746w, 719w, 700m, 682w, 657w, 643w, 620m.
1H-NMR (600 MHz, CD3OD): 0.82 (t, J = 7.2, δCH3Ile), 0.86-1.01 (m, 2 δCH3Leu, 2
δCH3Leu, 2 δCH3Leuol, γCH3Ile), 1.09-1.21 (m, γCH2aIle), 1.24-1.40 (m, βCH2aLeuol), 1.42-
1.46 (m, γCH2bIle), 1.46, 1.47 (2 br. s, 4 βCH3Aib), 1.50-1.68 (m, βCH2Leu,  βCH2bLeu,
 βCH2bLeuol, γCHLeu,  γCHLeu,  γCHLeuol), 1.68-1.80 (m, βCH2bPro, βCH2bPro), 1.79-1.88
(m, γCH2aPro,  γCH2Pro), 1.88-2.00 (m, βCHIle, γCH2bPro, βCH2aLeu), 2.20-2.33 (m,
βCH2aPro, βCH2aPro), 3.23-3.31 (m, δCH2bPro), 3.47-3.59 (m, δCH2abPro, CH2OHLeuol),
3.77-3.86 (m, δCH2aPro), 3.92-4.05 (m, αCHLeuol), 4.12 (dd, J = 8.7, 5.7, αCHLeu), 4.16-
4.25 (m, αCHLeu), 4.25-4.36 (m, αCHIle, αCHPro), 4.43 (t, J = 7.7, αCHPro), 5.08, 5.19
(AB, J = 12.6, CH2Z), 7.27-7.43 (m, 5 arom. CHZ).
13C-NMR (150.9 MHz, CD3OD): 11.7 (q, δCH3Ile), 16.3 (q, γCH3Ile), 21.0 (q, δCH3Leu),
21.2 (q, δCH3Leu), 22.1 (q, βCH3Aib), 23.4 (q, δCH3Leu), 23.5 (q, βCH3Aib), 23.7 (q,
δCH3Leu), 24.1 (q, δCH3Leuol), 24.3 (q, δCH3Leuol), 25.8 (q, βCH3Aib), 26.0 (d, γCHLeuol),
26.0 (d, γCHLeu), 26.1 (q, βCH3Aib), 26.2 (d, γCHLeu), 26.7 (t, γCH2Ile), 26.8 (t, γCH2Pro),
27.0 (t, γCH2Pro), 29.8 (t, βCH2Pro), 30.2 (t, βCH2Pro), 38.0 (d, βCHIle), 40.4 (t, βCH2Leu),
 40.4 (t, βCH2Leuol), 41.3 (t, βCH2Leu), 49.9 (t, δCH2Pro), 50.3 (t, δCH2Pro), 51.2 (d,
αCHLeuol), 53.1 (d, αCHLeu), 55.1 (d, αCHLeu), 57.9 (s, 2 αCAib), 62.0 (d, αCHIle), 64.3
(d, αCHPro), 65.1 (d, αCHPro), 65.8 (t, CH2OHLeuol), 67.9 (t, CH2Z), 128.9, 129.2, 129.6
(3 d, 5 arom. CHZ), 138.3 (s, arom. CZ), 158.4 (s, OCONHZ), 174.3, 174.4, 174.5,
174.7, 175.0, 175.8 (6 s, 7 CO).
ESI-MS (MeOH+NaI): 977.5 (100%, [M+Na]+).
Anal. calc. for C50H82N8O10 · H2O (MG 973.22): C 61.71, H 8.70, N 11.51; found: C
61.72, H 8.73, N 11.48.
[α] 20D  = − 5.5 (c = 1.00, MeOH).
Synthesis of H-Leu-Aib-Pro-Leu-Ile-Aib-Pro-Leuol (81)
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According to protocol D, to a solution of 80 (155 mg, 0.162 mmol) in MeOH (30 ml),
Pd/C was added and the mixture was stirred under an H2 atmosphere overnight. After
completion of the reaction and filtration through Celite, the solvent was evaporated to
give 81 (130.4 mg, 98%). White foam. Rf(C) = 0.22. M.p. 95-96 °C. RP-HPLC (II): tR
85, λ 217.
IR (KBr): 3312vs, 2959vs, 2873s, 1647vs, 1536vs, 1469vs, 1412vs, 1384s, 1365s,
1340m, 1286s, 1245m, 1196s, 1172s, 1147m, 1101w, 1069m, 1039w, 673w, 618m.
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1H-NMR (300 MHz, CD3OD): 0.84 (t, J = 7.4, δCH3Ile), 0.87-1.03 (m, 2 δCH3Leu, 2
δCH3Leu, 2 δCH3Leuol, γCH3Ile), 1.28-1.44 (m, βCH2bLeu, γCH2bIle), 1.44-1.69 (m, γCH2aIle,
βCH2bLeu, βCH2Leuol, βCH2aLeu, γCHLeu), 1.47, 1.48, 1.50, 1.53 (4 br. s, 4 βCH3Aib), 1.69-
1.85 (m, βCH2bPro, βCH2bPro, γCHLeu, γCHLeuol), 1.85-2.04 (m, βCH2aLeu, γCH2Pro, βCHIle,
γCH2Pro), 2.21-2.43 (m, βCH2aPro, βCH2aPro), 3.24-3.32 (m, δCH2bPro), 3.39-3.45 (m,
αCHLeu), 3.46-3.60 (m, δCH2bPro, CH2OHLeuol), 3.78-4.02 (m, δCH2aPro, δCH2aPro,
αCHLeuol), 4.21 (dd, J = 11.3, 3.8, αCHLeu), 4.28-4.40 (m, αCHIle, αCHPro), 4.44 (t, J =
7.5, αCHPro).
13C-NMR (75.5 MHz, CD3OD): 10.8 (q, δCH3Ile), 16.1 (q, γCH3Ile), 21.2 (q, δCH3Leu),
22.1 (q, δCH3Leu), 22.2 (q, βCH3Aib), 23.6 (q, δCH3Leu), 23.8 (q, βCH3Aib), 24.0 (q,
δCH3Leu), 24.0 (q, δCH3Leuol), 24.3 (q, δCH3Leuol), 25.8 (q, βCH3Aib), 26.0 (d, γCHLeuol),
26.3 (d, γCHLeu), 26.4 (q, βCH3Aib), 26.4 (d, γCHLeu), 26.7 (t, γCH2Ile), 26.9 (t, γCH2Pro),
27.1 (t, γCH2Pro), 30.1 (t, βCH2Pro), 30.2 (t, βCH2Pro), 37.8 (d, βCHIle), 40.5 (t,
βCH2Leuol), 40.7 (t, βCH2Leu), 45.4 (t, βCH2Leu), 50.1 (t, δCH2Pro), 50.3 (t, δCH2Pro), 51.2
(d, αCHLeuol), 54.6 (d, αCHLeu), 55.0 (d, αCHLeu), 57.4, 58.1 (2 s, 2 αCAib), 59.3 (d,
αCHIle), 64.5 (d, αCHPro), 65.0 (d, αCHPro), 65.8 (t, CH2OHLeuol), 173.2, 174.4, 174.6,
175.1, 175.4, 175.8, 178.6 (7 s, 7 CO).
ESI-MS (MeOH+NaI): 843.5 (100%, [M+Na]+).
Anal. calc. for C42H76N8O8 · 0.5 H2O (MG 831.11): C 60.77, H 9.35, N 13.50; found: C
60.75, H 9.35, N 13.50.
[α] 20D  = − 1.4 (c = 1.00, MeOH).
Synthesis of Hypomurocin A3, Ac-Aib-Gln-Val-Leu-Aib-Pro-Leu-Ile-Aib-Pro-
Leuol (6)
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According to protocol A, a mixture of 81 (130.4 mg, 0.16 mmol), Ac-Aib-Gln-Val-OH
51 (59.1 mg, 0.16 mmol), TBTU (51 mg, 0.16 mmol), and HOBt (24.4 mg, 0.16 mmol)
was dissolved in MeCN (15 ml), and TEA (67 µl, 0.48 mmol) was added. After
completion of the reaction, the mixture was purified by flash chromatography to give 6
(126 mg, 68%). White foam. Rf(C) = 0.26. M.p. 239-240 °C. RP-HPLC (II): tR 117, λ
217.
IR (KBr): 3394vs, 3059w, 2959vs, 2928vs, 2874s, 1647vs, 1539vs, 1469vs, 1440s,
1415s, 1384s, 1364s, 1290s, 1265s, 1219s, 1193s, 1172s, 1126m, 1094m, 1050m,
1030m, 688w, 618s.
1H-NMR (600 MHz, CD3OD): 0.84 (t, J = 7.3, δCH3Ile), 0.87 (d, J = 6.4, δCH3Leu),
0.90-0.94 (m, δCH3Leu, δCH3Leuol, δCH3Leu), 0.95-0.98 (m, γCH3Ile, δCH3Leuol), 1.00-1.03
(m, γCH3Val, δCH3Leu), 1.06 (d, J = 6.9, γCH3Val), 1.28-1.38 (m, γCH2bIle, βCH2bLeuol),
1.47, 1.48, 1.49 (3 br. s, 6 βCH3Aib), 1.49-1.55 (m, γCH2aIle), 1.57-1.64 (m, βCH2aLeuol,
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βCH2bLeu, βCH2bLeu), 1.64-1.69 (m, γCHLeuol), 1.71-1.81 (m, γCHLeu, βCH2bPro, βCH2bPro,
 βCH2aLeu), 1.81-1.86 (m, γCHLeu), 1.86-1.91 (m, γCH2bPro), 1.91-2.02 (m, βCH2aLeu,
βCHIle, γCH2aPro, γCH2bPro), 2.05-2.08 (m, γCH2aPro), 2.08-2.15 (m, βCH2Gln), 2.24-2.31
(m, βCH2aPro, βCHVal), 2.31-2.38 (m, βCH2aPro), 2.38-2.45 (m, γCH2bGln), 2.45-2.51 (m,
γCH2aGln), 3.25-3.30 (m, δCH2bPro), 3.50, 3.56 (ABX, J = 11.3, J = 5.7, CH2OHLeuol),
3.58-3.63 (m, δCH2bPro), 3.80-3.86 (m, δCH2aPro, δCH2aPro), 3.94 (d, J = 8.3, αCHVal),
3.94-3.99 (m, αCHLeuol), 4.06 (dd, J = 7.7, 4.7, αCHGln), 4.20 (dd, J = 11.7, 3.7,
αCHLeu), 4.28 (d, J = 7.9, αCHIle), 4.33-4.37 (m, αCHPro, αCHLeu), 4.44 (t, J = 7.7,
αCHPro).
13C-NMR (150.9 MHz, CD3OD): 10.9 (q, δCH3Ile), 16.0 (q, γCH3Ile), 19.7, 20.0 (2 q, 2
γCH3Val), 21.1 (q, δCH3Leu), 21.2 (q, δCH3Leuol), 22.1 (q, δCH3Leu), 23.2 (q, CH3Ac), 23.5
(q, δCH3Leu), 23.9 (q, δCH3Leu), 24.1 (q, δCH3Leuol), 24.1 (q, βCH3Aib), 24.2 (q, βCH3Aib),
25.7 (d, γCHLeu), 26.0 (d, γCHLeuol), 26.2 (d, γCHLeu), 26.3 (t, γCH2Ile), 26.4 (t, βCH2Gln),
26.4 (q, 2 βCH3Aib), 26.7 (t, γCH2Pro), 26.7 (q, βCH3Aib), 26.9 (t, γCH2Pro), 27.0 (q,
βCH3Aib), 30.2 (t, βCH2Pro), 30.2 (t, βCH2Pro), 30.5 (d, βCHVal), 32.2 (t, γCH2Gln), 37.8
(d, βCHIle), 40.4 (t, βCH2Leuol), 40.7 (t, βCH2Leu), 41.2 (t, βCH2Leu), 50.3 (t, δCH2Pro),
50.6 (t, δCH2Pro), 51.1 (d, αCHLeuol), 53.9 (d, αCHLeu), 55.0 (d, αCHLeu), 57.4 (s, αCAib),
57.8 (s, αCAib),  57.8 (d, αCHGln), 58.0 (s, αCAib), 59.4 (d, αCHIle), 63.0 (d, αCHVal),
64.4 (d, αCHPro), 64.9 (d, αCHPro), 65.8 (t, CH2OHLeuol), 173.2, 173.7, 174.3, 174.6,
175.0, 175.5, 175.9, 175.8, 178.0, 178.5 (10 s, 12 CO).
ESI-MS (MeOH+NaI): 1197.6 (100%, [M+Na]+).
Anal. calc. for C58H102N12O13 · H2O (MG 1193.52): C 58.37, H 8.78, N 14.08; found: C
58.26, H 9.00, N 13.93.
[α] 20D  = − 9.0 (c = 1.00, MeOH).
Synthesis of Z-Gln-Ile-OtBu (54)
N
H
H
N
O
OH2N
O
O
O
O
According to protocol A, a mixture of Z-Gln-OH (62.6 mg, 0.223 mmol), H-Ile-OtBu ·
HCl (50 mg, 0.223 mmol), TBTU (71.7 mg, 0.223 mmol), and HOBt (34.3 mg, 0.223
mmol) was dissolved in MeCN (14 ml), and TEA (94 µl, 0.67 mmol) was added. After
completion of the reaction, the mixture was purified by flash chromatography to give 54
(91.9 mg, 92%). White powder. Rf(B) = 0.80. M.p. 146 °C. RP-HPLC (II): tR 23.05, λ
213.
IR (KBr): 3411s, 3316s, 2969m, 2920m, 2855w, 1724s, 1689s, 1651vs, 1543s, 1455m,
1400w, 1369m, 1329w, 1289m, 1263m, 1168m, 1139m, 1088w, 1061m, 976w, 743w,
695w, 665w, 624w.
1H-NMR (300 MHz, CD3OD): 0.89-0.96 (m, γCH3Ile, δCH3Ile), 1.19-1.32 (m, γCH2aIle),
1.42-1.54 (m, γCH2bIle), 1.46 (s, 3 CH3OtBu), 1.81-1.95 (m, βCH2bGln, βCHIle), 2.01-2.14
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(m, βCH2aGln), 2.34 (t, J = 7.6, γCH2Gln), 4.18-4.27 (m, αCHGln, αCHIle), 5.09 (br. s,
CH2Z), 7.25-7.38 (m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 11.9 (q, δCH3Ile), 16.0 (q, γCH3Ile), 26.4 (t, γCH2Ile),
28.4 (q, 3 CH3OtBu), 29.3 (t, γCH2Gln), 32.6 (t, βCH2Gln), 38.5 (d, βCHIle), 55.7 (d,
αCHGln), 59.0 (d, αCHIle), 67.8 (t, CH2Z), 83.0 (s, COtBu), 128.9, 129.0, 129.5 (3 d, 5
arom. CHZ), 172.1, 177.9 (2 s, 3 CO). The OCONHZ and arom. CZ could not be
identified.
ESI-MS (MeOH+NaI): 921.4 (15%, [2M+Na]+), 488.2 (20%, [M+K]+), 472.2 (100%,
[M+Na]+).
Anal. calc. for C23H35N3O6 (MG 449.54): C 61.45, H 7.85, N 9.35; found: C 61.35, H
7.90, N 9.34.
[α] 20D  = − 19.1 (c = 1.56, MeOH).
Synthesis of H-Gln-Ile-OtBu (56)
H2N
H
N
O
OH2N
O
O
According to protocol D, to a solution of 54 (638.7 mg, 1.421 mmol) in MeOH (42 ml),
Pd/C was added and the mixture was stirred under an H2 atmosphere overnight. After
completion of the reaction and filtration through Celite, the solvent was evaporated to
give 56 (448 mg, quant.). White foam. Rf(B) = 0.09. RP-HPLC (II): tR 19.27, λ 203.
1H-NMR (300 MHz, CD3OD): 0.92-0.99 (m, γCH3Ile, δCH3Ile), 1.20-1.36 (m, γCH2aIle),
1.42-1.56 (m, γCH2bIle), 1.47 (s, 3 CH3OtBu), 1.84-1.98 (m, βCH2bGln, βCHIle), 1.98-2.11
(m, βCH2aGln), 2.42 (t, J = 7.8, γCH2Gln), 3.68 (t, J = 6.4, αCHGln), 4.27 (d, J = 5.4,
αCHIle).
13C-NMR (75.5 MHz, CD3OD): 11.9 (q, δCH3Ile), 16.0 (q, γCH3Ile), 26.4 (t, γCH2Ile),
28.3 (3 q, CH3OtBu), 31.0 (t, γCH2Gln), 32.3 (t, βCH2Gln), 38.4 (d, βCHIle), 54.7 (d,
αCHGln), 58.9 (d, αCHIle), 83.1 (s, COtBu), 172.1, 174.5, 178.0 (3 s, 3 CO).
Synthesis of Ac-Aib-Gln-Ile-OtBu (58)
H
N
N
H
OH2N
O
O
N
H
O
O
O
According to protocol A, a mixture of 56 (338 mg, 1.072 mmol), Ac-Aib-OH (155.6
mg, 1.072 mmol), TBTU (344.2 mg, 1.072 mmol), and HOBt (164.6 mg, 1.072 mmol)
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was dissolved in MeCN (65 ml), and TEA (452 µl, 3.215 mmol) was added. After
completion of the reaction, the mixture was purified by flash chromatography to give 58
(311.2 mg, 66%). White foam. Rf(B) = 0.30. M.p. 80-85 °C. RP-HPLC (II): tR 18.09, λ
203.
IR (KBr): 3417vs, 3064w, 2973s, 2935s, 2878w, 1731vs, 1660vs, 1536vs, 1454s, 1383s,
1368s, 1300s, 1257m, 1221s, 1147vs, 1038w, 987w, 847w, 589m.
1H-NMR (300 MHz, CD3OD): 0.89-0.97 (m, γCH3Ile, δCH3Ile), 1.16-1.32 (m, γCH2aIle),
1.43-1.57 (m, γCH2bIle), 1.43, 1.45 (2 s, 2 CH3Aib), 1.46 (s, 3 CH3OtBu), 1.85-2.02 (m,
βCH2bGln, βCHIle), 1.97 (s, CH3Ac), 2.08-2.20 (m, βCH2aGln), 2.31 (t, J = 7.1, γCH2Gln),
4.16 (d, J = 6.3, αCHIle), 4.36 (dd, J = 9.6, 4.5, αCHGln).
13C-NMR (75.5 MHz, CD3OD): 11.8 (q, δCH3Ile), 15.9 (q, γCH3Ile), 23.2 (q, βCH3Aib),
25.6 (q, βCH3Aib), 25.7 (q, CH3Ac), 26.6 (t, γCH2Ile), 28.4 (q, 3 CH3OtBu), 32.5 (t,
βCH2Gln, γCH2Gln), 38.0 (d, βCHIle), 54.4 (d, αCHGln), 57.7 (s, αCAib), 59.2 (d, αCHIle),
82.8 (s, COtBu), 172.0, 173.2, 173.9, 177.0, 178.1 (5 s, 5 CO).
ESI-MS (MeOH+NaI): 465.2 (100%, [M+Na]+).
Anal. calc. for C21H38N4O6 · 0.5 H2O (MG 451.56): C 55.86, H 8.71, N 12.41; found: C
55.94, H 8.54, N 12.41.
[α] 20D  = − 26.4 (c = 2.97, MeOH).
Synthesis of Ac-Aib-Gln-Ile-OH (52)
H
N
N
H
OH2N
O
O
N
H
O
O
OH
At 0 °C, 58 (275 mg, 0.621 mmol) was dissolved in TFA (15 ml) under an N2
atmosphere. After 2.5 h, the reaction was quenched by evaporating the TFA. The
residue was dissolved in a mixture of CH2Cl2/Et2O 1:1 (v/v) and evaporated (3x) to give
52 (238 mg, quant.). White powder. Rf(B) = 0.15, Rf(C) = 0.26. RP-HPLC (II): tR
30.46, λ 205.
IR (KBr): 3437vs, 2926s, 2853m, 1659vs, 1541vs, 1455s, 1204vs, 1139s, 835m, 802m,
723m, 673m, 619m.
1H-NMR (300 MHz, CD3OD): 0.89-0.98 (m, γCH3Ile, δCH3Ile), 1.18-1.33 (m, γCH2aIle),
1.45-1.58 (m, γCH2bIle), 1.44, 1.45 (2 s, 2 CH3Aib), 1.88-2.01 (m, βCH2bGln, βCHIle), 1.96
(s, CH3Ac), 2.07-2.19 (m, βCH2aGln), 2.31 (t, J = 7.1, γCH2Gln), 4.31 (d, J = 6.0, αCHIle),
4.37 (dd, J = 9.2, 4.4, αCHGln).
13C-NMR (75.5 MHz, CD3OD): 11.8 (q, δCH3Ile), 16.0 (q, γCH3Ile), 23.1 (q, βCH3Aib),
25.3 (q, βCH3Aib), 25.9 (q, CH3Ac), 26.4 (t, γCH2Ile), 28.4 (t, βCH2Gln), 32.5 (t, γCH2Gln),
38.1 (d, βCHIle), 54.4 (d, αCHGln), 57.8 (s, αCAib), 58.5 (d, αCHIle), 82.8 (s, COtBu),
173.2, 173.9, 174.4, 177.1, 178.2 (5 s, 5 CO).
ESI-MS (MeOH+NaI): 409.3 (100%, [M+Na]+), 387.3 (20%, [M+H]+).
9. Experimental Part
118
Synthesis of Z-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol (82)
N
H
H
N
N
O
O
H
N
O
OH
H
N
O
N
H
H
N
N
O
O
O
O
O
According to protocol A, a mixture of Z-Ile-Aib-Pro-OH (75) (546 mg, 1.22 mmol), H-
Leu-Leu-Aib-Pro-Leuol (67) (641 mg, 1.22 mmol), TBTU (392 mg, 1.22 mmol), and
HOBt (187.3 mg, 1.22 mmol) was dissolved in MeCN (70 ml), and TEA (514 µl, 3.66
mmol) was added. After completion of the reaction, the mixture was purified by flash
chromatography to give 82 (739 mg, 63%). White foam. Rf(B) = 0.50. M.p. 144 °C. RP-
HPLC (II): tR 58.21, λ 205.
IR (KBr): 3441vs, 2960s, 2872m, 1726s, 1624vs, 1529vs, 1468s, 1412s, 1385s, 1365m,
1339m, 1253s, 1218s, 1171s, 1126m, 1100m, 1039m, 750w, 699w, 616m.
1H-NMR (300 MHz, CD3OD): 0.82-0.99 (m, γCH3Ile, δCH3Ile, 2 δCH3Leuol, 2 δCH3Leu, 2
δCH3Leu), 1.21-1.31 (m, γCH2aIle), 1.32-1.40 (m, βCH2aLeuol), 1.45, 1.48 (2 br. s, 4
βCH3Aib), 1.51-1.57 (m, γCH2bIle), 1.57-1.61 (m, βCH2bLeu, βCH2bLeuol), 1.62-1.71 (m,
βCH2Leu, γCHLeu, γCHLeuol), 1.71-1.79 (m, βCH2bPro, βCH2bPro, γCHLeu), 1.79-1.88 (m,
γCH2Pro, γCH2bPro), 1.88-2.00 (m, βCH2aLeu, βCHIle, γCH2aPro), 2.21-2.32 (m, βCH2aPro,
βCH2aPro), 3.28-3.37 (m, δCH2bPro), 3.46-3.64 (m, CH2OHLeuol, δCH2abPro), 3.79-3.86 (m,
δCH2aPro), 3.91-4.03 (m, αCHIle, αCHLeuol), 4.18 (dd, J = 11.5, 4.0, αCHLeu), 4.28-4.35
(m, αCHPro), 4.40-4.49 (m, αCHPro, αCHLeu), 5.09, 5.20 (AB, J = 12.6, CH2Z), 7.28-7.50
(m, 5 arom. CHZ).
13C-NMR (75.5 MHz, CD3OD): 11.7 (q, δCH3Ile), 16.3 (q, γCH3Ile), 21.0 (q, δCH3Leu),
21.2 (q, δCH3Leu), 22.1, 23.5 (2 q, 2 δCH3Leuol), 23.6 (q, δCH3Leu), 23.7 (q, δCH3Leu),
24.1, 24.3 (2 q, 2 βCH3Aib), 25.8 (d, γCHLeu), 26.0 (d, γCHLeuol), 26.1 (q, βCH3Aib), 26.2
(d, γCHLeu), 26.7 (t, γCH2Ile, γCH2Pro), 26.8 (q, βCH3Aib), 27.0 (t, γCH2Pro), 29.9 (t,
βCH2Pro), 30.2 (t, βCH2Pro), 38.0 (d, βCHIle), 40.4 (t, βCH2Leu, βCH2Leuol), 41.3 (t,
βCH2Leu), 49.5 (t, δCH2Pro), 50.3 (t, δCH2Pro), 51.3 (d, αCHLeuol), 53.2 (d, αCHLeu), 55.1
(d, αCHLeu), 57.9 (s, 2 αCAib), 62.1 (d, αCHIle), 64.4 (d, αCHPro), 65.1 (d, αCHPro), 65.8
(t, CH2OHLeuol), 67.9 (t, CH2Z), 129.0, 129.2, 129.6 (3 d, 5 arom. CHZ), 138.3 (s, arom.
CZ), 158.4 (s, OCONHZ), 174.3, 174.4, 174.5, 174.7, 175.0, 175.9, 176.0 (7 s, 7 CO).
ESI-MS (MeOH+NaI): 977.6 (100%, [M+Na]+), 500.3 (100%, [M+2Na]2+).
Anal. calc. for C50H82N8O10 · 2 H2O (MG 991.27): C 60.58, H 8.75, N 11.30; found: C
60.83, H 8.42, N 11.28.
[α] 20D  = − 4.5 (c = 2.40, MeOH).
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Synthesis of H-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol (83)
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According to protocol D, to a solution of 82 (14 mg, 0.015 mmol) in MeOH (10 ml),
Pd/C was added and the mixture was stirred under an H2 atmosphere overnight. After
completion of the reaction and filtration through Celite, the solvent was evaporated to
give 83 (12 mg, quant.). White foam. Rf(B) = 0.08. M.p. 100-105 °C. RP-HPLC (II): tR
92.86, λ 207.
IR (KBr): 3311vs, 2959vs, 2873s, 1644vs, 1536vs, 1470s, 1412vs, 1385s, 1365s, 1340m,
1283m, 1196m, 1172s, 1101w, 1069w, 1038w, 618m.
1H-NMR (300 MHz, CD3OD): 0.82-1.02 (m, γCH3Ile, δCH3Ile, 2 δCH3Leuol, 2 δCH3Leu, 2
δCH3Leu), 1.11-1.42 (m, γCH2aIle, βCH2aLeuol), 1.44, 1.48, 1.51, 1.54 (4 br. s, 4 βCH3Aib),
1.54-1.83 (m, γCH2bIle, βCH2bLeuol, βCH2bLeu, γCHLeu, βCH2bPro, βCH2bPro,  βCHIle,
 γCHLeuol, βCH2bLeu,  γCHLeu), 1.83-2.05 (m, βCH2aLeu, γCH2Pro, γCH2Pro, βCH2aLeu),
2.20-2.32 (m, βCH2aPro), 2.32-2.42 (m, βCH2aPro), 3.29-3.38 (m, δCH2bPro, αCHIle), 3.43-
3.59 (m, CH2OHLeuol, δCH2bPro), 3.77-4.02 (m, δCH2aPro, δCH2aPro, αCHLeuol), 4.18 (dd, J
= 11.4, 4.2, αCHLeu), 4.31 (t, J = 8.0, αCHPro), 4.40-4.48 (m, αCHPro, αCHLeu).
13C-NMR (75.5 MHz, CD3OD): 12.4 (q, δCH3Ile), 16.4 (q, γCH3Ile), 21.1 (q, δCH3Leu),
21.3 (q, δCH3Leu), 22.2, 23.5 (2 q, 2 δCH3Leuol), 23.6 (q, δCH3Leu), 23.7 (q, δCH3Leu),
24.2, 24.4 (2 q, 2 βCH3Aib), 25.2 (d, γCHLeu), 25.8 (d, γCHLeuol), 26.0 (q, βCH3Aib), 26.2
(d, γCHLeu), 26.2 (t, γCH2Ile), 26.7 (t, γCH2Pro), 26.8 (q, βCH3Aib), 26.8 (t, γCH2Pro), 30.0
(t, βCH2Pro), 30.1 (t, βCH2Pro), 39.9 (d, βCHIle), 40.3 (t, βCH2Leu, βCH2Leuol), 41.2 (t,
βCH2Leu), 49.9 (t, δCH2Pro), 50.2 (t, δCH2Pro), 51.2 (d, αCHLeuol), 53.1 (d, αCHLeu), 55.0
(d, αCHLeu), 57.5, 57.8 (2 s, 2 αCAib), 60.8 (d, αCHIle), 64.3 (d, αCHPro), 65.1 (d,
αCHPro), 65.8 (t, CH2OHLeuol), 174.2, 174.4, 174.6, 175.3, 175.8, 177.5 (6 s, 7 CO).
ESI-MS (MeOH+NaI): 843.6 (100%, [M+Na]+).
Anal. calc. for C42H76N8O8 · H2O (MG 839.12): C 60.12, H 9.37, N 13.35; found: C
59.96, H 9.13, N 13.15.
[α] 20D  = − 5.4 (c = 1.20, MeOH).
Synthesis of Hypomurocin A5, Ac-Aib-Gln-Ile-Ile-Aib-Pro-Leu-Leu-Aib-Pro-Leuol
(7)
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According to protocol A, a mixture of 85 (440 mg, 0.536 mmol), 52 (207 mg, 1.22
mmol), TBTU (172 mg, 0.536 mmol), and HOBt (187.3 mg, 0.536 mmol) was
dissolved in MeCN (30 ml), and TEA (226 µl, 1.608 mmol) was added. After
completion of the reaction, the mixture was purified by flash chromatography to give 7
(195.3 mg, 31%). White foam. Rf(C) = 0.28. M.p. 156-158 °C. RP-HPLC (II): tR
49.51, λ 203.
IR (KBr): 3436vs, 2960s, 2875m, 1641vs, 1539s, 1469m, 1415m, 1385m, 1365m,
1341m, 1292m, 1171m, 1101m, 1068m, 614m.
1H-NMR (300 MHz, CD3OD): 0.83-0.99 (m, δCH3Leu, δCH3Ile, δCH3Leu, δCH3Leuol,
δCH3Leu, δCH3Ile, δCH3Leuol, γCH3Ile, γCH3Ile), 1.01 (d, J = 7.0, δCH3Leu), 1.27-1.39 (m,
βCH2bLeuol, γCH2bIle, γCH2bIle), 1.46, 1.49, 1.51, 1.55 (4 br. s, 8 CH3Aib), 1.54-1.68 (m,
γCHLeuol, βCH2aLeuol, γCH2aIle, γCH2aIle, βCH2bLeu, βCH2bLeu), 1.68-1.82 (m, βCH2aLeu,
βCH2bPro, γCHLeu, βCH2bPro), 1.83-1.91 (m, γCH2bPro, γCHLeu), 1.93-2.01 (m, γCH2bPro,
γCH2aPro, βCHIle), 2.01-2.15 (m, βCH2Gln, γCH2aPro, βCHIle, βCH2aLeu), 2.25-2.31 (m,
βCH2aPro), 2.31-2.37 (m, βCH2aPro), 2.38-2.43 (m, γCH2bGln), 2.45-2.51 (m, γCH2aGln),
3.31-3.36 (m, δCH2bPro), 3.48-3.53 (m, CH2aOHLeuol), 3.53-3.56 (m, CH2bOHLeuol,
δCH2bPro), 3.78-3.83 (m, δCH2aPro), 3.83-3.87 (m, δCH2aPro), 3.94-3.99 (m, αCHLeuol),
4.00 (d, J = 8.8, αCHIle), 4.05 (dd, J = 7.8, 4.4, αCHGln), 4.15-4.20 (m, αCHLeu), 4.18
(d, J = 8.5, αCHIle), 4.33 (t, J = 7.8, αCHPro), 4.43-4.48 (m, αCHPro, αCHLeu).
13C-NMR (75.5 MHz, CD3OD): 10.8 (q, δCH3Ile), 11.1 (q, δCH3Ile), 15.9 (q, γCH3Ile),
16.3 (q, γCH3Ile), 21.0 (q, δCH3Leu), 21.1 (q, δCH3Leu), 22.1 (q, δCH3Leuol), 23.2 (q,
CH3Ac), 23.5 (q, δCH3Leu), 23.7 (q, δCH3Leu), 23.8 (q, δCH3Leuol), 24.1, 24.2, 24.3 (3 q, 3
βCH3Aib), 25.8 (d, γCHLeu), 26.0 (d, γCHLeu), 26.0 (q, βCH3Aib), 26.1 (d, γCHLeuol), 26.5
(t, γCH2Pro), 26.6 (t, βCH2Gln), 26.7 (d, γCHIle), 26.7 (q, βCH3Aib), 27.0 (q, βCH3Aib),
27.1 (t, γCH2Pro), 27.2 (d, γCHIle), 30.0 (t, βCH2Pro), 30.2 (t, βCH2Pro), 32.3 (t, γCH2Gln),
36.7 (d, βCHIle), 37.4 (d, βCHIle), 40.4 (t, βCH2Leu), 41.3 (t, βCH2Leuol), 50.3 (t,
δCH2Pro), 50.6 (t, δCH2Pro), 51.1 (d, αCHLeuol), 53.1 (d, αCHLeu), 55.1 (d, αCHLeu), 57.4
(s, αCAib), 57.5 (d, αCHGln), 57.8 (s, αCAib), 58.0 (s, αCAib), 60.1 (d, αCHIle), 61.4 (d,
αCHIle), 64.3 (d, αCHPro), 65.2 (d, αCHPro), 65.8 (t, CH2OHLeuol).
ESI-MS (MeOH+NaI): 1212.5 (100%, [M+Na]+), 617.4 (55%, [M+2Na]2+).
Anal. calc. for C59H104N12O13 · 2 H2O (MG 1225.37): C 57.82, H 8.88, N 13.71; found:
C 57.75, H 8.85, N 13.81.
[α] 20D  = − 9.0 (c = 0.67, MeOH).
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9.4 RP-HPLC  correlation of synthetic and natural Hypomurocins
MS/MS Nomenclature
Many factors like the primary sequence, the amount of internal energy, the way
the energy is introduced, and the charge state, influence the types of fragment ions
observed in an MS/MS spectrum. Roepstorff and Fohlman [91] were the first who
proposed the accepted nomenclature for these fragment ions. This nomenclature was
modified by Biemann [92].
Figure 38. MS/MS Ion Classification of Peptide Fragments
Fragments can only be detected if they carry at least one charge. If this charge is
retained on the N terminal fragment, the ion is classified as either a, b or c. If the charge
is retained on the C terminus, the ion type is called either x, y or z (Figure 38). A
subscript indicates the number of residues in the fragment.
In addition to the proton(s) at the charge d atom or group, c ions and y ions
abstract an additional proton from the precursor peptide. The structures of the six mono-
charged sequence ions are shown in Figure 39.
Figure 39. Structures of the Six Monocharged Sequence Ions
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According to Brueckner [88], the fragments Pro6-Leu, Pro6-Leu-Leu, Pro6-Leu-
Leu-Aib9, Pro6-Leu-Ile and Pro6-Leu-Ile-Aib9 were labeled PL, PLL, PLLU, PLI and
PLIU, respectively.
HM A1
HPLC-MS: tR 28.9 min; 539.2 (100, b5+), 623.5 (91, y6+), 947.6 (8, b9+), 1161.5 (<1, [M
+ H]+).
MS/MS (539.2): 256.1 (14, b2+), 327.2 (4, b3+ – CO), 355.2 (46, b3+), 454.2 (100, b4+).
MS/MS (623.5): 183.2 (11, [PL + H – CO]+), 211.1 (30, [PL + H]+), 215.2 (6, y2+),
279.2 (6), 296.2 (3, [PLL + H – CO]+), 324.2 (97, [PLL + H]+), 381.2 (6, [PLLU + H –
CO]+), 409.3 (100, [PLLU + H]+).
HM A3
HPLC-MS: tR 29.7 min; 215.2 (5, y2+), 553.3 (100, b5+), 623.4 (95, y6+), 962.5 (9, b9+),
1175.6 (<1, [M + H]+).
MS/MS (553.3): 256.1 (18, b2+), 327.2 (4, b3+ – CO), 355.2 (51, b3+), 440.3 (<1, b4+ –
CO), 468.2 (100, b4+).
MS/MS (623.4): 183.2 (12, [PL + H – CO]+), 211.1 (32, [PL + H]+), 215.2 (6, y2+),
279.2 (3), 296.2 (2, [PLI + H – CO]+), 324.2 (71, [PLI + H]+), 381.3 (3, [PLIU + H –
CO]+), 409.3 (100, [PLIU + H]+).
HM A5
HPLC-MS: tR 31.2 min; 567.4 (77, b5+), 623.4 (100, y6+), 975.5 (9, b9+), 1189.6 (<1, [M
+ H]+).
MS/MS (567.4): 256.1 (25, b2+), 341.2 (4, b3+ – CO), 369.2 (61, b3+), 482.3 (100, b4+).
MS/MS (623.4): 183.1 (14, [PL + H – CO]+), 211.1 (33, [PL + H]+), 215.1 (5, y2+),
279.2 (8), 324.2 (98, [PLL + H]+), 381.3 (6, [PLLU + H – CO]+), 409.3 (100, [PLLU +
H]+).
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9.5 X-Ray Cry stal-Structure Determination
Details of the determination of the X-ray crystal structures of compounds 6, 33,
38, 47, 60, 68, 69, 72, 76, 77, 79, 82, 84 and 85 are consigned in the database of the
Institute of Organic Chemistry (OCI) of the University of Zürich (see chapter 9.1.2, X-
ray crystal-structures).
In Table 10, the data collection and refinement parameters are listed, and views
of the molecules are shown in Figures 28, 11, 12, 19, 20, 21, 24, 25, 27, 26, 30, 40 and
41, respectively.
Finally, crystals of 84, the cyclization product of Z-Gln-OH unit used in the
experiments of this work, were obtained. They were suitable for an X-ray crystal-
structure determination (Scheme 23 and Figure 40).
Scheme 23. Proposed Mechanism for the Formation of 84
N
H
O
X
OH2N
Z NHN
H
O
O
Z
84X: leaving group
Figure 40. ORTEP Plot [86] of the Molecular Structure of 84 (50% probability
ellipsoids; H-atoms given arbitrary displacement parameters for clarity)
The space group permits the compound 84 in the crystal to be enantiomerically
pure, but the absolute configuration of the molecule has not been determined. The
enantiomer used in the refinement was based on the expected S-configuration of the
molecule. Intermolecular H-bonds involving both N-H groups as donors and the chain
amide O-atom as the acceptor of both interactions links the molecules into infinite two-
dimensional networks. Each N-H group of the molecule acts as a donor for H-bonds.
The chain amide O-atom acts as the acceptor of both interactions, but these interactions
come from two different neighboring molecules. The interaction involving the chain N-
H group as donor links the molecules into extended chains. The interaction involving
the ring N-H group as donor also links the molecules into extended chains. The
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combination of both interactions links the molecules into infinite two-dimensional
networks.
Compound 85, which resulted from the reaction of acetic acid with 1, gave also
suitable crystals for an X-ray crystal-structure determination (Scheme 24 and Figure
41).
Scheme 24. Synthesis of 85
O
OH CH2Cl2
N
H
N
O
O
+ 1
85
Figure 41. ORTEP Plot [86] of the Molecular Structure of 85 (50% probability
ellipsoids; H-atoms given arbitrary displacement parameters for clarity)
The space group of the molecular strcture of 85 is non-centrosymmetric, but the
absolute structure has not been determined and the direction of the polar axis has been
chosen arbitrarily. The primary amide group forms an intermolecular H-bond with the
primary amide O-atom of a neighboring molecule and thereby links the molecules into
extended chains.
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Table 10. Crystallographic Data
6 (HG 0534) 33 (HG 0301)
Crystallized from H2O/MeOH MeOH
Empirical formula C58H104N12O14 C5H8N2O2
Formula weight [g mol-1] 1193.53 128.13
Crystal color, habit colorless, needle colorless, prism
Crystal dimensions [mm] 0.05 × 0.08 × 0.30 0.22 × 0.25 × 0.32
Temperature [K] 160(1) 160(1)
Crystal system monoclinic orthorhombic
Space group C2 P212121
Z 4 4
Reflections for cell determination 4995 1065
2θ range for cell determination [°] 4 – 46 4 – 60
Unit cell parameters a [Å] 32.8020(8) 6.4457 (2)
b [Å] 11.2610(3) 9.5398 (2)
c [Å] 19.3206(6) 9.8862 (3)
α [°] 90 90
β [°] 106.921(2) 90
γ [°] 90 90
V [Å3] 6827.7(3) 607.91 (3)
Dx [g cm-3] 1.161 1.400
µ(MoKα) [mm-1] 0.0832 0.110
Scan type φ and ω φ and ω
2θ (max) [°] 46 60
Transmission factors (min; max) - -
Total reflections measured 36755 11706
Symmetry independent reflections 5025 1051
Reflections with I > 2σ (I) 4046 879
Reflections used in refinement 5018 1051
Parameters refined; restraints 852; 163 95
Final R(F) [I>2σ (I) reflections] 0.0808 0.0380
wR(F2) (all data) 0.2316 0.1023
Weights [a; b] 1) 0.1455; 9.6387 0.0562; 0.0391
Goodness of fit 1.069 1.078
Secondary extinction coefficient 0.0025(6) 0.06 (2)
Final ∆ max /σ 0.001 0.001
∆ρ (max; min) [e Å-3] 0.82; -0.34 0.20; -0.19
1) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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Table 10 (continued). Crystallographic Data
38 (HG 0422) 47 (HG 0531)
Crystallized from CDCl3 MeOH/hexane/AcOEt
Empirical formula C30H35N3O5 C30H39N3O7
Formula weight [g mol-1] 517.62 553.65
Crystal color, habit colorless, tablet colorless, prism
Crystal dimensions [mm] 0.05 × 0.10 × 0.22 0.15 × 0.25 × 0.33
Temperature [K] 160(1) 160(1)
Crystal system orthorhombic triclinic
Space group P212121 P1
Z 4 1
Reflections for cell determination 2773 3287
2θ range for cell determination [°] 4 – 50 4 – 55
Unit cell parameters a [Å] 10.4178(2) 6.2705(1)
b [Å] 10.6996(2) 9.7577(2)
c [Å] 24.6636(5) 13.2491(3)
α [°] 90 106.648(1)
β [°] 90 94.273(1)
γ [°] 90 105.726(1)
V [Å3] 2749.16(9) 737.36(3)
Dx [g cm-3] 1.251 1.247
µ(MoKα) [mm-1] 0.0855 0.0888
Scan type φ and ω φ and ω
2θ (max) [°] 50 55
Transmission factors (min; max) - -
Total reflections measured 30620 17488
Symmetry independent reflections 2759 3359
Reflections with I > 2σ (I) 2388 3096
Reflections used in refinement 2757 3359
Parameters refined; restraints 356 375; 3
Final R(F) [I>2σ (I) reflections] 0.0374 0.0358
wR(F2) (all data) 0.0897 0.0852
Weights [a; b] 1) 0.0473; 0.3586 0.0367; 0.1302
Goodness of fit 1. 072 1.070
Secondary extinction coefficient 0.009(1) 0.090(9)
Final ∆ max /σ 0.001 0.001
∆ρ (max; min) [e Å-3] 0.17; -0.15 0.15; -0.16
1) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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Table 10 (continued). Crystallographic Data
60 (HG 0424) 68 (HG 0430)
Crystallized from - MeOH
Empirical formula C10H17NO2S C22H31N3O6·H2O·MeOH
Formula weight [g mol-1] 215.31 583.56
Crystal color, habit colorless, prism colorless, prism
Crystal dimensions [mm] 0.15 × 0.22 × 0.35 0.35 × 0.37 × 0.45
Temperature [K] 160(1) 273(1)
Crystal system monoclinic monoclinic
Space group P21 P21
Z 2 2
Reflections for cell determination 32910 2412
2θ range for cell determination [°] 4 – 55 4 – 50
Unit cell parameters a [Å] 6.6553(3) 9.7126(6)
b [Å] 9.4541(6) 11.5221(8)
c [Å] 9.2508(5) 12.2597(8)
α [°] 90 90
β [°] 103.508(3) 107.614(4)
γ [°] 90 90
V [Å3] 565.96(5) 1307.7(2)
Dx [g cm-3] 1.263 1.228
µ(MoKα) [mm-1] 0.262 0.0926
Scan type φ and ω ω
2θ (max) [°] 55 50
Transmission factors (min; max) 0.872; 0.964 -
Total reflections measured 13752 18981
Symmetry independent reflections 2568 2409
Reflections with I > 2σ (I) 2373 1762
Reflections used in refinement 2566 2407
Parameters refined; restraints 131; 1 285; 1
Final R(F) [I>2σ (I) reflections] 0.0326 0.0754
wR(F2) (all data) 0.0829 0.1861
Weights [a; b] 1) 0.0481; 0.0924 0.1224; 0
Goodness of fit 1.029 1.005
Secondary extinction coefficient 0.05(1) -
Final ∆ max /σ 0.001 0.001
∆ρ (max; min) [e Å-3] 0.18; -0.25 0.29; -0.30
1) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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Table 10 (continued). Crystallographic Data
69 (HG 0458) 72 (HG 0442)
Crystallized from 1) -
Empirical formula C49H80N8O10·0.5Et2O C41H74N8O8·0.5H2O
Formula weight [g mol-1] 985.27 816.09
Crystal color, habit colorless, prism colorless, prism
Crystal dimensions [mm] 0.10 × 0.20 × 0.30 0.07 × 0.10 × 0.20
Temperature [K] 160(1) 160(1)
Crystal system orthorhombic orthorhombic
Space group P212121 P212121
Z 4 4
Reflections for cell determination 5557 4550
2θ range for cell determination [°] 4 – 50 4 – 50
Unit cell parameters a [Å] 27.2779(6) 11.0876(2)
b [Å] 19.0207(4) 11.4371(2)
c [Å] 10.8797(2) 36.0079(8)
α [°] 90 90
β [°] 90 90
γ [°] 90 90
V [Å3] 5644.9(2) 4566.2(2)
Dx [g cm-3] 1.159 1.187
µ(MoKα) [mm-1] 0.0816 0.0833
Scan type φ and ω ω
2θ (max) [°] 50 50
Transmission factors (min; max) - -
Total reflections measured 84234 69389
Symmetry independent reflections 5539 4529
Reflections with I > 2σ (I) 4023 2559
Reflections used in refinement 5530 4525
Parameters refined; restraints 711; 114 562; 2
Final R(F) [I>2σ (I) reflections] 0.0570 0.0588
wR(F2) (all data) 0.1615 0.1565
Weights [a; b] 2) 0.0797; 2.0779 0.0699; 0.5735
Goodness of fit 1.042 1.014
Secondary extinction coefficient 0.007(1) -
Final ∆ max /σ 0.001 0.002
∆ρ (max; min) [e Å-3] 0.26; -0.36 0.23; -0.20
1) AcOEt/hexane/cyclohexane/Et2O 
2) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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Table 10 (continued). Crystallographic Data
76 (HG 0426) 77 (HG 0529)
Crystallized from MeCN 1)
Empirical formula C29H46N4O6 C21H40.25N4O4.125
Formula weight [g mol-1] 546.70 414.82
Crystal color, habit colorless, tablet colorless, prism
Crystal dimensions [mm] 0.12 × 0.15 × 0.35 0.13 × 0.25 × 0.33
Temperature [K] 160(1) 160(1)
Crystal system tetragonal monoclinic
Space group P43 C2
Z 4 8
Reflections for cell determination 2879 5677
2θ range for cell determination [°] 4 – 52 4 – 55
Unit cell parameters a [Å] 8.9668(4) 26.9659(4)
b [Å] 8.9668(4) 12.7698(3)
c [Å] 37.304(2) 19.2335(4)
α [°] 90 90
β [°] 90 134.1707(9)
γ [°] 90 90
V [Å3] 2999.4(2) 4750.5(2)
Dx [g cm-3] 1.211 1.160
µ(MoKα) [mm-1] 0.0847 0.0806
Scan type φ and ω φ and ω
2θ (max) [°] 52 55
Transmission factors (min; max) - -
Total reflections measured 16072 53382
Symmetry independent reflections 2966 5690
Reflections with I > 2σ (I) 2481 4529
Reflections used in refinement 2964 5685
Parameters refined; restraints 375; 1 577; 51
Final R(F) [I>2σ (I) reflections] 0.0403 0.0462
wR(F2) (all data) 0.0894 0.1222
Weights [a; b] 2) 0.0359; 0.4167 0.0671; 1.3005
Goodness of fit 1.099 1.023
Secondary extinction coefficient 0.014(2) 0.0038(5)
Final ∆ max /σ 0.002 0.001
∆ρ (max; min) [e Å-3] 0.15; -0.15 0.49; -0.20
1) MeOH/AcOEt/hexane/CH2Cl2/pet. ether 
2) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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Table 10 (continued). Crystallographic Data
79 (HG 0455) 82 (HG 0459)
Crystallized from - 1)
Empirical formula C29H46N4O6 C54H90N8O12
Formula weight [g mol-1] 546.70 1043.35
Crystal color, habit colorless, prism colorless, plate
Crystal dimensions [mm] 0.15 × 0.25 × 0.33 0.02 × 0.20 × 0.20
Temperature [K] 160(1) 160(1)
Crystal system monoclinic monoclinic
Space group P21 P21
Z 4 4
Reflections for cell determination 5633 10599
2θ range for cell determination [°] 5 – 50 4 – 50
Unit cell parameters a [Å] 13.0906(6) 10.8603(2)
b [Å] 11.7084(5) 27.0371(5)
c [Å] 20.0843(8) 20.5452(4)
α [°] 90 90
β [°] 91.218(3) 102.967(1)
γ [°] 90 90
V [Å3] 3077.6(2) 5878.9(2)
Dx [g cm-3] 1.180 1.179
µ(MoKα) [mm-1] 0.0825 0.0832
Scan type ω φ and ω
2θ (max) [°] 50 50
Transmission factors (min; max) - -
Total reflections measured 33105 95928
Symmetry independent reflections 5652 10587
Reflections with I > 2σ (I) 4627 6978
Reflections used in refinement 5652 10578
Parameters refined; restraints 852; 421 1409; 304
Final R(F) [I>2σ (I) reflections] 0.0978 0.0663
wR(F2) (all data) 0.3009 0.1895
Weights [a; b] 2) 0.2; 0 0.1280; 0
Goodness of fit 1.294 0.961
Secondary extinction coefficient 0.013(5) -
Final ∆ max /σ 0.011 0.001
∆ρ (max; min) [e Å-3] 0.40; -0.35 0.44; -0.29
1) Et2O/MeOH/AcOEt/hexane/cyclohexane
2) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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Table 10 (continued). Crystallographic Data
84 (HG 0352) 85 (HG 0530)
Crystallized from CD3OD MeOH
Empirical formula C13H14N2O4 C13H18N2O2
Formula weight [g mol-1] 262.26 234.30
Crystal color, habit colorless, tablet colorless, plate
Crystal dimensions [mm] 0.07 × 0.25 × 0.27 0.05 × 0.15 × 0.30
Temperature [K] 160(1) 160(1)
Crystal system orthorhombic monoclinic
Space group P212121 Cc
Z 4 4
Reflections for cell determination 2098 1392
2θ range for cell determination [°] 4 – 60 4 – 52
Unit cell parameters a [Å] 5.7466(1) 14.0195(5)
b [Å] 8.7276(2) 9.8942(3)
c [Å] 24.3618(5) 9.7724(3)
α [°] 90 90
β [°] 90 98.262(2)
γ [°] 90 90
V [Å3] 1221.84(4) 1341.48(8)
Dx [g cm-3] 1.426 1.160
µ(MoKα) [mm-1] 0.107 0.0789
Scan type φ and ω ω
2θ (max) [°] 60 52
Transmission factors (min; max) - -
Total reflections measured 21560 10426
Symmetry independent reflections 2081 1312
Reflections with I > 2σ (I) 1786 1187
Reflections used in refinement 2079 1312
Parameters refined; restraints 181 163; 2
Final R(F) [I>2σ (I) reflections] 0.0372 0.0366
wR(F2) (all data) 0.0926 0.0944
Weights [a; b] 1) 0.0446; 0.1237 0.0533; 0.3271
Goodness of fit 1.046 1.038
Secondary extinction coefficient 0.022(5) 0.024(3)
Final ∆ max /σ 0.001 0.001
∆ρ (max; min) [e Å-3] 0.19; -0.18 0.13; -0.11
1) w = [σ 2(Fo2) + (aP)2 + bP]-1 where P = (Fo2 + 2Fc2) / 3
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